User login
The effect of insurance-driven medication changes on patient care
Purpose Insurance plans periodically change their formularies to enhance medical efficacy and cost savings. Patients face challenges when formulary changes affect their treatment. This study assessed the impact of insurance-driven medication changes on primary care patients and examined implications for patient care.
Methods We mailed questionnaires to a cross-sectional random sample of 1200 adult patients who had visited one of 3 family medicine practices within the past 6 months, asking them to describe problems they had encountered in filling medication prescriptions. We performed descriptive analyses of the frequency and distribution of demographic variables and conditions being treated. Using logistic regression analysis, we identified demographic and health-related variables independently associated with patient-reported problems caused by formulary changes.
Results Three variables—a greater number of prescription medications taken, younger patient age, and reliance on government insurance—were independently associated with an increased likelihood of encountering a problem filling a medication. Patients who reported an insurance-related issue filling a new or existing prescription over the past year (23%) encountered an average of 3 distinct problems. Patients experienced adverse medical outcomes (41%), decreased satisfaction with the health care system (68%), and problems that burdened the physician practice (83%). Formulary changes involving cardiac/hypertension/lipid and neurologic/psychiatric medications caused the most problems.
Conclusions Insurance-driven medication changes adversely affect patient care and access to treatment, particularly for patients with government insurance. A better understanding of the negative impact of formulary changes on patient care and indirect health care expenditures should inform formulary change practices in order to minimize cost-shifting and maximize continuity of care.
To maintain the cost-effectiveness of health insurance, many organizations, including government agencies, routinely evaluate and choose to adopt alternative treatment modalities. But how do such changes affect patient outcomes? And do near-term cost savings from formulary changes lead to long-term cost benefits?
Chronic disease management and associated complex medication regimens account for most health insurance expenditures.1,2 Changes to prescription formularies are common,3 with medications being added or removed to reduce costs or to respond to revised practice guidelines.4,5
Researchers have examined the clinical risks and merits of changing from one drug to another, as well as the impact of implementing formulary changes on administrative and other costs, overall effectiveness of disease management, and the operational adeptness of health systems.6-10 Routine formulary changes may yield immediate cost savings, but net costs may increase downstream due to disruptions in patient care.11,12 Insurance-driven medication changes have also been shown to negatively affect patient adherence to medical treatment and also disease outcomes.13,14
Patient-level data related to formulary restrictions are limited,15 and analyses of patients’ experiences of medication changes are rare. A better understanding of patients’ experiences in this context could guide interventions to minimize treatment delays and improve outcomes. Our study assessed the effect of insurance-driven medication changes on primary care patients; specifically, the prevalence of difficulty in filling a prescription, resultant problems, and patient characteristics associated with reporting a problem.
Methods
Data collection
We mailed questionnaires to a random sample of 1200 adult patients (≥40 years) who had been seen within the previous 6 months at one of 3 family practices in northeastern Ohio. We asked respondents to quantify and describe any insurance-driven problems they encountered while attempting to fill or refill a prescription over the past year. We recorded each respondent’s insurance status, the name of the medication at issue and other medications they were taking, and demographic data. Comparative data for age and sex were collected for nonrespondents. The University Hospitals Case Medical Center Institutional Review Board approved all data collection procedures and methods for this cross-sectional study.
Data analysis
We tabulated and analyzed data from the surveys using Statistical Package for the Social Sciences (SPSS). We compared age and sex data (using t-test and chi-square test, respectively) between respondents and nonrespondents. We calculated descriptive statistics for all demographic, control, and outcome variables, and computed measures of association between demographic and health-related variables and insurance-driven problems encountered while filling a prescription. Using logistic regression analysis, we identified demographic and health-related variables independently associated with a problematic prescription.
We calculated the frequencies of problems encountered while trying to fill a prescription, and grouped the problems into 3 mutually exclusive categories: adverse medical outcomes, decreased patient satisfaction, and burden on physician practice. Adverse medical outcomes included missed doses of medication, inability to obtain medication, worsened medical condition, new medication adverse effects, and having to go to the emergency department (ED) because of a medication issue. We sorted medications into categories, and calculated the frequency of problems associated with each category.
We based our decision to mail 1200 surveys on a power calculation assuming a 40% response rate and approximately 25% of patients reporting a problem. A sample size of 480 or more provides 80% power to detect moderate differences in characteristics between those reporting a problem and those not reporting a problem.
Results
Four-hundred thirty-four patients returned the survey (36% response rate). We excluded 6 participants from analysis due to incomplete data for the primary outcome variable (problem with a prescription). Respondents and nonrespondents were similar in sex ratio, but respondents on average were 3 years older (P<.001). The average number of prescriptions taken was 3.4, and most patients (85%) had some form of private insurance ( TABLE 1 ). Most patients were female, in good health, and well educated.
Of the 428 study participants, 100 (23%) reported at least one problem obtaining a prescribed medication due to insurance. Generally, those who experienced a problem were younger, more likely to be female, and reported poorer health status than those reporting no problem ( TABLE 1 ). Additionally, those who encountered a problem were more than twice as likely to rely solely on Medicaid or Medicare, and were also taking more prescription medications. Problems filling a prescription were also reported more often in an urban setting than in suburban or semirural areas.
TABLE 1
Demographic variables for patients who did and didn’t report problems filling prescriptions
Variable | Total (n=428) | Problem (n=100) | No problem (n=328) | P |
---|---|---|---|---|
Number of prescriptions, mean (SD) | 3.4 (3.2) | 4.8 (3.2) | 3.0 (3.1) | .001 |
Age, mean (SD) | 60.0 (12) | 57.8 (13) | 60.6 (12) | .04 |
Sex, n (%) | .02 | |||
Male | 139 (32) | 23 (23) | 116 (35) | |
Female | 289 (68) | 77 (77) | 212 (65) | |
Health status, n (%) | .002 | |||
Excellent/very good | 342 (81) | 69 (70)* | 273 (84)* | |
Fair/poor | 80 (19) | 29 (30)* | 51 (16)* | |
Education, n (%) | .46 | |||
High school or less | 112 (27) | 30 (31)* | 82 (25)* | |
Some college/trade | 140 (33) | 31 (33)* | 109 (34)* | |
College graduate | 166 (40) | 34 (36)* | 132 (41) | |
Insurance, n (%) | .001 | |||
Government (Medicaid or Medicare) | 65 (15) | 27 (27) | 38 (12)* | |
Nongovernment | 356 (85) | 72 (73)* | 284 (88)* | |
Practice, n (%) | .005 | |||
Semirural | 191 (45) | 35 (35) | 156 (48) | |
Suburban | 116 (27) | 24 (24) | 92 (28) | |
Urban | 121 (28) | 41 (41) | 80 (24) | |
SD, standard deviation. *Some data are missing (<2.5%) from columns 2 and 3. |
Using logistic regression, we analyzed a model that included all significant variables (age, total number of prescription drugs taken, sex, health status, insurance type, and practice location). The final logistic regression model showed statistical significance for only 3 variables: type of insurance, total number of prescription drugs taken, and age. (When we included type of insurance in the analysis, practice location was not associated with a problem filling a prescription.)
Specifically, the independent predictors of an insurance-related problem in filling a prescription were reliance solely on government-provided insurance, as opposed to private insurance or government insurance supplemented with private insurance (odds ratio [OR]=1.90; 95% confidence interval [CI], 1.02-3.61); taking more prescription medications (OR=1.19; 95% CI, 1.10-1.29); and being younger (OR=0.96; 95% CI, 0.94-0.99).
Respondents reporting at least one insurance-driven impediment to filling a prescription encountered an average of 2.9 different types of resultant problems ( TABLE 2 ). Insurance-related problems with medications were not limited to new prescriptions. Of the 100 patients reporting a problem with a medication, 21% had a problem with a new prescription, 42% with a medication they were already taking, and 37% with both a new and a previously prescribed medication.
TABLE 2
Resultant problems when patients had at least one insurance-related issue filling a prescription in the previous year
Problem encountered | Percent of patients reporting problem* (n=100) |
---|---|
Adverse medical outcomes | |
Missed doses of medication | 23 |
Couldn’t get any medication | 19 |
Medical condition got worse | 8 |
New medication adverse effects | 6 |
Had to go to emergency department | 5 |
Overall any adverse outcome | 41 |
Decreased patient satisfaction | |
Got upset with insurance company | 44 |
Got upset with pharmacist | 15 |
Got upset with doctor | 12 |
Overall any decreased satisfaction | 68 |
Increased practice burden | |
Had to wait for pharmacist authorization | 69 |
Made extra phone calls to practice | 36 |
Had to get a different medication | 36 |
Had extra doctor visits | 13 |
Overall any increased burden | 83 |
*Patients reported, on average, 2.9 problems; therefore, categories exceed 100%. |
Forty-one percent of patients reporting a problem experienced adverse medical outcomes. The most serious adverse medical outcomes were reported least often, but occurred nonetheless: worsening of medical condition (8%), new medication adverse effects (6%), and requiring a visit to the ED (5%). More commonly reported was decreased satisfaction with the health care system (68%). Patients were less likely to report being upset with their physician than their insurance company or pharmacist. Problems that burdened the physician practice were reported most frequently (83%).
TABLE 3 shows the medication categories that were affected when respondents reported at least one problem. Formulary changes or restrictions involving cardiac/hypertension/lipid and neurologic/psychiatric medications were linked to the most problems.
TABLE 3
Which medication categories were most affected when patients had a problem filling a prescription?
Medication category | Frequency of occurrence |
---|---|
Cardiac/HTN/lipids | 23 |
Neurologic/psychiatric | 23 |
Metabolic/endocrine | 16 |
Gastrointestinal | 15 |
Pain | 13 |
Respiratory | 11 |
Other | 9 |
Dermatologic | 7 |
Total | 117* |
HTN, hypertension. *Total exceeds 100 because some of the 100 patients had problems with medications in more than one category. |
Discussion
Nearly one quarter of patients in our sample (23%) experienced problems caused by insurance constraints while they attempted to follow the treatment regimens prescribed by their physicians. Although the most commonly reported insurance-related problems (waiting for pharmacist authorization, making extra phone calls to the physician’s office) could be perceived as minor inconveniences, serious consequences were also common. Our study showed that patients who rely solely on Medicaid or Medicare bore the greatest burden of insurance-related obstacles when filling prescriptions, although others were also affected.
Consistent with prior research in Medicare and Medicaid populations, our study found that medication access restrictions can negatively affect patient adherence.13,16,17 Our study showed that 41% of patients who encountered a problem experienced a medically meaningful adverse outcome; 19% reported they received no medication for their condition. Similarly, a study of Medicare beneficiaries who had failed to fill or refill a prescription found that 20% cited lack of insurance coverage for the medication as a reason for not filling the prescription.17
In our study, 23% of patients reported missing doses of their medication due to insurance-related difficulties, and 8% reported a worsening of their medical condition. The increased costs associated with poor chronic care management are well documented.18 Less well described is the potential net savings produced when insurance formularies are adjusted to expand coverage and lower patient costs for prescription treatments for chronic conditions. In an analysis of cost data from the Pitney-Bowes Corporation, Mahoney12 revealed a significant net savings in health care costs and lost productivity when treatments for chronic conditions were moved to the lowest tier of the formulary, thereby making them available to health plan participants at the lowest cost.
We could not link patient reports of treatment disruptions empirically to medical outcomes or increased costs, due to the constraints of our research question and study design. However, it is reasonable to suggest that longer-term insurance costs for these patients could, in fact, negate any short-term cost savings generated from formulary restrictions. In particular, the 5% of our patient sample who reported using the ED as a consequence of an insurance-related disruption of their prescribed treatment likely added significant unnecessary cost to their treatment. This effect has been seen in other studies.19,20 In our study, cardiac/hypertension/lipid medications and medications for neurologic or psychiatric conditions were the most likely to be problematic. In these categories, competition of branded products may contribute to more frequent formulary changes. Furthermore, increases in morbidity and mortality associated with inadequate treatment of the conditions represented in these 2 categories of medications represent a significant burden to the US health system, including insurers, employers, and individuals.21-23
Although patients were less likely to report being upset with their physician than their insurance company or pharmacist, physicians bore a considerable burden for resolving a number of prevalent patient issues. Most of these problems required extra phone calls to the practice, additional medication authorization, or extra office visits. Physicians and their support staff may serve as buffers between patients and the insurance formulary rules, but at significant cost in their time and effort.
Electronic prescribing systems with real-time pharmacy benefit verification may provide additional efficiencies and help physicians and patients avoid some of the problems cited by our respondents. Providers with such systems receive immediate notification of formulary status, including tier and co-pay levels, which can aid in shared decision-making at the point of prescribing. Physicians without access to e-prescribing may want to use newer formulary search engines that can check formulary status of medications across multiple insurance plans. However, these electronic tools often fail to account for variations in formularies within the same insurance plan for different employers based on their benefit structure. Still, when a medication is not on formulary or a co-payment is required, the physician may be forced to play the role of apologist for the constraints imposed by the insurance formulary.
In cases where formularies restrict the patient’s potential access to a preferred treatment plan, the burden of prior authorizations continues to be borne by physicians. Coverage limitations lead to financial and medical consequences that must be managed in partnership with the patient. A system should be put in place by insurance companies that facilitates out-of-formulary authorizations to prevent lapses in patient care or deleterious changes in medical management.
Study limitations
The findings reported here should be interpreted in light of some limitations of this study. The response rate to our mailed patient survey was modest (36%), although typical for this method. The sex mix of respondents was similar to that of nonrespondents, but nonrespondents were slightly younger. Given that younger age is associated with a greater likelihood of experiencing a problem filling a medication, our findings may underestimate the frequency of this dilemma. In addition, our survey asked patients to recall events that occurred over the past year, introducing a potential for recall bias.
While the overall sample size was relatively small (n=428), it is close to the number calculated for sufficient power to conduct the analyses (n=480). Furthermore, data were collected from 3 distinct patient populations: urban, suburban and semirural. Although the scope of our study included only one geographic region, variability in practice setting lends some tentative support to the generalizability of the findings.
Looking forward
As a standard method to control costs and update treatment guidelines, insurance-mediated medication changes will continue to present unique challenges for patients and health care providers. Formulary changes burden the downstream delivery of medical care with expensive administrative responsibilities and disrupt effective disease management and prevention. Until insurance companies and pharmacy benefit managers start paying heed to total costs of care when contemplating formulary changes, physicians should try to identify formulary conflicts as early as possible in the prescribing process so as to save time for all parties later and improve compliance.
As practices proceed toward adoption of electronic health records, e-prescribing, and the Centers for Medicare & Medicaid Services’ “meaningful use” criteria, physicians may use systems that provide real-time formulary information, which can flag issues before the patient leaves the exam room. Future research should explore the ways formulary changes might be implemented to provide the strongest continuity of patient care with the least amount of cost shifting.
CORRESPONDENCE
Susan A. Flocke, PhD, CWRU Department of Family Medicine & Community Health, 11000 Cedar Avenue, Suite 402, Cleveland, OH 44106; [email protected]
1. Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion. Chronic diseases: the power to prevent, the call to control: at a glance 2009. Available at: http://www.cdc.gov/chronicdisease/resources/publications/aag/chronic.htm. Page last updated December 17, 2009. Accessed June 21, 2012.
2. Mueller C, Schur C, O’Connell J. Prescription drug spending: the impact of age and chronic disease status. Am J Public Health. 1997;87:1626-1629.
3. Kaiser Family Foundation. Prescription drug trends. Available at: http://www.kff.org/rxdrugs/upload/3057_07.pdf. Published September 2008. Accessed December 1, 2009.
4. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood). 2004;23:124-134.
5. Simon GE, Psaty BM, Hrachovec JB, et al. Principles for evidence-based drug formulary policy. J Gen Intern Med. 2005;20:964-968.
6. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
7. Meissner B, Dickson M, Shinogle J, et al. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. J Manag Care Pharm. 2006;12:331-340.
8. Ovsag K, Hydery S, Mousa SA. Preferred drug lists: potential impact on healthcare economics. Vasc Health Risk Manag. 2008;4:403-413.
9. Raisch DW, Klaurens LM, Hayden C, et al. Impact of a formulary change in proton pump inhibitors on health care costs and patients’ symptoms. Dig Dis Sci. 2001;46:1533-1539.
10. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23:135-146.
11. Johnson TJ, Stahl-Moncada S. Medicaid prescription formulary restrictions and arthritis treatment costs. Am J Public Health. 2008;98:1300-1305.
12. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 suppl):S170-S176.
13. Ridley DB, Axelsen KJ. Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics. 2006;24 (suppl 3):65-78.
14. Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med. 2001;16:793-799.
15. Jean CD, Triplett JW. Investigating patient experiences after a formulary change. Am J Health Syst Pharm. 2000;57:1052-1054.
16. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care. 2005;11 (spec no):SP27-SP34.
17. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm. 2008;14:553-560.
18. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26:38-48.
19. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
20. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
21. Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface. 2002;15:28-36.
22. Hall RC, Wise MG. The clinical and financial burden of mood disorders. Cost and outcome. Psychosomatics. 1995;36:S11-S18.
23. McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994;32:214-226.
Purpose Insurance plans periodically change their formularies to enhance medical efficacy and cost savings. Patients face challenges when formulary changes affect their treatment. This study assessed the impact of insurance-driven medication changes on primary care patients and examined implications for patient care.
Methods We mailed questionnaires to a cross-sectional random sample of 1200 adult patients who had visited one of 3 family medicine practices within the past 6 months, asking them to describe problems they had encountered in filling medication prescriptions. We performed descriptive analyses of the frequency and distribution of demographic variables and conditions being treated. Using logistic regression analysis, we identified demographic and health-related variables independently associated with patient-reported problems caused by formulary changes.
Results Three variables—a greater number of prescription medications taken, younger patient age, and reliance on government insurance—were independently associated with an increased likelihood of encountering a problem filling a medication. Patients who reported an insurance-related issue filling a new or existing prescription over the past year (23%) encountered an average of 3 distinct problems. Patients experienced adverse medical outcomes (41%), decreased satisfaction with the health care system (68%), and problems that burdened the physician practice (83%). Formulary changes involving cardiac/hypertension/lipid and neurologic/psychiatric medications caused the most problems.
Conclusions Insurance-driven medication changes adversely affect patient care and access to treatment, particularly for patients with government insurance. A better understanding of the negative impact of formulary changes on patient care and indirect health care expenditures should inform formulary change practices in order to minimize cost-shifting and maximize continuity of care.
To maintain the cost-effectiveness of health insurance, many organizations, including government agencies, routinely evaluate and choose to adopt alternative treatment modalities. But how do such changes affect patient outcomes? And do near-term cost savings from formulary changes lead to long-term cost benefits?
Chronic disease management and associated complex medication regimens account for most health insurance expenditures.1,2 Changes to prescription formularies are common,3 with medications being added or removed to reduce costs or to respond to revised practice guidelines.4,5
Researchers have examined the clinical risks and merits of changing from one drug to another, as well as the impact of implementing formulary changes on administrative and other costs, overall effectiveness of disease management, and the operational adeptness of health systems.6-10 Routine formulary changes may yield immediate cost savings, but net costs may increase downstream due to disruptions in patient care.11,12 Insurance-driven medication changes have also been shown to negatively affect patient adherence to medical treatment and also disease outcomes.13,14
Patient-level data related to formulary restrictions are limited,15 and analyses of patients’ experiences of medication changes are rare. A better understanding of patients’ experiences in this context could guide interventions to minimize treatment delays and improve outcomes. Our study assessed the effect of insurance-driven medication changes on primary care patients; specifically, the prevalence of difficulty in filling a prescription, resultant problems, and patient characteristics associated with reporting a problem.
Methods
Data collection
We mailed questionnaires to a random sample of 1200 adult patients (≥40 years) who had been seen within the previous 6 months at one of 3 family practices in northeastern Ohio. We asked respondents to quantify and describe any insurance-driven problems they encountered while attempting to fill or refill a prescription over the past year. We recorded each respondent’s insurance status, the name of the medication at issue and other medications they were taking, and demographic data. Comparative data for age and sex were collected for nonrespondents. The University Hospitals Case Medical Center Institutional Review Board approved all data collection procedures and methods for this cross-sectional study.
Data analysis
We tabulated and analyzed data from the surveys using Statistical Package for the Social Sciences (SPSS). We compared age and sex data (using t-test and chi-square test, respectively) between respondents and nonrespondents. We calculated descriptive statistics for all demographic, control, and outcome variables, and computed measures of association between demographic and health-related variables and insurance-driven problems encountered while filling a prescription. Using logistic regression analysis, we identified demographic and health-related variables independently associated with a problematic prescription.
We calculated the frequencies of problems encountered while trying to fill a prescription, and grouped the problems into 3 mutually exclusive categories: adverse medical outcomes, decreased patient satisfaction, and burden on physician practice. Adverse medical outcomes included missed doses of medication, inability to obtain medication, worsened medical condition, new medication adverse effects, and having to go to the emergency department (ED) because of a medication issue. We sorted medications into categories, and calculated the frequency of problems associated with each category.
We based our decision to mail 1200 surveys on a power calculation assuming a 40% response rate and approximately 25% of patients reporting a problem. A sample size of 480 or more provides 80% power to detect moderate differences in characteristics between those reporting a problem and those not reporting a problem.
Results
Four-hundred thirty-four patients returned the survey (36% response rate). We excluded 6 participants from analysis due to incomplete data for the primary outcome variable (problem with a prescription). Respondents and nonrespondents were similar in sex ratio, but respondents on average were 3 years older (P<.001). The average number of prescriptions taken was 3.4, and most patients (85%) had some form of private insurance ( TABLE 1 ). Most patients were female, in good health, and well educated.
Of the 428 study participants, 100 (23%) reported at least one problem obtaining a prescribed medication due to insurance. Generally, those who experienced a problem were younger, more likely to be female, and reported poorer health status than those reporting no problem ( TABLE 1 ). Additionally, those who encountered a problem were more than twice as likely to rely solely on Medicaid or Medicare, and were also taking more prescription medications. Problems filling a prescription were also reported more often in an urban setting than in suburban or semirural areas.
TABLE 1
Demographic variables for patients who did and didn’t report problems filling prescriptions
Variable | Total (n=428) | Problem (n=100) | No problem (n=328) | P |
---|---|---|---|---|
Number of prescriptions, mean (SD) | 3.4 (3.2) | 4.8 (3.2) | 3.0 (3.1) | .001 |
Age, mean (SD) | 60.0 (12) | 57.8 (13) | 60.6 (12) | .04 |
Sex, n (%) | .02 | |||
Male | 139 (32) | 23 (23) | 116 (35) | |
Female | 289 (68) | 77 (77) | 212 (65) | |
Health status, n (%) | .002 | |||
Excellent/very good | 342 (81) | 69 (70)* | 273 (84)* | |
Fair/poor | 80 (19) | 29 (30)* | 51 (16)* | |
Education, n (%) | .46 | |||
High school or less | 112 (27) | 30 (31)* | 82 (25)* | |
Some college/trade | 140 (33) | 31 (33)* | 109 (34)* | |
College graduate | 166 (40) | 34 (36)* | 132 (41) | |
Insurance, n (%) | .001 | |||
Government (Medicaid or Medicare) | 65 (15) | 27 (27) | 38 (12)* | |
Nongovernment | 356 (85) | 72 (73)* | 284 (88)* | |
Practice, n (%) | .005 | |||
Semirural | 191 (45) | 35 (35) | 156 (48) | |
Suburban | 116 (27) | 24 (24) | 92 (28) | |
Urban | 121 (28) | 41 (41) | 80 (24) | |
SD, standard deviation. *Some data are missing (<2.5%) from columns 2 and 3. |
Using logistic regression, we analyzed a model that included all significant variables (age, total number of prescription drugs taken, sex, health status, insurance type, and practice location). The final logistic regression model showed statistical significance for only 3 variables: type of insurance, total number of prescription drugs taken, and age. (When we included type of insurance in the analysis, practice location was not associated with a problem filling a prescription.)
Specifically, the independent predictors of an insurance-related problem in filling a prescription were reliance solely on government-provided insurance, as opposed to private insurance or government insurance supplemented with private insurance (odds ratio [OR]=1.90; 95% confidence interval [CI], 1.02-3.61); taking more prescription medications (OR=1.19; 95% CI, 1.10-1.29); and being younger (OR=0.96; 95% CI, 0.94-0.99).
Respondents reporting at least one insurance-driven impediment to filling a prescription encountered an average of 2.9 different types of resultant problems ( TABLE 2 ). Insurance-related problems with medications were not limited to new prescriptions. Of the 100 patients reporting a problem with a medication, 21% had a problem with a new prescription, 42% with a medication they were already taking, and 37% with both a new and a previously prescribed medication.
TABLE 2
Resultant problems when patients had at least one insurance-related issue filling a prescription in the previous year
Problem encountered | Percent of patients reporting problem* (n=100) |
---|---|
Adverse medical outcomes | |
Missed doses of medication | 23 |
Couldn’t get any medication | 19 |
Medical condition got worse | 8 |
New medication adverse effects | 6 |
Had to go to emergency department | 5 |
Overall any adverse outcome | 41 |
Decreased patient satisfaction | |
Got upset with insurance company | 44 |
Got upset with pharmacist | 15 |
Got upset with doctor | 12 |
Overall any decreased satisfaction | 68 |
Increased practice burden | |
Had to wait for pharmacist authorization | 69 |
Made extra phone calls to practice | 36 |
Had to get a different medication | 36 |
Had extra doctor visits | 13 |
Overall any increased burden | 83 |
*Patients reported, on average, 2.9 problems; therefore, categories exceed 100%. |
Forty-one percent of patients reporting a problem experienced adverse medical outcomes. The most serious adverse medical outcomes were reported least often, but occurred nonetheless: worsening of medical condition (8%), new medication adverse effects (6%), and requiring a visit to the ED (5%). More commonly reported was decreased satisfaction with the health care system (68%). Patients were less likely to report being upset with their physician than their insurance company or pharmacist. Problems that burdened the physician practice were reported most frequently (83%).
TABLE 3 shows the medication categories that were affected when respondents reported at least one problem. Formulary changes or restrictions involving cardiac/hypertension/lipid and neurologic/psychiatric medications were linked to the most problems.
TABLE 3
Which medication categories were most affected when patients had a problem filling a prescription?
Medication category | Frequency of occurrence |
---|---|
Cardiac/HTN/lipids | 23 |
Neurologic/psychiatric | 23 |
Metabolic/endocrine | 16 |
Gastrointestinal | 15 |
Pain | 13 |
Respiratory | 11 |
Other | 9 |
Dermatologic | 7 |
Total | 117* |
HTN, hypertension. *Total exceeds 100 because some of the 100 patients had problems with medications in more than one category. |
Discussion
Nearly one quarter of patients in our sample (23%) experienced problems caused by insurance constraints while they attempted to follow the treatment regimens prescribed by their physicians. Although the most commonly reported insurance-related problems (waiting for pharmacist authorization, making extra phone calls to the physician’s office) could be perceived as minor inconveniences, serious consequences were also common. Our study showed that patients who rely solely on Medicaid or Medicare bore the greatest burden of insurance-related obstacles when filling prescriptions, although others were also affected.
Consistent with prior research in Medicare and Medicaid populations, our study found that medication access restrictions can negatively affect patient adherence.13,16,17 Our study showed that 41% of patients who encountered a problem experienced a medically meaningful adverse outcome; 19% reported they received no medication for their condition. Similarly, a study of Medicare beneficiaries who had failed to fill or refill a prescription found that 20% cited lack of insurance coverage for the medication as a reason for not filling the prescription.17
In our study, 23% of patients reported missing doses of their medication due to insurance-related difficulties, and 8% reported a worsening of their medical condition. The increased costs associated with poor chronic care management are well documented.18 Less well described is the potential net savings produced when insurance formularies are adjusted to expand coverage and lower patient costs for prescription treatments for chronic conditions. In an analysis of cost data from the Pitney-Bowes Corporation, Mahoney12 revealed a significant net savings in health care costs and lost productivity when treatments for chronic conditions were moved to the lowest tier of the formulary, thereby making them available to health plan participants at the lowest cost.
We could not link patient reports of treatment disruptions empirically to medical outcomes or increased costs, due to the constraints of our research question and study design. However, it is reasonable to suggest that longer-term insurance costs for these patients could, in fact, negate any short-term cost savings generated from formulary restrictions. In particular, the 5% of our patient sample who reported using the ED as a consequence of an insurance-related disruption of their prescribed treatment likely added significant unnecessary cost to their treatment. This effect has been seen in other studies.19,20 In our study, cardiac/hypertension/lipid medications and medications for neurologic or psychiatric conditions were the most likely to be problematic. In these categories, competition of branded products may contribute to more frequent formulary changes. Furthermore, increases in morbidity and mortality associated with inadequate treatment of the conditions represented in these 2 categories of medications represent a significant burden to the US health system, including insurers, employers, and individuals.21-23
Although patients were less likely to report being upset with their physician than their insurance company or pharmacist, physicians bore a considerable burden for resolving a number of prevalent patient issues. Most of these problems required extra phone calls to the practice, additional medication authorization, or extra office visits. Physicians and their support staff may serve as buffers between patients and the insurance formulary rules, but at significant cost in their time and effort.
Electronic prescribing systems with real-time pharmacy benefit verification may provide additional efficiencies and help physicians and patients avoid some of the problems cited by our respondents. Providers with such systems receive immediate notification of formulary status, including tier and co-pay levels, which can aid in shared decision-making at the point of prescribing. Physicians without access to e-prescribing may want to use newer formulary search engines that can check formulary status of medications across multiple insurance plans. However, these electronic tools often fail to account for variations in formularies within the same insurance plan for different employers based on their benefit structure. Still, when a medication is not on formulary or a co-payment is required, the physician may be forced to play the role of apologist for the constraints imposed by the insurance formulary.
In cases where formularies restrict the patient’s potential access to a preferred treatment plan, the burden of prior authorizations continues to be borne by physicians. Coverage limitations lead to financial and medical consequences that must be managed in partnership with the patient. A system should be put in place by insurance companies that facilitates out-of-formulary authorizations to prevent lapses in patient care or deleterious changes in medical management.
Study limitations
The findings reported here should be interpreted in light of some limitations of this study. The response rate to our mailed patient survey was modest (36%), although typical for this method. The sex mix of respondents was similar to that of nonrespondents, but nonrespondents were slightly younger. Given that younger age is associated with a greater likelihood of experiencing a problem filling a medication, our findings may underestimate the frequency of this dilemma. In addition, our survey asked patients to recall events that occurred over the past year, introducing a potential for recall bias.
While the overall sample size was relatively small (n=428), it is close to the number calculated for sufficient power to conduct the analyses (n=480). Furthermore, data were collected from 3 distinct patient populations: urban, suburban and semirural. Although the scope of our study included only one geographic region, variability in practice setting lends some tentative support to the generalizability of the findings.
Looking forward
As a standard method to control costs and update treatment guidelines, insurance-mediated medication changes will continue to present unique challenges for patients and health care providers. Formulary changes burden the downstream delivery of medical care with expensive administrative responsibilities and disrupt effective disease management and prevention. Until insurance companies and pharmacy benefit managers start paying heed to total costs of care when contemplating formulary changes, physicians should try to identify formulary conflicts as early as possible in the prescribing process so as to save time for all parties later and improve compliance.
As practices proceed toward adoption of electronic health records, e-prescribing, and the Centers for Medicare & Medicaid Services’ “meaningful use” criteria, physicians may use systems that provide real-time formulary information, which can flag issues before the patient leaves the exam room. Future research should explore the ways formulary changes might be implemented to provide the strongest continuity of patient care with the least amount of cost shifting.
CORRESPONDENCE
Susan A. Flocke, PhD, CWRU Department of Family Medicine & Community Health, 11000 Cedar Avenue, Suite 402, Cleveland, OH 44106; [email protected]
Purpose Insurance plans periodically change their formularies to enhance medical efficacy and cost savings. Patients face challenges when formulary changes affect their treatment. This study assessed the impact of insurance-driven medication changes on primary care patients and examined implications for patient care.
Methods We mailed questionnaires to a cross-sectional random sample of 1200 adult patients who had visited one of 3 family medicine practices within the past 6 months, asking them to describe problems they had encountered in filling medication prescriptions. We performed descriptive analyses of the frequency and distribution of demographic variables and conditions being treated. Using logistic regression analysis, we identified demographic and health-related variables independently associated with patient-reported problems caused by formulary changes.
Results Three variables—a greater number of prescription medications taken, younger patient age, and reliance on government insurance—were independently associated with an increased likelihood of encountering a problem filling a medication. Patients who reported an insurance-related issue filling a new or existing prescription over the past year (23%) encountered an average of 3 distinct problems. Patients experienced adverse medical outcomes (41%), decreased satisfaction with the health care system (68%), and problems that burdened the physician practice (83%). Formulary changes involving cardiac/hypertension/lipid and neurologic/psychiatric medications caused the most problems.
Conclusions Insurance-driven medication changes adversely affect patient care and access to treatment, particularly for patients with government insurance. A better understanding of the negative impact of formulary changes on patient care and indirect health care expenditures should inform formulary change practices in order to minimize cost-shifting and maximize continuity of care.
To maintain the cost-effectiveness of health insurance, many organizations, including government agencies, routinely evaluate and choose to adopt alternative treatment modalities. But how do such changes affect patient outcomes? And do near-term cost savings from formulary changes lead to long-term cost benefits?
Chronic disease management and associated complex medication regimens account for most health insurance expenditures.1,2 Changes to prescription formularies are common,3 with medications being added or removed to reduce costs or to respond to revised practice guidelines.4,5
Researchers have examined the clinical risks and merits of changing from one drug to another, as well as the impact of implementing formulary changes on administrative and other costs, overall effectiveness of disease management, and the operational adeptness of health systems.6-10 Routine formulary changes may yield immediate cost savings, but net costs may increase downstream due to disruptions in patient care.11,12 Insurance-driven medication changes have also been shown to negatively affect patient adherence to medical treatment and also disease outcomes.13,14
Patient-level data related to formulary restrictions are limited,15 and analyses of patients’ experiences of medication changes are rare. A better understanding of patients’ experiences in this context could guide interventions to minimize treatment delays and improve outcomes. Our study assessed the effect of insurance-driven medication changes on primary care patients; specifically, the prevalence of difficulty in filling a prescription, resultant problems, and patient characteristics associated with reporting a problem.
Methods
Data collection
We mailed questionnaires to a random sample of 1200 adult patients (≥40 years) who had been seen within the previous 6 months at one of 3 family practices in northeastern Ohio. We asked respondents to quantify and describe any insurance-driven problems they encountered while attempting to fill or refill a prescription over the past year. We recorded each respondent’s insurance status, the name of the medication at issue and other medications they were taking, and demographic data. Comparative data for age and sex were collected for nonrespondents. The University Hospitals Case Medical Center Institutional Review Board approved all data collection procedures and methods for this cross-sectional study.
Data analysis
We tabulated and analyzed data from the surveys using Statistical Package for the Social Sciences (SPSS). We compared age and sex data (using t-test and chi-square test, respectively) between respondents and nonrespondents. We calculated descriptive statistics for all demographic, control, and outcome variables, and computed measures of association between demographic and health-related variables and insurance-driven problems encountered while filling a prescription. Using logistic regression analysis, we identified demographic and health-related variables independently associated with a problematic prescription.
We calculated the frequencies of problems encountered while trying to fill a prescription, and grouped the problems into 3 mutually exclusive categories: adverse medical outcomes, decreased patient satisfaction, and burden on physician practice. Adverse medical outcomes included missed doses of medication, inability to obtain medication, worsened medical condition, new medication adverse effects, and having to go to the emergency department (ED) because of a medication issue. We sorted medications into categories, and calculated the frequency of problems associated with each category.
We based our decision to mail 1200 surveys on a power calculation assuming a 40% response rate and approximately 25% of patients reporting a problem. A sample size of 480 or more provides 80% power to detect moderate differences in characteristics between those reporting a problem and those not reporting a problem.
Results
Four-hundred thirty-four patients returned the survey (36% response rate). We excluded 6 participants from analysis due to incomplete data for the primary outcome variable (problem with a prescription). Respondents and nonrespondents were similar in sex ratio, but respondents on average were 3 years older (P<.001). The average number of prescriptions taken was 3.4, and most patients (85%) had some form of private insurance ( TABLE 1 ). Most patients were female, in good health, and well educated.
Of the 428 study participants, 100 (23%) reported at least one problem obtaining a prescribed medication due to insurance. Generally, those who experienced a problem were younger, more likely to be female, and reported poorer health status than those reporting no problem ( TABLE 1 ). Additionally, those who encountered a problem were more than twice as likely to rely solely on Medicaid or Medicare, and were also taking more prescription medications. Problems filling a prescription were also reported more often in an urban setting than in suburban or semirural areas.
TABLE 1
Demographic variables for patients who did and didn’t report problems filling prescriptions
Variable | Total (n=428) | Problem (n=100) | No problem (n=328) | P |
---|---|---|---|---|
Number of prescriptions, mean (SD) | 3.4 (3.2) | 4.8 (3.2) | 3.0 (3.1) | .001 |
Age, mean (SD) | 60.0 (12) | 57.8 (13) | 60.6 (12) | .04 |
Sex, n (%) | .02 | |||
Male | 139 (32) | 23 (23) | 116 (35) | |
Female | 289 (68) | 77 (77) | 212 (65) | |
Health status, n (%) | .002 | |||
Excellent/very good | 342 (81) | 69 (70)* | 273 (84)* | |
Fair/poor | 80 (19) | 29 (30)* | 51 (16)* | |
Education, n (%) | .46 | |||
High school or less | 112 (27) | 30 (31)* | 82 (25)* | |
Some college/trade | 140 (33) | 31 (33)* | 109 (34)* | |
College graduate | 166 (40) | 34 (36)* | 132 (41) | |
Insurance, n (%) | .001 | |||
Government (Medicaid or Medicare) | 65 (15) | 27 (27) | 38 (12)* | |
Nongovernment | 356 (85) | 72 (73)* | 284 (88)* | |
Practice, n (%) | .005 | |||
Semirural | 191 (45) | 35 (35) | 156 (48) | |
Suburban | 116 (27) | 24 (24) | 92 (28) | |
Urban | 121 (28) | 41 (41) | 80 (24) | |
SD, standard deviation. *Some data are missing (<2.5%) from columns 2 and 3. |
Using logistic regression, we analyzed a model that included all significant variables (age, total number of prescription drugs taken, sex, health status, insurance type, and practice location). The final logistic regression model showed statistical significance for only 3 variables: type of insurance, total number of prescription drugs taken, and age. (When we included type of insurance in the analysis, practice location was not associated with a problem filling a prescription.)
Specifically, the independent predictors of an insurance-related problem in filling a prescription were reliance solely on government-provided insurance, as opposed to private insurance or government insurance supplemented with private insurance (odds ratio [OR]=1.90; 95% confidence interval [CI], 1.02-3.61); taking more prescription medications (OR=1.19; 95% CI, 1.10-1.29); and being younger (OR=0.96; 95% CI, 0.94-0.99).
Respondents reporting at least one insurance-driven impediment to filling a prescription encountered an average of 2.9 different types of resultant problems ( TABLE 2 ). Insurance-related problems with medications were not limited to new prescriptions. Of the 100 patients reporting a problem with a medication, 21% had a problem with a new prescription, 42% with a medication they were already taking, and 37% with both a new and a previously prescribed medication.
TABLE 2
Resultant problems when patients had at least one insurance-related issue filling a prescription in the previous year
Problem encountered | Percent of patients reporting problem* (n=100) |
---|---|
Adverse medical outcomes | |
Missed doses of medication | 23 |
Couldn’t get any medication | 19 |
Medical condition got worse | 8 |
New medication adverse effects | 6 |
Had to go to emergency department | 5 |
Overall any adverse outcome | 41 |
Decreased patient satisfaction | |
Got upset with insurance company | 44 |
Got upset with pharmacist | 15 |
Got upset with doctor | 12 |
Overall any decreased satisfaction | 68 |
Increased practice burden | |
Had to wait for pharmacist authorization | 69 |
Made extra phone calls to practice | 36 |
Had to get a different medication | 36 |
Had extra doctor visits | 13 |
Overall any increased burden | 83 |
*Patients reported, on average, 2.9 problems; therefore, categories exceed 100%. |
Forty-one percent of patients reporting a problem experienced adverse medical outcomes. The most serious adverse medical outcomes were reported least often, but occurred nonetheless: worsening of medical condition (8%), new medication adverse effects (6%), and requiring a visit to the ED (5%). More commonly reported was decreased satisfaction with the health care system (68%). Patients were less likely to report being upset with their physician than their insurance company or pharmacist. Problems that burdened the physician practice were reported most frequently (83%).
TABLE 3 shows the medication categories that were affected when respondents reported at least one problem. Formulary changes or restrictions involving cardiac/hypertension/lipid and neurologic/psychiatric medications were linked to the most problems.
TABLE 3
Which medication categories were most affected when patients had a problem filling a prescription?
Medication category | Frequency of occurrence |
---|---|
Cardiac/HTN/lipids | 23 |
Neurologic/psychiatric | 23 |
Metabolic/endocrine | 16 |
Gastrointestinal | 15 |
Pain | 13 |
Respiratory | 11 |
Other | 9 |
Dermatologic | 7 |
Total | 117* |
HTN, hypertension. *Total exceeds 100 because some of the 100 patients had problems with medications in more than one category. |
Discussion
Nearly one quarter of patients in our sample (23%) experienced problems caused by insurance constraints while they attempted to follow the treatment regimens prescribed by their physicians. Although the most commonly reported insurance-related problems (waiting for pharmacist authorization, making extra phone calls to the physician’s office) could be perceived as minor inconveniences, serious consequences were also common. Our study showed that patients who rely solely on Medicaid or Medicare bore the greatest burden of insurance-related obstacles when filling prescriptions, although others were also affected.
Consistent with prior research in Medicare and Medicaid populations, our study found that medication access restrictions can negatively affect patient adherence.13,16,17 Our study showed that 41% of patients who encountered a problem experienced a medically meaningful adverse outcome; 19% reported they received no medication for their condition. Similarly, a study of Medicare beneficiaries who had failed to fill or refill a prescription found that 20% cited lack of insurance coverage for the medication as a reason for not filling the prescription.17
In our study, 23% of patients reported missing doses of their medication due to insurance-related difficulties, and 8% reported a worsening of their medical condition. The increased costs associated with poor chronic care management are well documented.18 Less well described is the potential net savings produced when insurance formularies are adjusted to expand coverage and lower patient costs for prescription treatments for chronic conditions. In an analysis of cost data from the Pitney-Bowes Corporation, Mahoney12 revealed a significant net savings in health care costs and lost productivity when treatments for chronic conditions were moved to the lowest tier of the formulary, thereby making them available to health plan participants at the lowest cost.
We could not link patient reports of treatment disruptions empirically to medical outcomes or increased costs, due to the constraints of our research question and study design. However, it is reasonable to suggest that longer-term insurance costs for these patients could, in fact, negate any short-term cost savings generated from formulary restrictions. In particular, the 5% of our patient sample who reported using the ED as a consequence of an insurance-related disruption of their prescribed treatment likely added significant unnecessary cost to their treatment. This effect has been seen in other studies.19,20 In our study, cardiac/hypertension/lipid medications and medications for neurologic or psychiatric conditions were the most likely to be problematic. In these categories, competition of branded products may contribute to more frequent formulary changes. Furthermore, increases in morbidity and mortality associated with inadequate treatment of the conditions represented in these 2 categories of medications represent a significant burden to the US health system, including insurers, employers, and individuals.21-23
Although patients were less likely to report being upset with their physician than their insurance company or pharmacist, physicians bore a considerable burden for resolving a number of prevalent patient issues. Most of these problems required extra phone calls to the practice, additional medication authorization, or extra office visits. Physicians and their support staff may serve as buffers between patients and the insurance formulary rules, but at significant cost in their time and effort.
Electronic prescribing systems with real-time pharmacy benefit verification may provide additional efficiencies and help physicians and patients avoid some of the problems cited by our respondents. Providers with such systems receive immediate notification of formulary status, including tier and co-pay levels, which can aid in shared decision-making at the point of prescribing. Physicians without access to e-prescribing may want to use newer formulary search engines that can check formulary status of medications across multiple insurance plans. However, these electronic tools often fail to account for variations in formularies within the same insurance plan for different employers based on their benefit structure. Still, when a medication is not on formulary or a co-payment is required, the physician may be forced to play the role of apologist for the constraints imposed by the insurance formulary.
In cases where formularies restrict the patient’s potential access to a preferred treatment plan, the burden of prior authorizations continues to be borne by physicians. Coverage limitations lead to financial and medical consequences that must be managed in partnership with the patient. A system should be put in place by insurance companies that facilitates out-of-formulary authorizations to prevent lapses in patient care or deleterious changes in medical management.
Study limitations
The findings reported here should be interpreted in light of some limitations of this study. The response rate to our mailed patient survey was modest (36%), although typical for this method. The sex mix of respondents was similar to that of nonrespondents, but nonrespondents were slightly younger. Given that younger age is associated with a greater likelihood of experiencing a problem filling a medication, our findings may underestimate the frequency of this dilemma. In addition, our survey asked patients to recall events that occurred over the past year, introducing a potential for recall bias.
While the overall sample size was relatively small (n=428), it is close to the number calculated for sufficient power to conduct the analyses (n=480). Furthermore, data were collected from 3 distinct patient populations: urban, suburban and semirural. Although the scope of our study included only one geographic region, variability in practice setting lends some tentative support to the generalizability of the findings.
Looking forward
As a standard method to control costs and update treatment guidelines, insurance-mediated medication changes will continue to present unique challenges for patients and health care providers. Formulary changes burden the downstream delivery of medical care with expensive administrative responsibilities and disrupt effective disease management and prevention. Until insurance companies and pharmacy benefit managers start paying heed to total costs of care when contemplating formulary changes, physicians should try to identify formulary conflicts as early as possible in the prescribing process so as to save time for all parties later and improve compliance.
As practices proceed toward adoption of electronic health records, e-prescribing, and the Centers for Medicare & Medicaid Services’ “meaningful use” criteria, physicians may use systems that provide real-time formulary information, which can flag issues before the patient leaves the exam room. Future research should explore the ways formulary changes might be implemented to provide the strongest continuity of patient care with the least amount of cost shifting.
CORRESPONDENCE
Susan A. Flocke, PhD, CWRU Department of Family Medicine & Community Health, 11000 Cedar Avenue, Suite 402, Cleveland, OH 44106; [email protected]
1. Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion. Chronic diseases: the power to prevent, the call to control: at a glance 2009. Available at: http://www.cdc.gov/chronicdisease/resources/publications/aag/chronic.htm. Page last updated December 17, 2009. Accessed June 21, 2012.
2. Mueller C, Schur C, O’Connell J. Prescription drug spending: the impact of age and chronic disease status. Am J Public Health. 1997;87:1626-1629.
3. Kaiser Family Foundation. Prescription drug trends. Available at: http://www.kff.org/rxdrugs/upload/3057_07.pdf. Published September 2008. Accessed December 1, 2009.
4. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood). 2004;23:124-134.
5. Simon GE, Psaty BM, Hrachovec JB, et al. Principles for evidence-based drug formulary policy. J Gen Intern Med. 2005;20:964-968.
6. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
7. Meissner B, Dickson M, Shinogle J, et al. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. J Manag Care Pharm. 2006;12:331-340.
8. Ovsag K, Hydery S, Mousa SA. Preferred drug lists: potential impact on healthcare economics. Vasc Health Risk Manag. 2008;4:403-413.
9. Raisch DW, Klaurens LM, Hayden C, et al. Impact of a formulary change in proton pump inhibitors on health care costs and patients’ symptoms. Dig Dis Sci. 2001;46:1533-1539.
10. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23:135-146.
11. Johnson TJ, Stahl-Moncada S. Medicaid prescription formulary restrictions and arthritis treatment costs. Am J Public Health. 2008;98:1300-1305.
12. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 suppl):S170-S176.
13. Ridley DB, Axelsen KJ. Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics. 2006;24 (suppl 3):65-78.
14. Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med. 2001;16:793-799.
15. Jean CD, Triplett JW. Investigating patient experiences after a formulary change. Am J Health Syst Pharm. 2000;57:1052-1054.
16. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care. 2005;11 (spec no):SP27-SP34.
17. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm. 2008;14:553-560.
18. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26:38-48.
19. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
20. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
21. Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface. 2002;15:28-36.
22. Hall RC, Wise MG. The clinical and financial burden of mood disorders. Cost and outcome. Psychosomatics. 1995;36:S11-S18.
23. McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994;32:214-226.
1. Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion. Chronic diseases: the power to prevent, the call to control: at a glance 2009. Available at: http://www.cdc.gov/chronicdisease/resources/publications/aag/chronic.htm. Page last updated December 17, 2009. Accessed June 21, 2012.
2. Mueller C, Schur C, O’Connell J. Prescription drug spending: the impact of age and chronic disease status. Am J Public Health. 1997;87:1626-1629.
3. Kaiser Family Foundation. Prescription drug trends. Available at: http://www.kff.org/rxdrugs/upload/3057_07.pdf. Published September 2008. Accessed December 1, 2009.
4. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood). 2004;23:124-134.
5. Simon GE, Psaty BM, Hrachovec JB, et al. Principles for evidence-based drug formulary policy. J Gen Intern Med. 2005;20:964-968.
6. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
7. Meissner B, Dickson M, Shinogle J, et al. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. J Manag Care Pharm. 2006;12:331-340.
8. Ovsag K, Hydery S, Mousa SA. Preferred drug lists: potential impact on healthcare economics. Vasc Health Risk Manag. 2008;4:403-413.
9. Raisch DW, Klaurens LM, Hayden C, et al. Impact of a formulary change in proton pump inhibitors on health care costs and patients’ symptoms. Dig Dis Sci. 2001;46:1533-1539.
10. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23:135-146.
11. Johnson TJ, Stahl-Moncada S. Medicaid prescription formulary restrictions and arthritis treatment costs. Am J Public Health. 2008;98:1300-1305.
12. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 suppl):S170-S176.
13. Ridley DB, Axelsen KJ. Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics. 2006;24 (suppl 3):65-78.
14. Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med. 2001;16:793-799.
15. Jean CD, Triplett JW. Investigating patient experiences after a formulary change. Am J Health Syst Pharm. 2000;57:1052-1054.
16. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care. 2005;11 (spec no):SP27-SP34.
17. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm. 2008;14:553-560.
18. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26:38-48.
19. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
20. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
21. Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface. 2002;15:28-36.
22. Hall RC, Wise MG. The clinical and financial burden of mood disorders. Cost and outcome. Psychosomatics. 1995;36:S11-S18.
23. McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994;32:214-226.
Suicide rehearsals: A high-risk psychiatric emergency
A suicide rehearsal is a behavioral enactment of a suicide method, usually as part of a suicide plan. A mental suicide rehearsal is a process that evolves over time into a plan. Patients who are intent on attempting suicide usually do not reveal their plans. However, behavioral rehearsals display specific clinical characteristics that speak louder than the guarded patient’s denials, revealing the patient’s suicide plan (Table).
Suicide rehearsals may precede suicide attempts or suicide completions. The percentage of patients who stage suicide rehearsals before attempting or completing suicide is unknown; however, in my experience, suicide rehearsals are relatively common. This article describes suicide rehearsals, and offers 4 cases that illustrate what clinicians can learn from rehearsals to improve their patients’ safety.
Table
Clinical characteristics of suicide rehearsals
Guarded patient |
Behavioral enactment of a suicide method |
Lethal means |
Presumptive acute, high risk of suicide |
Severe mental illness |
Suicide attempt often within hours or days |
Rehearsal usually covert |
Rehearsal event or multiple events |
The psychology behind suicide rehearsals
Rehearsing suicidal behavior can lower the barrier to a suicide plan, thereby increasing a patient’s resolve and risk. Joiner1 notes that engaging in behavioral or mental suicide rehearsals increases the risk of suicide. Moreover, rehearsals diminish the prohibition against suicidal behavior and the fear of pain and dying. Examples of rehearsal psychology include:
- overcoming ambivalence about dying
- desensitizing anxiety about performing the suicide act
- testing or “perfecting” the method of a planned suicide
- firming one’s resolve to complete suicide.
Other non-lethal motivations include “a cry for help” and self-injurious behaviors motivated by external gains. Patients who do not intend to attempt suicide may openly rehearse low-risk methods, such as superficial cutting.
Rehearsal characteristics
Suicide rehearsals can be confused with aborted, interrupted, or failed suicide attempts. Suicide rehearsals usually are associated with severe psychiatric illness and high-risk lethal methods of attempting suicide. My experience is that suicide attempts or suicide completions often follow a rehearsal within a few hours or days. However, no short-term suicide risk factors—within hours, days, or weeks—can predict when or if a rehearsed suicide will proceed to a suicide attempt.2
A suicide rehearsal is presumptive evidence that the patient is at acute, high risk for suicide and immediate clinical intervention is necessary. A rehearsal allows the clinician to explore the various methods of suicide that the patient has considered, including prior rehearsals. Knowledge of prior rehearsals can inform the clinician’s management of the current suicide rehearsal.
Suicide rehearsals often are conducted covertly. On inpatient psychiatric units, the rehearsal usually is discovered by staff members or reported by other patients. In outpatient settings, the patient or a significant other may report a rehearsal.
The suicide method displayed in a rehearsal may change. A patient who is rehearsing a hanging may attempt suicide by overdose or a firearm. In a systematic review of prior suicide attempts (N = 1,397), Isometsä et al3 found that 82% of patients used 2 or more different methods in suicide attempts, including the completed suicide. However, in a cohort study of 48,649 individuals admitted to a hospital after an attempted suicide, Runeson et al4 found that patients who attempt suicide often used the same method in completed suicide (ie, >90% by hanging for both men and women). Therefore, when taking measures to restrict the patient’s access to lethal means, safety efforts should not be limited to the method used in the suicide rehearsal. Patients can always substitute methods.
Making overall preparations for suicide—for example, making a will, giving away valuable possessions, or putting financial affairs in order—could be confused with a suicide rehearsal, which displays the lethal method to be used in a suicide attempt, often after preparations are made. Suicide rehearsals tend to occur much closer in time to the suicide attempt than preparations for suicide. Similarly, a patient’s plan to hoard drugs for a suicide attempt is not the same as ingesting a sub-lethal dose of a drug to test his or her resolve to die.
By definition, impulsive suicide attempts are not rehearsed. However, an individual’s suicide rehearsal can impulsively segue into a suicide attempt. In a case control study (N = 153) Simon et al5 found that 24% of patients spent 6 found that 26% of individuals with lifetime suicide ideation transitioned from suicide ideation to an unplanned suicide attempt. In my experience, a suicide rehearsal before a suicide completion is presumptive evidence against an impulsive suicide.
Patients contemplating suicide may visit Web sites with instructions on “how to suicide,” providing “virtual” opportunities to rehearse suicide.7 Patients who are at risk for suicide should be asked if they have searched the Internet for suicide methodology.
What we can learn from rehearsals
Although the following case examples are fictional, they illustrate suicide rehearsals encountered in my clinical and forensic practice.
CASE 1: Looking for a location
Ms. B, a 28-year-old divorced mother of 2, is observed tarrying at the high point of a bridge on successive days. When police arrive and question her, she becomes agitated and distraught. Ms. B admits to “scoping out” the bridge and is taken to a hospital emergency room (ER). In the ER, Ms. B discloses, “I was looking for a good spot to jump.” She tells the triage nurse that she is very depressed but, “I couldn’t do it to my children.” Ms. B is placed in an unlocked room while she waits to be assessed by a psychiatrist. She leaves the ER, runs to a nearby parking garage, and jumps from the top level to her death.
Comment: A patient’s denial of suicide intent following a suicide rehearsal cannot be relied upon. Ms. B’s rehearsal revealed a plan with high-risk suicide intent and a lethal suicide method. Systematic suicide assessment that informs immediate clinical intervention is required.
CASE 2: Changing lethal means
Mr. N, a 43-year-old chief executive officer of a large company, is observed by an assistant loading and unloading a revolver at his desk. Alarmed, the assistant calls the company physician. Mr. N refuses psychiatric treatment, saying, “I’ll be all right; this is just a passing thing.” His wife tells the physician that her husband has a history of bipolar disorder but no prior suicide attempts. Guns and ammunition are removed from the home. One week later, Mr. N is found hanging in his garage. A loaded pistol is discovered in the glove compartment of his car.
Comment: There is no certainty that a subsequent suicide attempt will replicate the rehearsed method. A psychological autopsy was conducted, but no explanation was found for why Mr. N chose hanging after having rehearsed suicide with a loaded handgun. His wife thought that her husband, a very tidy person, did not want to leave a mess.
CASE 3: Grieving and depressed
Mr. O, age 67, is depressed after recently losing his wife. He considers a number of suicide methods. Mr. O decides to use a plastic bag to suffocate himself because he believes that this method will allow him to change his mind. Mr. O practices tying the bag tight around his neck. During this rehearsal, he realizes that he does not want to die. Instead, he pursues grief counseling.
Comment: For some patients, the act of rehearsing suicide can help them resolve ambivalent feelings about wanting to die in favor of wanting to live.
CASE 4: Suicide method and the Internet
Ms. S, a 22-year-old college student, is undergoing outpatient treatment for depression. She is accumulating prescription drugs to take as an overdose. Ms. S also searches the Internet for information about other suicide methods. Because she wants a “sure” method of suicide, she persuades an acquaintance to purchase a handgun. In private, Ms. S places the unloaded gun to her head and plays “Russian roulette,” pulling the trigger several times. Her mother discovers the gun and confronts her daughter. Ms. S is hospitalized on a closed psychiatric unit and tells a staff member, “I was practicing suicide with the gun.” Before Ms. S is discharged from the hospital, her parents are advised to watch for suicidal behaviors, especially the recurrence of rehearsals that indicate an acute, high suicide risk. Ms. S’s Internet use is restricted and monitored.
Comment: Suicide rehearsal with a gun reinforces the belief that a firearm death is quick and easy.8 Reaching for a loaded gun takes less time than most other methods of suicide. Patients who rehearse suicide with a gun should be prevented from having access to any firearms, weapons, or other highly lethal means of suicide.
Recognition and intervention
A guarded psychiatric inpatient who is intent on attempting suicide is unmasked when the discovery of a suicidal rehearsal reveals a suicide plan. This creates an opportunity for clinicians to intervene. The patient may attempt to cover up suicidal intent by stating, “I was just playing around” or “I just wanted to get attention.” Recognizing the emergency posed by a suicide rehearsal informs treatment. Safety measures—including 1-to-1 supervision—may be necessary during a period of acute, high suicide risk. The patient’s diagnosis, severity of illness, and treatment require reevaluation.
An outpatient who performs a suicide rehearsal should be considered at acute, high risk for suicide, and immediate psychiatric hospitalization may be necessary. Whether as an inpatient or outpatient, the patient’s suicide intent and plan require careful exploration. The information gained will guide treatment and management decisions. Continuing systematic suicide risk assessment is essential.
Related Resources
- American Association of Suicidology. www.suicidology.org.
- Joiner T. Why people die by suicide. Cambridge, MA: Harvard University Press; 2007.
- American Psychiatric Association. Practice guideline for the assessment and treatment of patients with suicidal behaviors. Washington, DC: American Psychiatric Publishing, Inc. 2003.
- Simon RI. Preventing patient suicide: clinical assessment and management. Arlington, VA: American Psychiatric Publishing, Inc.; 2011.
Disclosure
Dr. Simon reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Joiner TE, Jr. The trajectory of suicidal behavior over time. Suicide Life Threat Behav. 2002;32(1):33-41.
2. Simon RI. Imminent suicide: the illusion of short-term prediction. Suicide Life Threat Behav. 2006;36(3):296-301.
3. Isometsä ET, Lönnqvist JK. Suicide attempts preceding completed suicide. Br J Psychiatry. 1998;173:531-535.
4. Runeson B, Tidemalm D, Dahlin M, et al. Method of attempted suicide as a predictor of subsequent successful suicide: national long-term cohort study. BMJ. 2010;341:c3222. doi:10.1136/bmj.63222.
5. Simon TR, Swann AC, Powell KE, et al. Characteristics of impulsive suicide attempts and attempters. Suicide Life Threat Behav. 2001;32(suppl):49-59.
6. Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Study. Arch Gen Psychiatry. 1999;56(7):617-626.
7. Recupero PR. Suicide and the Internet. In: Simon RI Hales RE, eds. The American Psychiatric Publishing textbook of suicide assessment and management. 2nd ed. Arlington, VA: American Psychiatric Publishing, Inc.; 2012:515–538.
8. Simon RI. Gun safety management with patients at risk for suicide. Suicide Life Threat Behav. 2007;37(5):518-526.
A suicide rehearsal is a behavioral enactment of a suicide method, usually as part of a suicide plan. A mental suicide rehearsal is a process that evolves over time into a plan. Patients who are intent on attempting suicide usually do not reveal their plans. However, behavioral rehearsals display specific clinical characteristics that speak louder than the guarded patient’s denials, revealing the patient’s suicide plan (Table).
Suicide rehearsals may precede suicide attempts or suicide completions. The percentage of patients who stage suicide rehearsals before attempting or completing suicide is unknown; however, in my experience, suicide rehearsals are relatively common. This article describes suicide rehearsals, and offers 4 cases that illustrate what clinicians can learn from rehearsals to improve their patients’ safety.
Table
Clinical characteristics of suicide rehearsals
Guarded patient |
Behavioral enactment of a suicide method |
Lethal means |
Presumptive acute, high risk of suicide |
Severe mental illness |
Suicide attempt often within hours or days |
Rehearsal usually covert |
Rehearsal event or multiple events |
The psychology behind suicide rehearsals
Rehearsing suicidal behavior can lower the barrier to a suicide plan, thereby increasing a patient’s resolve and risk. Joiner1 notes that engaging in behavioral or mental suicide rehearsals increases the risk of suicide. Moreover, rehearsals diminish the prohibition against suicidal behavior and the fear of pain and dying. Examples of rehearsal psychology include:
- overcoming ambivalence about dying
- desensitizing anxiety about performing the suicide act
- testing or “perfecting” the method of a planned suicide
- firming one’s resolve to complete suicide.
Other non-lethal motivations include “a cry for help” and self-injurious behaviors motivated by external gains. Patients who do not intend to attempt suicide may openly rehearse low-risk methods, such as superficial cutting.
Rehearsal characteristics
Suicide rehearsals can be confused with aborted, interrupted, or failed suicide attempts. Suicide rehearsals usually are associated with severe psychiatric illness and high-risk lethal methods of attempting suicide. My experience is that suicide attempts or suicide completions often follow a rehearsal within a few hours or days. However, no short-term suicide risk factors—within hours, days, or weeks—can predict when or if a rehearsed suicide will proceed to a suicide attempt.2
A suicide rehearsal is presumptive evidence that the patient is at acute, high risk for suicide and immediate clinical intervention is necessary. A rehearsal allows the clinician to explore the various methods of suicide that the patient has considered, including prior rehearsals. Knowledge of prior rehearsals can inform the clinician’s management of the current suicide rehearsal.
Suicide rehearsals often are conducted covertly. On inpatient psychiatric units, the rehearsal usually is discovered by staff members or reported by other patients. In outpatient settings, the patient or a significant other may report a rehearsal.
The suicide method displayed in a rehearsal may change. A patient who is rehearsing a hanging may attempt suicide by overdose or a firearm. In a systematic review of prior suicide attempts (N = 1,397), Isometsä et al3 found that 82% of patients used 2 or more different methods in suicide attempts, including the completed suicide. However, in a cohort study of 48,649 individuals admitted to a hospital after an attempted suicide, Runeson et al4 found that patients who attempt suicide often used the same method in completed suicide (ie, >90% by hanging for both men and women). Therefore, when taking measures to restrict the patient’s access to lethal means, safety efforts should not be limited to the method used in the suicide rehearsal. Patients can always substitute methods.
Making overall preparations for suicide—for example, making a will, giving away valuable possessions, or putting financial affairs in order—could be confused with a suicide rehearsal, which displays the lethal method to be used in a suicide attempt, often after preparations are made. Suicide rehearsals tend to occur much closer in time to the suicide attempt than preparations for suicide. Similarly, a patient’s plan to hoard drugs for a suicide attempt is not the same as ingesting a sub-lethal dose of a drug to test his or her resolve to die.
By definition, impulsive suicide attempts are not rehearsed. However, an individual’s suicide rehearsal can impulsively segue into a suicide attempt. In a case control study (N = 153) Simon et al5 found that 24% of patients spent 6 found that 26% of individuals with lifetime suicide ideation transitioned from suicide ideation to an unplanned suicide attempt. In my experience, a suicide rehearsal before a suicide completion is presumptive evidence against an impulsive suicide.
Patients contemplating suicide may visit Web sites with instructions on “how to suicide,” providing “virtual” opportunities to rehearse suicide.7 Patients who are at risk for suicide should be asked if they have searched the Internet for suicide methodology.
What we can learn from rehearsals
Although the following case examples are fictional, they illustrate suicide rehearsals encountered in my clinical and forensic practice.
CASE 1: Looking for a location
Ms. B, a 28-year-old divorced mother of 2, is observed tarrying at the high point of a bridge on successive days. When police arrive and question her, she becomes agitated and distraught. Ms. B admits to “scoping out” the bridge and is taken to a hospital emergency room (ER). In the ER, Ms. B discloses, “I was looking for a good spot to jump.” She tells the triage nurse that she is very depressed but, “I couldn’t do it to my children.” Ms. B is placed in an unlocked room while she waits to be assessed by a psychiatrist. She leaves the ER, runs to a nearby parking garage, and jumps from the top level to her death.
Comment: A patient’s denial of suicide intent following a suicide rehearsal cannot be relied upon. Ms. B’s rehearsal revealed a plan with high-risk suicide intent and a lethal suicide method. Systematic suicide assessment that informs immediate clinical intervention is required.
CASE 2: Changing lethal means
Mr. N, a 43-year-old chief executive officer of a large company, is observed by an assistant loading and unloading a revolver at his desk. Alarmed, the assistant calls the company physician. Mr. N refuses psychiatric treatment, saying, “I’ll be all right; this is just a passing thing.” His wife tells the physician that her husband has a history of bipolar disorder but no prior suicide attempts. Guns and ammunition are removed from the home. One week later, Mr. N is found hanging in his garage. A loaded pistol is discovered in the glove compartment of his car.
Comment: There is no certainty that a subsequent suicide attempt will replicate the rehearsed method. A psychological autopsy was conducted, but no explanation was found for why Mr. N chose hanging after having rehearsed suicide with a loaded handgun. His wife thought that her husband, a very tidy person, did not want to leave a mess.
CASE 3: Grieving and depressed
Mr. O, age 67, is depressed after recently losing his wife. He considers a number of suicide methods. Mr. O decides to use a plastic bag to suffocate himself because he believes that this method will allow him to change his mind. Mr. O practices tying the bag tight around his neck. During this rehearsal, he realizes that he does not want to die. Instead, he pursues grief counseling.
Comment: For some patients, the act of rehearsing suicide can help them resolve ambivalent feelings about wanting to die in favor of wanting to live.
CASE 4: Suicide method and the Internet
Ms. S, a 22-year-old college student, is undergoing outpatient treatment for depression. She is accumulating prescription drugs to take as an overdose. Ms. S also searches the Internet for information about other suicide methods. Because she wants a “sure” method of suicide, she persuades an acquaintance to purchase a handgun. In private, Ms. S places the unloaded gun to her head and plays “Russian roulette,” pulling the trigger several times. Her mother discovers the gun and confronts her daughter. Ms. S is hospitalized on a closed psychiatric unit and tells a staff member, “I was practicing suicide with the gun.” Before Ms. S is discharged from the hospital, her parents are advised to watch for suicidal behaviors, especially the recurrence of rehearsals that indicate an acute, high suicide risk. Ms. S’s Internet use is restricted and monitored.
Comment: Suicide rehearsal with a gun reinforces the belief that a firearm death is quick and easy.8 Reaching for a loaded gun takes less time than most other methods of suicide. Patients who rehearse suicide with a gun should be prevented from having access to any firearms, weapons, or other highly lethal means of suicide.
Recognition and intervention
A guarded psychiatric inpatient who is intent on attempting suicide is unmasked when the discovery of a suicidal rehearsal reveals a suicide plan. This creates an opportunity for clinicians to intervene. The patient may attempt to cover up suicidal intent by stating, “I was just playing around” or “I just wanted to get attention.” Recognizing the emergency posed by a suicide rehearsal informs treatment. Safety measures—including 1-to-1 supervision—may be necessary during a period of acute, high suicide risk. The patient’s diagnosis, severity of illness, and treatment require reevaluation.
An outpatient who performs a suicide rehearsal should be considered at acute, high risk for suicide, and immediate psychiatric hospitalization may be necessary. Whether as an inpatient or outpatient, the patient’s suicide intent and plan require careful exploration. The information gained will guide treatment and management decisions. Continuing systematic suicide risk assessment is essential.
Related Resources
- American Association of Suicidology. www.suicidology.org.
- Joiner T. Why people die by suicide. Cambridge, MA: Harvard University Press; 2007.
- American Psychiatric Association. Practice guideline for the assessment and treatment of patients with suicidal behaviors. Washington, DC: American Psychiatric Publishing, Inc. 2003.
- Simon RI. Preventing patient suicide: clinical assessment and management. Arlington, VA: American Psychiatric Publishing, Inc.; 2011.
Disclosure
Dr. Simon reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
A suicide rehearsal is a behavioral enactment of a suicide method, usually as part of a suicide plan. A mental suicide rehearsal is a process that evolves over time into a plan. Patients who are intent on attempting suicide usually do not reveal their plans. However, behavioral rehearsals display specific clinical characteristics that speak louder than the guarded patient’s denials, revealing the patient’s suicide plan (Table).
Suicide rehearsals may precede suicide attempts or suicide completions. The percentage of patients who stage suicide rehearsals before attempting or completing suicide is unknown; however, in my experience, suicide rehearsals are relatively common. This article describes suicide rehearsals, and offers 4 cases that illustrate what clinicians can learn from rehearsals to improve their patients’ safety.
Table
Clinical characteristics of suicide rehearsals
Guarded patient |
Behavioral enactment of a suicide method |
Lethal means |
Presumptive acute, high risk of suicide |
Severe mental illness |
Suicide attempt often within hours or days |
Rehearsal usually covert |
Rehearsal event or multiple events |
The psychology behind suicide rehearsals
Rehearsing suicidal behavior can lower the barrier to a suicide plan, thereby increasing a patient’s resolve and risk. Joiner1 notes that engaging in behavioral or mental suicide rehearsals increases the risk of suicide. Moreover, rehearsals diminish the prohibition against suicidal behavior and the fear of pain and dying. Examples of rehearsal psychology include:
- overcoming ambivalence about dying
- desensitizing anxiety about performing the suicide act
- testing or “perfecting” the method of a planned suicide
- firming one’s resolve to complete suicide.
Other non-lethal motivations include “a cry for help” and self-injurious behaviors motivated by external gains. Patients who do not intend to attempt suicide may openly rehearse low-risk methods, such as superficial cutting.
Rehearsal characteristics
Suicide rehearsals can be confused with aborted, interrupted, or failed suicide attempts. Suicide rehearsals usually are associated with severe psychiatric illness and high-risk lethal methods of attempting suicide. My experience is that suicide attempts or suicide completions often follow a rehearsal within a few hours or days. However, no short-term suicide risk factors—within hours, days, or weeks—can predict when or if a rehearsed suicide will proceed to a suicide attempt.2
A suicide rehearsal is presumptive evidence that the patient is at acute, high risk for suicide and immediate clinical intervention is necessary. A rehearsal allows the clinician to explore the various methods of suicide that the patient has considered, including prior rehearsals. Knowledge of prior rehearsals can inform the clinician’s management of the current suicide rehearsal.
Suicide rehearsals often are conducted covertly. On inpatient psychiatric units, the rehearsal usually is discovered by staff members or reported by other patients. In outpatient settings, the patient or a significant other may report a rehearsal.
The suicide method displayed in a rehearsal may change. A patient who is rehearsing a hanging may attempt suicide by overdose or a firearm. In a systematic review of prior suicide attempts (N = 1,397), Isometsä et al3 found that 82% of patients used 2 or more different methods in suicide attempts, including the completed suicide. However, in a cohort study of 48,649 individuals admitted to a hospital after an attempted suicide, Runeson et al4 found that patients who attempt suicide often used the same method in completed suicide (ie, >90% by hanging for both men and women). Therefore, when taking measures to restrict the patient’s access to lethal means, safety efforts should not be limited to the method used in the suicide rehearsal. Patients can always substitute methods.
Making overall preparations for suicide—for example, making a will, giving away valuable possessions, or putting financial affairs in order—could be confused with a suicide rehearsal, which displays the lethal method to be used in a suicide attempt, often after preparations are made. Suicide rehearsals tend to occur much closer in time to the suicide attempt than preparations for suicide. Similarly, a patient’s plan to hoard drugs for a suicide attempt is not the same as ingesting a sub-lethal dose of a drug to test his or her resolve to die.
By definition, impulsive suicide attempts are not rehearsed. However, an individual’s suicide rehearsal can impulsively segue into a suicide attempt. In a case control study (N = 153) Simon et al5 found that 24% of patients spent 6 found that 26% of individuals with lifetime suicide ideation transitioned from suicide ideation to an unplanned suicide attempt. In my experience, a suicide rehearsal before a suicide completion is presumptive evidence against an impulsive suicide.
Patients contemplating suicide may visit Web sites with instructions on “how to suicide,” providing “virtual” opportunities to rehearse suicide.7 Patients who are at risk for suicide should be asked if they have searched the Internet for suicide methodology.
What we can learn from rehearsals
Although the following case examples are fictional, they illustrate suicide rehearsals encountered in my clinical and forensic practice.
CASE 1: Looking for a location
Ms. B, a 28-year-old divorced mother of 2, is observed tarrying at the high point of a bridge on successive days. When police arrive and question her, she becomes agitated and distraught. Ms. B admits to “scoping out” the bridge and is taken to a hospital emergency room (ER). In the ER, Ms. B discloses, “I was looking for a good spot to jump.” She tells the triage nurse that she is very depressed but, “I couldn’t do it to my children.” Ms. B is placed in an unlocked room while she waits to be assessed by a psychiatrist. She leaves the ER, runs to a nearby parking garage, and jumps from the top level to her death.
Comment: A patient’s denial of suicide intent following a suicide rehearsal cannot be relied upon. Ms. B’s rehearsal revealed a plan with high-risk suicide intent and a lethal suicide method. Systematic suicide assessment that informs immediate clinical intervention is required.
CASE 2: Changing lethal means
Mr. N, a 43-year-old chief executive officer of a large company, is observed by an assistant loading and unloading a revolver at his desk. Alarmed, the assistant calls the company physician. Mr. N refuses psychiatric treatment, saying, “I’ll be all right; this is just a passing thing.” His wife tells the physician that her husband has a history of bipolar disorder but no prior suicide attempts. Guns and ammunition are removed from the home. One week later, Mr. N is found hanging in his garage. A loaded pistol is discovered in the glove compartment of his car.
Comment: There is no certainty that a subsequent suicide attempt will replicate the rehearsed method. A psychological autopsy was conducted, but no explanation was found for why Mr. N chose hanging after having rehearsed suicide with a loaded handgun. His wife thought that her husband, a very tidy person, did not want to leave a mess.
CASE 3: Grieving and depressed
Mr. O, age 67, is depressed after recently losing his wife. He considers a number of suicide methods. Mr. O decides to use a plastic bag to suffocate himself because he believes that this method will allow him to change his mind. Mr. O practices tying the bag tight around his neck. During this rehearsal, he realizes that he does not want to die. Instead, he pursues grief counseling.
Comment: For some patients, the act of rehearsing suicide can help them resolve ambivalent feelings about wanting to die in favor of wanting to live.
CASE 4: Suicide method and the Internet
Ms. S, a 22-year-old college student, is undergoing outpatient treatment for depression. She is accumulating prescription drugs to take as an overdose. Ms. S also searches the Internet for information about other suicide methods. Because she wants a “sure” method of suicide, she persuades an acquaintance to purchase a handgun. In private, Ms. S places the unloaded gun to her head and plays “Russian roulette,” pulling the trigger several times. Her mother discovers the gun and confronts her daughter. Ms. S is hospitalized on a closed psychiatric unit and tells a staff member, “I was practicing suicide with the gun.” Before Ms. S is discharged from the hospital, her parents are advised to watch for suicidal behaviors, especially the recurrence of rehearsals that indicate an acute, high suicide risk. Ms. S’s Internet use is restricted and monitored.
Comment: Suicide rehearsal with a gun reinforces the belief that a firearm death is quick and easy.8 Reaching for a loaded gun takes less time than most other methods of suicide. Patients who rehearse suicide with a gun should be prevented from having access to any firearms, weapons, or other highly lethal means of suicide.
Recognition and intervention
A guarded psychiatric inpatient who is intent on attempting suicide is unmasked when the discovery of a suicidal rehearsal reveals a suicide plan. This creates an opportunity for clinicians to intervene. The patient may attempt to cover up suicidal intent by stating, “I was just playing around” or “I just wanted to get attention.” Recognizing the emergency posed by a suicide rehearsal informs treatment. Safety measures—including 1-to-1 supervision—may be necessary during a period of acute, high suicide risk. The patient’s diagnosis, severity of illness, and treatment require reevaluation.
An outpatient who performs a suicide rehearsal should be considered at acute, high risk for suicide, and immediate psychiatric hospitalization may be necessary. Whether as an inpatient or outpatient, the patient’s suicide intent and plan require careful exploration. The information gained will guide treatment and management decisions. Continuing systematic suicide risk assessment is essential.
Related Resources
- American Association of Suicidology. www.suicidology.org.
- Joiner T. Why people die by suicide. Cambridge, MA: Harvard University Press; 2007.
- American Psychiatric Association. Practice guideline for the assessment and treatment of patients with suicidal behaviors. Washington, DC: American Psychiatric Publishing, Inc. 2003.
- Simon RI. Preventing patient suicide: clinical assessment and management. Arlington, VA: American Psychiatric Publishing, Inc.; 2011.
Disclosure
Dr. Simon reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Joiner TE, Jr. The trajectory of suicidal behavior over time. Suicide Life Threat Behav. 2002;32(1):33-41.
2. Simon RI. Imminent suicide: the illusion of short-term prediction. Suicide Life Threat Behav. 2006;36(3):296-301.
3. Isometsä ET, Lönnqvist JK. Suicide attempts preceding completed suicide. Br J Psychiatry. 1998;173:531-535.
4. Runeson B, Tidemalm D, Dahlin M, et al. Method of attempted suicide as a predictor of subsequent successful suicide: national long-term cohort study. BMJ. 2010;341:c3222. doi:10.1136/bmj.63222.
5. Simon TR, Swann AC, Powell KE, et al. Characteristics of impulsive suicide attempts and attempters. Suicide Life Threat Behav. 2001;32(suppl):49-59.
6. Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Study. Arch Gen Psychiatry. 1999;56(7):617-626.
7. Recupero PR. Suicide and the Internet. In: Simon RI Hales RE, eds. The American Psychiatric Publishing textbook of suicide assessment and management. 2nd ed. Arlington, VA: American Psychiatric Publishing, Inc.; 2012:515–538.
8. Simon RI. Gun safety management with patients at risk for suicide. Suicide Life Threat Behav. 2007;37(5):518-526.
1. Joiner TE, Jr. The trajectory of suicidal behavior over time. Suicide Life Threat Behav. 2002;32(1):33-41.
2. Simon RI. Imminent suicide: the illusion of short-term prediction. Suicide Life Threat Behav. 2006;36(3):296-301.
3. Isometsä ET, Lönnqvist JK. Suicide attempts preceding completed suicide. Br J Psychiatry. 1998;173:531-535.
4. Runeson B, Tidemalm D, Dahlin M, et al. Method of attempted suicide as a predictor of subsequent successful suicide: national long-term cohort study. BMJ. 2010;341:c3222. doi:10.1136/bmj.63222.
5. Simon TR, Swann AC, Powell KE, et al. Characteristics of impulsive suicide attempts and attempters. Suicide Life Threat Behav. 2001;32(suppl):49-59.
6. Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Study. Arch Gen Psychiatry. 1999;56(7):617-626.
7. Recupero PR. Suicide and the Internet. In: Simon RI Hales RE, eds. The American Psychiatric Publishing textbook of suicide assessment and management. 2nd ed. Arlington, VA: American Psychiatric Publishing, Inc.; 2012:515–538.
8. Simon RI. Gun safety management with patients at risk for suicide. Suicide Life Threat Behav. 2007;37(5):518-526.
‘Bugs in my skin’: What you should know about delusional infestation
Patients with delusional infestation (DI) falsely believe that they are infested with tiny infectious agents—typically vermin, insects, or small animals—that crawl on, in, or under their skin, leaving marks and building nests.1 Patients often describe the pathogens on the skin of hands, arms, feet, lower legs, scalp, or genital areas. They state the pathogen is difficult to diagnose and usually is contracted by human contact. Most patients with DI engage in intensive, repetitive, and often dangerous self-cleansing to get rid of the pathogens, which results in skin lesions.1 Less often, patients believe they are infested with bacteria or viruses.1
The typical DI patient is a middle age or older female with few social contacts, no psychiatric history, and normal cognitive and social function.1 Geriatric patients with dementia and vision or hearing impairment who live in a nursing home may develop DI; it also may be seen in geriatric patients with vascular encephalopathy.
What to consider
First rule out a genuine infestation by referring your patient for dermatologic and microbiologic testing. Order basic laboratory tests to assess inflammation markers—complete blood cell count, erythrocyte sedimentation rate, C-reactive protein, electrolytes, liver function, thyroid-stimulating hormone, and fasting glucose.1 Suggest a cranial MRI to rule out a brain disorder. Also, perform a urinalysis for cocaine, amphetamines, or cannabinoids, which can cause DI.1 Rule out medical conditions that are associated with pruritus and psychiatric symptoms, including endocrine, renal, hepatic, rheumatoid, and nutritional conditions.
Treating DI patients
Collaborate with a dermatologist, microbiologist, and primary care physician because these clinicians can deliver medical interventions, such as treating skin lesions and prescribing non-sedating antihistamines to alleviate pruritus. The Table1 offers other suggestions for managing DI patients.
Pharmacotherapy. Although high-quality evidence supporting antipsychotics for treating DI is lacking, olanzapine and risperidone are considered first-line agents; haloperidol and perphenazine also are recommended.1 Response and remission rates are similar with typical and atypical antipsychotics and the median onset of efficacy with antipsychotics is approximately 1.5 weeks.1,2 Antidepressants—including escitalopram, sertraline, mirtazapine, and venlafaxine—have been shown to effectively treat DI.3 In treatment-resistant cases, pimozide and electroconvulsive therapy have been used.1
Psychotherapy is effective for only 10% of DI patients.4
Table
Treating patients with DI: What to do and what to avoid
Do’s | Don’t |
---|---|
Do acknowledge and empathize with your patient’s concerns | Don’t try to convince your patient he or she is wrong about the self-diagnosis |
Do perform a thorough physical exam and diagnostic investigation | Don’t use words such as “delusional” or “psychotic” |
Do paraphrase symptoms as “sensations” or “crawling” instead of reinforcing or questioning them | Don’t start psychopharmacology until you establish rapport with your patient |
Do indicate that symptoms could be secondary to overactivity of the nervous system or “unexplained dermopathy” | |
Do suggest that antipsychotics may help reduce your patient’s distress and itching | |
DI: delusional infestation Source: Adapted from reference 1 |
Disclosure
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Freudenmann RW, Lepping P. Delusional infestation. Clin Microbiol Rev. 2009;22(4):690-732.
2. Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. J Clin Psychopharmacol. 2008;28(5):500-508.
3. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-758.
4. Wykoff RF. Delusions of parasitosis: a review. Rev Infect Dis. 1987;9(3):433-437.
Patients with delusional infestation (DI) falsely believe that they are infested with tiny infectious agents—typically vermin, insects, or small animals—that crawl on, in, or under their skin, leaving marks and building nests.1 Patients often describe the pathogens on the skin of hands, arms, feet, lower legs, scalp, or genital areas. They state the pathogen is difficult to diagnose and usually is contracted by human contact. Most patients with DI engage in intensive, repetitive, and often dangerous self-cleansing to get rid of the pathogens, which results in skin lesions.1 Less often, patients believe they are infested with bacteria or viruses.1
The typical DI patient is a middle age or older female with few social contacts, no psychiatric history, and normal cognitive and social function.1 Geriatric patients with dementia and vision or hearing impairment who live in a nursing home may develop DI; it also may be seen in geriatric patients with vascular encephalopathy.
What to consider
First rule out a genuine infestation by referring your patient for dermatologic and microbiologic testing. Order basic laboratory tests to assess inflammation markers—complete blood cell count, erythrocyte sedimentation rate, C-reactive protein, electrolytes, liver function, thyroid-stimulating hormone, and fasting glucose.1 Suggest a cranial MRI to rule out a brain disorder. Also, perform a urinalysis for cocaine, amphetamines, or cannabinoids, which can cause DI.1 Rule out medical conditions that are associated with pruritus and psychiatric symptoms, including endocrine, renal, hepatic, rheumatoid, and nutritional conditions.
Treating DI patients
Collaborate with a dermatologist, microbiologist, and primary care physician because these clinicians can deliver medical interventions, such as treating skin lesions and prescribing non-sedating antihistamines to alleviate pruritus. The Table1 offers other suggestions for managing DI patients.
Pharmacotherapy. Although high-quality evidence supporting antipsychotics for treating DI is lacking, olanzapine and risperidone are considered first-line agents; haloperidol and perphenazine also are recommended.1 Response and remission rates are similar with typical and atypical antipsychotics and the median onset of efficacy with antipsychotics is approximately 1.5 weeks.1,2 Antidepressants—including escitalopram, sertraline, mirtazapine, and venlafaxine—have been shown to effectively treat DI.3 In treatment-resistant cases, pimozide and electroconvulsive therapy have been used.1
Psychotherapy is effective for only 10% of DI patients.4
Table
Treating patients with DI: What to do and what to avoid
Do’s | Don’t |
---|---|
Do acknowledge and empathize with your patient’s concerns | Don’t try to convince your patient he or she is wrong about the self-diagnosis |
Do perform a thorough physical exam and diagnostic investigation | Don’t use words such as “delusional” or “psychotic” |
Do paraphrase symptoms as “sensations” or “crawling” instead of reinforcing or questioning them | Don’t start psychopharmacology until you establish rapport with your patient |
Do indicate that symptoms could be secondary to overactivity of the nervous system or “unexplained dermopathy” | |
Do suggest that antipsychotics may help reduce your patient’s distress and itching | |
DI: delusional infestation Source: Adapted from reference 1 |
Disclosure
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Patients with delusional infestation (DI) falsely believe that they are infested with tiny infectious agents—typically vermin, insects, or small animals—that crawl on, in, or under their skin, leaving marks and building nests.1 Patients often describe the pathogens on the skin of hands, arms, feet, lower legs, scalp, or genital areas. They state the pathogen is difficult to diagnose and usually is contracted by human contact. Most patients with DI engage in intensive, repetitive, and often dangerous self-cleansing to get rid of the pathogens, which results in skin lesions.1 Less often, patients believe they are infested with bacteria or viruses.1
The typical DI patient is a middle age or older female with few social contacts, no psychiatric history, and normal cognitive and social function.1 Geriatric patients with dementia and vision or hearing impairment who live in a nursing home may develop DI; it also may be seen in geriatric patients with vascular encephalopathy.
What to consider
First rule out a genuine infestation by referring your patient for dermatologic and microbiologic testing. Order basic laboratory tests to assess inflammation markers—complete blood cell count, erythrocyte sedimentation rate, C-reactive protein, electrolytes, liver function, thyroid-stimulating hormone, and fasting glucose.1 Suggest a cranial MRI to rule out a brain disorder. Also, perform a urinalysis for cocaine, amphetamines, or cannabinoids, which can cause DI.1 Rule out medical conditions that are associated with pruritus and psychiatric symptoms, including endocrine, renal, hepatic, rheumatoid, and nutritional conditions.
Treating DI patients
Collaborate with a dermatologist, microbiologist, and primary care physician because these clinicians can deliver medical interventions, such as treating skin lesions and prescribing non-sedating antihistamines to alleviate pruritus. The Table1 offers other suggestions for managing DI patients.
Pharmacotherapy. Although high-quality evidence supporting antipsychotics for treating DI is lacking, olanzapine and risperidone are considered first-line agents; haloperidol and perphenazine also are recommended.1 Response and remission rates are similar with typical and atypical antipsychotics and the median onset of efficacy with antipsychotics is approximately 1.5 weeks.1,2 Antidepressants—including escitalopram, sertraline, mirtazapine, and venlafaxine—have been shown to effectively treat DI.3 In treatment-resistant cases, pimozide and electroconvulsive therapy have been used.1
Psychotherapy is effective for only 10% of DI patients.4
Table
Treating patients with DI: What to do and what to avoid
Do’s | Don’t |
---|---|
Do acknowledge and empathize with your patient’s concerns | Don’t try to convince your patient he or she is wrong about the self-diagnosis |
Do perform a thorough physical exam and diagnostic investigation | Don’t use words such as “delusional” or “psychotic” |
Do paraphrase symptoms as “sensations” or “crawling” instead of reinforcing or questioning them | Don’t start psychopharmacology until you establish rapport with your patient |
Do indicate that symptoms could be secondary to overactivity of the nervous system or “unexplained dermopathy” | |
Do suggest that antipsychotics may help reduce your patient’s distress and itching | |
DI: delusional infestation Source: Adapted from reference 1 |
Disclosure
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Freudenmann RW, Lepping P. Delusional infestation. Clin Microbiol Rev. 2009;22(4):690-732.
2. Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. J Clin Psychopharmacol. 2008;28(5):500-508.
3. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-758.
4. Wykoff RF. Delusions of parasitosis: a review. Rev Infect Dis. 1987;9(3):433-437.
1. Freudenmann RW, Lepping P. Delusional infestation. Clin Microbiol Rev. 2009;22(4):690-732.
2. Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. J Clin Psychopharmacol. 2008;28(5):500-508.
3. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-758.
4. Wykoff RF. Delusions of parasitosis: a review. Rev Infect Dis. 1987;9(3):433-437.
Playing through the pain: Psychiatric risks among athletes
Discuss this article at www.facebook.com/CurrentPsychiatry
Suck it up. Tough it out. There is no “I” in team. These are a few of the messages athletes receive from coaches, teammates, and fans. There are norms, values, and expectations in every culture, including sports, that affect behavior and emotional expression. When taking a patient’s history, clinicians may ask about participation in sports because it provides health and lifestyle information. However, many clinicians fail to consider the extent to which sport participation can influence a person’s explanatory style, experience of injury, and attitude toward medications. Whether your patient is an elite athlete or someone who participates in sports solely for exercise, the extent to which he or she identifies as an athlete is worth exploring.
Research on athletes has focused on physical aspects of injury, but this may be just a small component of an athlete’s devastation after serious injury. In this article, we discuss athletes’:
- psychiatric risks after injury
- expression of pain
- risks of having an identity driven solely by sports
- distress tolerance.
We also provide tips for making a differential diagnosis and providing treatment. This information is based on our experience treating athletes, supplemented by relevant literature.
Psychiatric risks after injury
Research has explored eating disorders and substance use among athletes, but clinicians generally are less aware of the prevalence of mood and anxiety disorders in this population. Although participating in sports can protect against emotional distress, athletes who sustain an injury are at risk for major depressive disorder, posttraumatic stress disorder (PTSD), or an adjustment disorder.1 Only about 10% of injured athletes have severe, long-term psychological consequences,2 but the prevalence of anger and depression after an injury is well documented.3,4 Researchers have found that injured athletes experience clinically significant depression 6 times as often as non-injured athletes.5 Injured athletes also exhibit significantly greater anxiety and lower self-esteem than non-injured controls immediately after injury and at 2-month follow-up; those with more severe injuries are more likely to become depressed.6 Non-injured athletes seem to experience depression at the same rate as the general population.7
Injury and expression of pain
Psychiatric illnesses often are underreported and undertreated in athletes.8 This may be because athletes feel that admitting they have a psychiatric illness or symptoms could threaten their status with their team. One professional figure skater we treated failed to seek recommended treatment for a psychiatric disorder because she feared she would be asked to leave her skating company. Her symptoms dangerously escalated before she was hospitalized.
Based on our clinical experience, many athletes feel acute pressure to play through psychological and physical pain. Some athletes continue to play with an injury to hold on to a paycheck or scholarship. Some continue to play even though they no longer enjoy the sport to prevent letting down parents or coaches; others know no other way but to “tough it out.” Supporters such as coaches, parents, or teammates may encourage athletes to play with injury, and sometimes provide medication to do so.
Mostly, however, the pressure to continue to play despite injury comes from athletes themselves. The culture of sport may lead athletes to minimize pain, fear, and self doubt.9 Athletes who fuse the culture of sport with their own being may underreport physical and psychiatric symptoms. In a survey of National Collegiate Athletic Association Division I athletes, Nixon9 found that 70% of respondents reported having been injured at least once, and more than one-half felt pressure to play while injured. Feeling pressure to perform with injury was affected by “starter” status, and whites and men scored highest on pressure scales, although women showed a roughly equal probability of playing through injury. Students who received an athletic scholarship experienced more injuries that required surgery. There was no difference in pain expression between players of contact and non-contact sports. Finally, athletes may be less likely to seek pharmacologic treatments because of cultural messages that emphasize ideas such as “the body is a temple.”
Loss of identity
An athlete’s injury should be analyzed for meaning; what may seem insignificant to one person may be quite different for another. When injury makes athletic activity impossible, an athlete may suffer more distress than someone who does not exercise regularly. Understanding the significance of the experience for an athlete is crucial to achieving recovery.10 For example, to a non-athlete a fractured wrist may be an annoyance, but it may be disastrous to a collegiate pitcher who is forced to be inactive when scouts for Major League Baseball teams search for prospects.
To an athlete, injury can mean loss of identity. Whereas most people become competent in many aspects of life, and develop support systems across multiple contexts, an athlete—particularly an extraordinarily talented one—may have focused only on his or her sport. Although athletics can help young people develop confidence, participation also can be a trap. Individuals with strong athletic identities are less likely to explore other career, educational, and lifestyle options.11 In the context of team sports, an athlete may feel less emotionally supported if an injury results in the loss of his or her central role with the team. Helping athletes form an identity that is not based solely on sports is ideal because subsequent injuries could lead to recurrent struggles with loss of identity.
Athletes who achieve higher levels of success have higher levels of depression and higher suicidal ideation after injury.12 An athlete may attempt or complete suicide, particularly those who are injured (Box).13-16
Student athletes. When working with student athletes, it is crucial to understand the lifestyle that promotes forming a single-factor identity. Student athletes may be required to train 2 or 3 times a day, rarely spend their school breaks in tropical locations, often miss social events, and may forgo commencement ceremonies. When an injury suddenly makes these perpetual sacrifices seem to be in vain, the risk of psychiatric illness may increase.
Suicides by several high-profile athletes have called attention to the severity of psychiatric risks among athletes. In June 2002, 20-year-old Nathan Eisert died of a self-inflicted gunshot wound 5 weeks after being released from the Western Kentucky University basketball team for academic reasons; the year before, he had suffered a serious ankle injury.13 Former National Football League (NFL) player Kenny McKinley committed suicide in September 2010, after a knee injury sidelined him.14 In May 2012, former NFL star Junior Seau, who had retired in 2011, fatally shot himself.15
For some athletes, career-ending injuries lead to suicidal behaviors. A study of 5 athletes who attempted suicide after sustaining an injury found 5 common characteristics:
- all were successful in their sport before getting injured
- all sustained an injury severe enough to warrant surgery
- all endured a lengthy rehabilitation
- all were not as successful at their sport when they returned to play
- all were replaced by a teammate.16
Tolerating distress
Athletes often use their sport as an outlet for emotional expression. When an injury removes that outlet, an athlete may develop anxiety and disappointment. Left alone to manage these emotions, an athlete may become irritable, passive, socially isolated, depressed, or suicidal.17 Trying but failing to find socially acceptable ways to express these feelings may intensify depression or anger. Difficult life issues, such as avoided losses, relationship issues, or various insecurities, may come to the surface when an athlete’s primary coping skill is lost. In addition, without the support of the athletic “family” (eg, teammates, coaches, staff) many athletes turn to alcohol or drugs unless they have alternate coping strategies and social supports.18
Overtraining and stress
The differential diagnosis for athletes who present with psychiatric symptoms includes several mood and anxiety disorders and other conditions (Table). When evaluating athletes who have depressive symptoms, it is essential to rule out overtraining syndrome (OTS). A common phenomenon among athletes, OTS is characterized by athletic “staleness” and chronic fatigue.19 Although there are no official OTS diagnostic criteria, characteristic symptoms include decreased physical performance or stamina, fatigue, insomnia, change in appetite, irritability, restlessness, excitability, anxiety, weight loss, loss of motivation, and poor concentration.19 The primary distinction between OTS and depression is that OTS results from athletic endeavors and can be reversed by reducing activity.
Experiencing an injury—or even a near-miss—can be terrifying to a person who derives his or her identity from a fully functioning body and feels that a perfectly working body is essential to an acceptable life. Such athletes may develop acute stress disorder or PTSD.20,21 We treated a hockey player who just missed being involved in a serious incident on the ice. “I watched my whole athletic career up to that point flash before my eyes.… I keep getting flashes of that,” he said. After the incident, he experienced hypervigilance, avoidance, and anxiety—both on and off the ice—and was diagnosed with acute stress disorder. Similarly, we cared for a young running back whose physical symptoms had abated after experiencing a concussion. He developed an irrational fear that he would become injured again. Neither athlete had a history of psychiatric illness or serious injury, and both were paralyzed by the idea of returning to play. One of these athletes successfully engaged in exposure therapy, and the other experienced severe avoidance, hopelessness, depression, nightmares, and flashbacks before seeking treatment.
Table
Differential diagnosis of conditions associated with athletic injury
Acute stress disorder |
Adjustment disorder |
Anxiety disorder NOS |
Depressive disorder NOS |
Major depressive disorder |
Overtraining syndrome |
Postconcussion syndrome |
Posttraumatic stress disorder |
NOS: Not otherwise specified |
Substance use: Common and risky
Anecdotal and clinical evidence suggests that athletes in different sports engage in different substance abuse patterns. Studies show that college athletes use alcohol at higher rates than non-athletes.22,23 In 2000, the American College of Sports Medicine reported that athletes’ abuse of recreational drugs far surpasses their abuse of performance-enhancing drugs.24 Some athletes may use prescription pain medications recreationally or to self-medicate emotional pain as a result of injury. Athletes may not understand the risks of recreational use of prescription medications or illicit substances—such as cocaine’s deleterious cardiovascular effects—and may hesitate to discuss their self-medicating with physicians.
Some athletes abuse performance-enhancing drugs, such as anabolic steroids, androstenedione, stimulants, diuretics, and creatine.25 Side effects of these substances include liver disease, brain hemorrhage, weight loss, and depression.25
Our recommendations
Working with athletes—particularly injured athletes who have internalized sports culture—requires informed clinical effort, whether your patient is a student athlete, elite athlete, leisure athlete, or former athlete. Successful diagnosis and treatment requires understanding the meaning of athletics in your patient’s life and the extent to which he or she has “back-up” stress relievers and support systems, and assessing for cognitive dysfunction that may contribute to mood or anxiety symptoms. During evaluation, take a careful history to distinguish major depression or adjustment disorders from OTS, and assess for PTSD symptoms. When treating an injured athlete, help the patient determine whether he or she can find another outlet—preferably more than one—to replace athletics.
For an athlete who has depressive symptoms, we recommend determining whether the patient’s symptoms remit after a brief period of rest before initiating pharmacotherapy. For patients who exhibit minimal neurovegetative features, we recommend psychotherapy as a first-line treatment. Many athletes are reluctant to take medication and would be more likely to follow through with cognitive-behavioral and biofeedback interventions.
If a patient requires pharmacotherapy, ask about his or her feelings toward medications that may impact adherence. For example, is a gymnast worried about weight gain? Is a sprinter concerned with lethargy? When prescribing, be aware of the prevalence of drug and alcohol problems among athletes, understand how habits and temptations differ among sports cultures, and provide patients with psychoeducation about substance abuse when appropriate.
Related Resources
- International Society for Sports Psychiatry. http://sportspsychiatry.org.
- Sabo D, Miller KE, Melnick MJ, et al. High school athletic participation and adolescent suicide: a nationwide U.S. study. Int Rev Sociol Sport. 2005;40(1):5-23. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563797. Accessed June 7, 2012.
Disclosure
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Brewer BW, Linder DE, Phelps CM. Situational correlates of emotional adjustment to athletic injury. Clin J Sport Med. 1995;5(4):241-245.
2. Brewer BW, Petrie TA. Psychopathology in sport and exercise. In: Van Raalte JL Brewer BW, eds. Exploring sport and exercise psychology. Washington, DC: American Psychological Association; 1996:257–274.
3. May J, Sieb G. Athletic injuries: psychosocial factors in the onset sequelae, rehabilitation and prevention. In: May JR, Asken MJ, eds. Sport psychology: the psychological health of the athlete. New York, NY: PMA Publishing; 1987: 157–185.
4. Quackenbush N, Crossman J. Injured athletes: a study of emotional responses. J Sport Behav. 1994;17:178-187.
5. Perna F, Roh J, Newcomer R, et al. Clinical depression among injured athletes: an empirical assessment. Presented at: Association for the Advancement of Applied Sport Psychology annual convention; September 1998; Hyannis, MA.
6. Leddy MH, Lambert MJ, Ogles BM. Psychological consequences of athletic injury among high-level competitors. Res Q Exerc Sport. 1994;65(4):347-354.
7. Schwenk TL. The stigmatisation and denial of mental illness in athletes. Br J Sports Med. 2000;34(1):4-5.
8. Rotella RJ, Heyman SR. Stress injury, and the psychological rehabilitation of athletes. In: Williams HR, ed. Applied sports psychology: personal growth to peak performance. 2nd ed. Mountain View, CA: Mayfield Publishing; 1993: 338–355.
9. Nixon HL, II. Explaining pain and injury attitudes and experiences in sport in terms of gender race, and sports status factors. Journal of Sport Social Issues. 1996;20(1):33-44.
10. Harris LL. Integrating and analyzing psychosocial and stage theories to challenge the development of the injured collegiate athlete. J Athl Train. 2003;38(1):75-82.
11. Brown C, Hartley DL. Athletic identity and career maturation of male college student athletes. International Journal of Sport Psychology. 1998;29(1):17-26.
12. Baum AL. Suicide in athletes: a review and commentary. Clin Sports Med. 2005;24(4):853-859, ix.
13. Ho J. Suicide on campus. CBS News. http://www.cbsnews.com/2100-500195_162-654130.html. Published February 11 2009. Accessed June 7, 2012.
14. Bunch J, Jones LH. Broncos WR Kenny McKinley found dead in apparent suicide. Denver Post. http://www.denverpost.com/sports/ci_16127852. Published September 20 2010. Accessed June 7, 2012.
15. Saraceno J. Junior Seau’s death came with ‘zero warning.’ USA Today. http://www.usatoday.com/sports/football/nfl/story/2012-05-02/junior-seau-dead-gunshot/54712488/1. Published May 3 2012. Accessed June 7, 2012.
16. Smith AM, Milliner EK. Injured athletes and the risk of suicide. J Athl Train. 1994;29(4):337-341.
17. Putukian M, Wilfert M. National Collegiate Athletic Association. Student-athletes also face dangers from depression. http://fs.ncaa.org/Docs/NCAANewsArchive/2004/Association-Wide/student-athletes+also+face+dangers+from+depression+-+4-12-04.html. Published April 12 2004. Accessed June 6, 2012.
18. Perna FM, Antoni MH, Baum A, et al. Cognitive behavioral stress management effects on injury and illness among competitive athletes: a randomized clinical trial. Ann Behav Med. 2003;25(1):66-73.
19. Armstrong LE, VanHeest JL. The unknown mechanism of the overtraining syndrome: clues from depression and psychoneuroimmunology. Sports Med. 2002;32(3):185-209.
20. Newcomer RR, Perna FM. Features of posttraumatic distress among adolescent athletes. J Athl Train. 2003;38(2):163-166.
21. Newcomer R, Roh J, Perna F, et al. Injury as a traumatic experience: Intrusive thoughts and avoidance behavior associated with injury among college student-athletes. J Appl Sport Psychol. 1998;10(suppl):S54.
22. Hildebrand KM, Johnson DJ, Bogle K. Comparison of patterns of alcohol use between high school and college athletes and non-athletes. College Student Journal. 2001;35:358-365.
23. Wilson GS, Pritchard ME, Schaffer J. Athletic status and drinking behavior in college students: the influence of gender and coping styles. J Am Coll Health. 2004;52(6):269-273.
24. Wadler GI. American College of Sports Medicine. Cocaine abuse in sports. http://www.acsm.org/docs/current-comments/cocainabuse.pdf. Accessed June 6, 2012.
25. Mayo Clinic. Performance-enhancing drugs: know the risks. http://www.mayoclinic.com/health/performance-enhancing-drugs/hq01105. Published December 23, 2010.
Discuss this article at www.facebook.com/CurrentPsychiatry
Suck it up. Tough it out. There is no “I” in team. These are a few of the messages athletes receive from coaches, teammates, and fans. There are norms, values, and expectations in every culture, including sports, that affect behavior and emotional expression. When taking a patient’s history, clinicians may ask about participation in sports because it provides health and lifestyle information. However, many clinicians fail to consider the extent to which sport participation can influence a person’s explanatory style, experience of injury, and attitude toward medications. Whether your patient is an elite athlete or someone who participates in sports solely for exercise, the extent to which he or she identifies as an athlete is worth exploring.
Research on athletes has focused on physical aspects of injury, but this may be just a small component of an athlete’s devastation after serious injury. In this article, we discuss athletes’:
- psychiatric risks after injury
- expression of pain
- risks of having an identity driven solely by sports
- distress tolerance.
We also provide tips for making a differential diagnosis and providing treatment. This information is based on our experience treating athletes, supplemented by relevant literature.
Psychiatric risks after injury
Research has explored eating disorders and substance use among athletes, but clinicians generally are less aware of the prevalence of mood and anxiety disorders in this population. Although participating in sports can protect against emotional distress, athletes who sustain an injury are at risk for major depressive disorder, posttraumatic stress disorder (PTSD), or an adjustment disorder.1 Only about 10% of injured athletes have severe, long-term psychological consequences,2 but the prevalence of anger and depression after an injury is well documented.3,4 Researchers have found that injured athletes experience clinically significant depression 6 times as often as non-injured athletes.5 Injured athletes also exhibit significantly greater anxiety and lower self-esteem than non-injured controls immediately after injury and at 2-month follow-up; those with more severe injuries are more likely to become depressed.6 Non-injured athletes seem to experience depression at the same rate as the general population.7
Injury and expression of pain
Psychiatric illnesses often are underreported and undertreated in athletes.8 This may be because athletes feel that admitting they have a psychiatric illness or symptoms could threaten their status with their team. One professional figure skater we treated failed to seek recommended treatment for a psychiatric disorder because she feared she would be asked to leave her skating company. Her symptoms dangerously escalated before she was hospitalized.
Based on our clinical experience, many athletes feel acute pressure to play through psychological and physical pain. Some athletes continue to play with an injury to hold on to a paycheck or scholarship. Some continue to play even though they no longer enjoy the sport to prevent letting down parents or coaches; others know no other way but to “tough it out.” Supporters such as coaches, parents, or teammates may encourage athletes to play with injury, and sometimes provide medication to do so.
Mostly, however, the pressure to continue to play despite injury comes from athletes themselves. The culture of sport may lead athletes to minimize pain, fear, and self doubt.9 Athletes who fuse the culture of sport with their own being may underreport physical and psychiatric symptoms. In a survey of National Collegiate Athletic Association Division I athletes, Nixon9 found that 70% of respondents reported having been injured at least once, and more than one-half felt pressure to play while injured. Feeling pressure to perform with injury was affected by “starter” status, and whites and men scored highest on pressure scales, although women showed a roughly equal probability of playing through injury. Students who received an athletic scholarship experienced more injuries that required surgery. There was no difference in pain expression between players of contact and non-contact sports. Finally, athletes may be less likely to seek pharmacologic treatments because of cultural messages that emphasize ideas such as “the body is a temple.”
Loss of identity
An athlete’s injury should be analyzed for meaning; what may seem insignificant to one person may be quite different for another. When injury makes athletic activity impossible, an athlete may suffer more distress than someone who does not exercise regularly. Understanding the significance of the experience for an athlete is crucial to achieving recovery.10 For example, to a non-athlete a fractured wrist may be an annoyance, but it may be disastrous to a collegiate pitcher who is forced to be inactive when scouts for Major League Baseball teams search for prospects.
To an athlete, injury can mean loss of identity. Whereas most people become competent in many aspects of life, and develop support systems across multiple contexts, an athlete—particularly an extraordinarily talented one—may have focused only on his or her sport. Although athletics can help young people develop confidence, participation also can be a trap. Individuals with strong athletic identities are less likely to explore other career, educational, and lifestyle options.11 In the context of team sports, an athlete may feel less emotionally supported if an injury results in the loss of his or her central role with the team. Helping athletes form an identity that is not based solely on sports is ideal because subsequent injuries could lead to recurrent struggles with loss of identity.
Athletes who achieve higher levels of success have higher levels of depression and higher suicidal ideation after injury.12 An athlete may attempt or complete suicide, particularly those who are injured (Box).13-16
Student athletes. When working with student athletes, it is crucial to understand the lifestyle that promotes forming a single-factor identity. Student athletes may be required to train 2 or 3 times a day, rarely spend their school breaks in tropical locations, often miss social events, and may forgo commencement ceremonies. When an injury suddenly makes these perpetual sacrifices seem to be in vain, the risk of psychiatric illness may increase.
Suicides by several high-profile athletes have called attention to the severity of psychiatric risks among athletes. In June 2002, 20-year-old Nathan Eisert died of a self-inflicted gunshot wound 5 weeks after being released from the Western Kentucky University basketball team for academic reasons; the year before, he had suffered a serious ankle injury.13 Former National Football League (NFL) player Kenny McKinley committed suicide in September 2010, after a knee injury sidelined him.14 In May 2012, former NFL star Junior Seau, who had retired in 2011, fatally shot himself.15
For some athletes, career-ending injuries lead to suicidal behaviors. A study of 5 athletes who attempted suicide after sustaining an injury found 5 common characteristics:
- all were successful in their sport before getting injured
- all sustained an injury severe enough to warrant surgery
- all endured a lengthy rehabilitation
- all were not as successful at their sport when they returned to play
- all were replaced by a teammate.16
Tolerating distress
Athletes often use their sport as an outlet for emotional expression. When an injury removes that outlet, an athlete may develop anxiety and disappointment. Left alone to manage these emotions, an athlete may become irritable, passive, socially isolated, depressed, or suicidal.17 Trying but failing to find socially acceptable ways to express these feelings may intensify depression or anger. Difficult life issues, such as avoided losses, relationship issues, or various insecurities, may come to the surface when an athlete’s primary coping skill is lost. In addition, without the support of the athletic “family” (eg, teammates, coaches, staff) many athletes turn to alcohol or drugs unless they have alternate coping strategies and social supports.18
Overtraining and stress
The differential diagnosis for athletes who present with psychiatric symptoms includes several mood and anxiety disorders and other conditions (Table). When evaluating athletes who have depressive symptoms, it is essential to rule out overtraining syndrome (OTS). A common phenomenon among athletes, OTS is characterized by athletic “staleness” and chronic fatigue.19 Although there are no official OTS diagnostic criteria, characteristic symptoms include decreased physical performance or stamina, fatigue, insomnia, change in appetite, irritability, restlessness, excitability, anxiety, weight loss, loss of motivation, and poor concentration.19 The primary distinction between OTS and depression is that OTS results from athletic endeavors and can be reversed by reducing activity.
Experiencing an injury—or even a near-miss—can be terrifying to a person who derives his or her identity from a fully functioning body and feels that a perfectly working body is essential to an acceptable life. Such athletes may develop acute stress disorder or PTSD.20,21 We treated a hockey player who just missed being involved in a serious incident on the ice. “I watched my whole athletic career up to that point flash before my eyes.… I keep getting flashes of that,” he said. After the incident, he experienced hypervigilance, avoidance, and anxiety—both on and off the ice—and was diagnosed with acute stress disorder. Similarly, we cared for a young running back whose physical symptoms had abated after experiencing a concussion. He developed an irrational fear that he would become injured again. Neither athlete had a history of psychiatric illness or serious injury, and both were paralyzed by the idea of returning to play. One of these athletes successfully engaged in exposure therapy, and the other experienced severe avoidance, hopelessness, depression, nightmares, and flashbacks before seeking treatment.
Table
Differential diagnosis of conditions associated with athletic injury
Acute stress disorder |
Adjustment disorder |
Anxiety disorder NOS |
Depressive disorder NOS |
Major depressive disorder |
Overtraining syndrome |
Postconcussion syndrome |
Posttraumatic stress disorder |
NOS: Not otherwise specified |
Substance use: Common and risky
Anecdotal and clinical evidence suggests that athletes in different sports engage in different substance abuse patterns. Studies show that college athletes use alcohol at higher rates than non-athletes.22,23 In 2000, the American College of Sports Medicine reported that athletes’ abuse of recreational drugs far surpasses their abuse of performance-enhancing drugs.24 Some athletes may use prescription pain medications recreationally or to self-medicate emotional pain as a result of injury. Athletes may not understand the risks of recreational use of prescription medications or illicit substances—such as cocaine’s deleterious cardiovascular effects—and may hesitate to discuss their self-medicating with physicians.
Some athletes abuse performance-enhancing drugs, such as anabolic steroids, androstenedione, stimulants, diuretics, and creatine.25 Side effects of these substances include liver disease, brain hemorrhage, weight loss, and depression.25
Our recommendations
Working with athletes—particularly injured athletes who have internalized sports culture—requires informed clinical effort, whether your patient is a student athlete, elite athlete, leisure athlete, or former athlete. Successful diagnosis and treatment requires understanding the meaning of athletics in your patient’s life and the extent to which he or she has “back-up” stress relievers and support systems, and assessing for cognitive dysfunction that may contribute to mood or anxiety symptoms. During evaluation, take a careful history to distinguish major depression or adjustment disorders from OTS, and assess for PTSD symptoms. When treating an injured athlete, help the patient determine whether he or she can find another outlet—preferably more than one—to replace athletics.
For an athlete who has depressive symptoms, we recommend determining whether the patient’s symptoms remit after a brief period of rest before initiating pharmacotherapy. For patients who exhibit minimal neurovegetative features, we recommend psychotherapy as a first-line treatment. Many athletes are reluctant to take medication and would be more likely to follow through with cognitive-behavioral and biofeedback interventions.
If a patient requires pharmacotherapy, ask about his or her feelings toward medications that may impact adherence. For example, is a gymnast worried about weight gain? Is a sprinter concerned with lethargy? When prescribing, be aware of the prevalence of drug and alcohol problems among athletes, understand how habits and temptations differ among sports cultures, and provide patients with psychoeducation about substance abuse when appropriate.
Related Resources
- International Society for Sports Psychiatry. http://sportspsychiatry.org.
- Sabo D, Miller KE, Melnick MJ, et al. High school athletic participation and adolescent suicide: a nationwide U.S. study. Int Rev Sociol Sport. 2005;40(1):5-23. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563797. Accessed June 7, 2012.
Disclosure
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Discuss this article at www.facebook.com/CurrentPsychiatry
Suck it up. Tough it out. There is no “I” in team. These are a few of the messages athletes receive from coaches, teammates, and fans. There are norms, values, and expectations in every culture, including sports, that affect behavior and emotional expression. When taking a patient’s history, clinicians may ask about participation in sports because it provides health and lifestyle information. However, many clinicians fail to consider the extent to which sport participation can influence a person’s explanatory style, experience of injury, and attitude toward medications. Whether your patient is an elite athlete or someone who participates in sports solely for exercise, the extent to which he or she identifies as an athlete is worth exploring.
Research on athletes has focused on physical aspects of injury, but this may be just a small component of an athlete’s devastation after serious injury. In this article, we discuss athletes’:
- psychiatric risks after injury
- expression of pain
- risks of having an identity driven solely by sports
- distress tolerance.
We also provide tips for making a differential diagnosis and providing treatment. This information is based on our experience treating athletes, supplemented by relevant literature.
Psychiatric risks after injury
Research has explored eating disorders and substance use among athletes, but clinicians generally are less aware of the prevalence of mood and anxiety disorders in this population. Although participating in sports can protect against emotional distress, athletes who sustain an injury are at risk for major depressive disorder, posttraumatic stress disorder (PTSD), or an adjustment disorder.1 Only about 10% of injured athletes have severe, long-term psychological consequences,2 but the prevalence of anger and depression after an injury is well documented.3,4 Researchers have found that injured athletes experience clinically significant depression 6 times as often as non-injured athletes.5 Injured athletes also exhibit significantly greater anxiety and lower self-esteem than non-injured controls immediately after injury and at 2-month follow-up; those with more severe injuries are more likely to become depressed.6 Non-injured athletes seem to experience depression at the same rate as the general population.7
Injury and expression of pain
Psychiatric illnesses often are underreported and undertreated in athletes.8 This may be because athletes feel that admitting they have a psychiatric illness or symptoms could threaten their status with their team. One professional figure skater we treated failed to seek recommended treatment for a psychiatric disorder because she feared she would be asked to leave her skating company. Her symptoms dangerously escalated before she was hospitalized.
Based on our clinical experience, many athletes feel acute pressure to play through psychological and physical pain. Some athletes continue to play with an injury to hold on to a paycheck or scholarship. Some continue to play even though they no longer enjoy the sport to prevent letting down parents or coaches; others know no other way but to “tough it out.” Supporters such as coaches, parents, or teammates may encourage athletes to play with injury, and sometimes provide medication to do so.
Mostly, however, the pressure to continue to play despite injury comes from athletes themselves. The culture of sport may lead athletes to minimize pain, fear, and self doubt.9 Athletes who fuse the culture of sport with their own being may underreport physical and psychiatric symptoms. In a survey of National Collegiate Athletic Association Division I athletes, Nixon9 found that 70% of respondents reported having been injured at least once, and more than one-half felt pressure to play while injured. Feeling pressure to perform with injury was affected by “starter” status, and whites and men scored highest on pressure scales, although women showed a roughly equal probability of playing through injury. Students who received an athletic scholarship experienced more injuries that required surgery. There was no difference in pain expression between players of contact and non-contact sports. Finally, athletes may be less likely to seek pharmacologic treatments because of cultural messages that emphasize ideas such as “the body is a temple.”
Loss of identity
An athlete’s injury should be analyzed for meaning; what may seem insignificant to one person may be quite different for another. When injury makes athletic activity impossible, an athlete may suffer more distress than someone who does not exercise regularly. Understanding the significance of the experience for an athlete is crucial to achieving recovery.10 For example, to a non-athlete a fractured wrist may be an annoyance, but it may be disastrous to a collegiate pitcher who is forced to be inactive when scouts for Major League Baseball teams search for prospects.
To an athlete, injury can mean loss of identity. Whereas most people become competent in many aspects of life, and develop support systems across multiple contexts, an athlete—particularly an extraordinarily talented one—may have focused only on his or her sport. Although athletics can help young people develop confidence, participation also can be a trap. Individuals with strong athletic identities are less likely to explore other career, educational, and lifestyle options.11 In the context of team sports, an athlete may feel less emotionally supported if an injury results in the loss of his or her central role with the team. Helping athletes form an identity that is not based solely on sports is ideal because subsequent injuries could lead to recurrent struggles with loss of identity.
Athletes who achieve higher levels of success have higher levels of depression and higher suicidal ideation after injury.12 An athlete may attempt or complete suicide, particularly those who are injured (Box).13-16
Student athletes. When working with student athletes, it is crucial to understand the lifestyle that promotes forming a single-factor identity. Student athletes may be required to train 2 or 3 times a day, rarely spend their school breaks in tropical locations, often miss social events, and may forgo commencement ceremonies. When an injury suddenly makes these perpetual sacrifices seem to be in vain, the risk of psychiatric illness may increase.
Suicides by several high-profile athletes have called attention to the severity of psychiatric risks among athletes. In June 2002, 20-year-old Nathan Eisert died of a self-inflicted gunshot wound 5 weeks after being released from the Western Kentucky University basketball team for academic reasons; the year before, he had suffered a serious ankle injury.13 Former National Football League (NFL) player Kenny McKinley committed suicide in September 2010, after a knee injury sidelined him.14 In May 2012, former NFL star Junior Seau, who had retired in 2011, fatally shot himself.15
For some athletes, career-ending injuries lead to suicidal behaviors. A study of 5 athletes who attempted suicide after sustaining an injury found 5 common characteristics:
- all were successful in their sport before getting injured
- all sustained an injury severe enough to warrant surgery
- all endured a lengthy rehabilitation
- all were not as successful at their sport when they returned to play
- all were replaced by a teammate.16
Tolerating distress
Athletes often use their sport as an outlet for emotional expression. When an injury removes that outlet, an athlete may develop anxiety and disappointment. Left alone to manage these emotions, an athlete may become irritable, passive, socially isolated, depressed, or suicidal.17 Trying but failing to find socially acceptable ways to express these feelings may intensify depression or anger. Difficult life issues, such as avoided losses, relationship issues, or various insecurities, may come to the surface when an athlete’s primary coping skill is lost. In addition, without the support of the athletic “family” (eg, teammates, coaches, staff) many athletes turn to alcohol or drugs unless they have alternate coping strategies and social supports.18
Overtraining and stress
The differential diagnosis for athletes who present with psychiatric symptoms includes several mood and anxiety disorders and other conditions (Table). When evaluating athletes who have depressive symptoms, it is essential to rule out overtraining syndrome (OTS). A common phenomenon among athletes, OTS is characterized by athletic “staleness” and chronic fatigue.19 Although there are no official OTS diagnostic criteria, characteristic symptoms include decreased physical performance or stamina, fatigue, insomnia, change in appetite, irritability, restlessness, excitability, anxiety, weight loss, loss of motivation, and poor concentration.19 The primary distinction between OTS and depression is that OTS results from athletic endeavors and can be reversed by reducing activity.
Experiencing an injury—or even a near-miss—can be terrifying to a person who derives his or her identity from a fully functioning body and feels that a perfectly working body is essential to an acceptable life. Such athletes may develop acute stress disorder or PTSD.20,21 We treated a hockey player who just missed being involved in a serious incident on the ice. “I watched my whole athletic career up to that point flash before my eyes.… I keep getting flashes of that,” he said. After the incident, he experienced hypervigilance, avoidance, and anxiety—both on and off the ice—and was diagnosed with acute stress disorder. Similarly, we cared for a young running back whose physical symptoms had abated after experiencing a concussion. He developed an irrational fear that he would become injured again. Neither athlete had a history of psychiatric illness or serious injury, and both were paralyzed by the idea of returning to play. One of these athletes successfully engaged in exposure therapy, and the other experienced severe avoidance, hopelessness, depression, nightmares, and flashbacks before seeking treatment.
Table
Differential diagnosis of conditions associated with athletic injury
Acute stress disorder |
Adjustment disorder |
Anxiety disorder NOS |
Depressive disorder NOS |
Major depressive disorder |
Overtraining syndrome |
Postconcussion syndrome |
Posttraumatic stress disorder |
NOS: Not otherwise specified |
Substance use: Common and risky
Anecdotal and clinical evidence suggests that athletes in different sports engage in different substance abuse patterns. Studies show that college athletes use alcohol at higher rates than non-athletes.22,23 In 2000, the American College of Sports Medicine reported that athletes’ abuse of recreational drugs far surpasses their abuse of performance-enhancing drugs.24 Some athletes may use prescription pain medications recreationally or to self-medicate emotional pain as a result of injury. Athletes may not understand the risks of recreational use of prescription medications or illicit substances—such as cocaine’s deleterious cardiovascular effects—and may hesitate to discuss their self-medicating with physicians.
Some athletes abuse performance-enhancing drugs, such as anabolic steroids, androstenedione, stimulants, diuretics, and creatine.25 Side effects of these substances include liver disease, brain hemorrhage, weight loss, and depression.25
Our recommendations
Working with athletes—particularly injured athletes who have internalized sports culture—requires informed clinical effort, whether your patient is a student athlete, elite athlete, leisure athlete, or former athlete. Successful diagnosis and treatment requires understanding the meaning of athletics in your patient’s life and the extent to which he or she has “back-up” stress relievers and support systems, and assessing for cognitive dysfunction that may contribute to mood or anxiety symptoms. During evaluation, take a careful history to distinguish major depression or adjustment disorders from OTS, and assess for PTSD symptoms. When treating an injured athlete, help the patient determine whether he or she can find another outlet—preferably more than one—to replace athletics.
For an athlete who has depressive symptoms, we recommend determining whether the patient’s symptoms remit after a brief period of rest before initiating pharmacotherapy. For patients who exhibit minimal neurovegetative features, we recommend psychotherapy as a first-line treatment. Many athletes are reluctant to take medication and would be more likely to follow through with cognitive-behavioral and biofeedback interventions.
If a patient requires pharmacotherapy, ask about his or her feelings toward medications that may impact adherence. For example, is a gymnast worried about weight gain? Is a sprinter concerned with lethargy? When prescribing, be aware of the prevalence of drug and alcohol problems among athletes, understand how habits and temptations differ among sports cultures, and provide patients with psychoeducation about substance abuse when appropriate.
Related Resources
- International Society for Sports Psychiatry. http://sportspsychiatry.org.
- Sabo D, Miller KE, Melnick MJ, et al. High school athletic participation and adolescent suicide: a nationwide U.S. study. Int Rev Sociol Sport. 2005;40(1):5-23. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563797. Accessed June 7, 2012.
Disclosure
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Brewer BW, Linder DE, Phelps CM. Situational correlates of emotional adjustment to athletic injury. Clin J Sport Med. 1995;5(4):241-245.
2. Brewer BW, Petrie TA. Psychopathology in sport and exercise. In: Van Raalte JL Brewer BW, eds. Exploring sport and exercise psychology. Washington, DC: American Psychological Association; 1996:257–274.
3. May J, Sieb G. Athletic injuries: psychosocial factors in the onset sequelae, rehabilitation and prevention. In: May JR, Asken MJ, eds. Sport psychology: the psychological health of the athlete. New York, NY: PMA Publishing; 1987: 157–185.
4. Quackenbush N, Crossman J. Injured athletes: a study of emotional responses. J Sport Behav. 1994;17:178-187.
5. Perna F, Roh J, Newcomer R, et al. Clinical depression among injured athletes: an empirical assessment. Presented at: Association for the Advancement of Applied Sport Psychology annual convention; September 1998; Hyannis, MA.
6. Leddy MH, Lambert MJ, Ogles BM. Psychological consequences of athletic injury among high-level competitors. Res Q Exerc Sport. 1994;65(4):347-354.
7. Schwenk TL. The stigmatisation and denial of mental illness in athletes. Br J Sports Med. 2000;34(1):4-5.
8. Rotella RJ, Heyman SR. Stress injury, and the psychological rehabilitation of athletes. In: Williams HR, ed. Applied sports psychology: personal growth to peak performance. 2nd ed. Mountain View, CA: Mayfield Publishing; 1993: 338–355.
9. Nixon HL, II. Explaining pain and injury attitudes and experiences in sport in terms of gender race, and sports status factors. Journal of Sport Social Issues. 1996;20(1):33-44.
10. Harris LL. Integrating and analyzing psychosocial and stage theories to challenge the development of the injured collegiate athlete. J Athl Train. 2003;38(1):75-82.
11. Brown C, Hartley DL. Athletic identity and career maturation of male college student athletes. International Journal of Sport Psychology. 1998;29(1):17-26.
12. Baum AL. Suicide in athletes: a review and commentary. Clin Sports Med. 2005;24(4):853-859, ix.
13. Ho J. Suicide on campus. CBS News. http://www.cbsnews.com/2100-500195_162-654130.html. Published February 11 2009. Accessed June 7, 2012.
14. Bunch J, Jones LH. Broncos WR Kenny McKinley found dead in apparent suicide. Denver Post. http://www.denverpost.com/sports/ci_16127852. Published September 20 2010. Accessed June 7, 2012.
15. Saraceno J. Junior Seau’s death came with ‘zero warning.’ USA Today. http://www.usatoday.com/sports/football/nfl/story/2012-05-02/junior-seau-dead-gunshot/54712488/1. Published May 3 2012. Accessed June 7, 2012.
16. Smith AM, Milliner EK. Injured athletes and the risk of suicide. J Athl Train. 1994;29(4):337-341.
17. Putukian M, Wilfert M. National Collegiate Athletic Association. Student-athletes also face dangers from depression. http://fs.ncaa.org/Docs/NCAANewsArchive/2004/Association-Wide/student-athletes+also+face+dangers+from+depression+-+4-12-04.html. Published April 12 2004. Accessed June 6, 2012.
18. Perna FM, Antoni MH, Baum A, et al. Cognitive behavioral stress management effects on injury and illness among competitive athletes: a randomized clinical trial. Ann Behav Med. 2003;25(1):66-73.
19. Armstrong LE, VanHeest JL. The unknown mechanism of the overtraining syndrome: clues from depression and psychoneuroimmunology. Sports Med. 2002;32(3):185-209.
20. Newcomer RR, Perna FM. Features of posttraumatic distress among adolescent athletes. J Athl Train. 2003;38(2):163-166.
21. Newcomer R, Roh J, Perna F, et al. Injury as a traumatic experience: Intrusive thoughts and avoidance behavior associated with injury among college student-athletes. J Appl Sport Psychol. 1998;10(suppl):S54.
22. Hildebrand KM, Johnson DJ, Bogle K. Comparison of patterns of alcohol use between high school and college athletes and non-athletes. College Student Journal. 2001;35:358-365.
23. Wilson GS, Pritchard ME, Schaffer J. Athletic status and drinking behavior in college students: the influence of gender and coping styles. J Am Coll Health. 2004;52(6):269-273.
24. Wadler GI. American College of Sports Medicine. Cocaine abuse in sports. http://www.acsm.org/docs/current-comments/cocainabuse.pdf. Accessed June 6, 2012.
25. Mayo Clinic. Performance-enhancing drugs: know the risks. http://www.mayoclinic.com/health/performance-enhancing-drugs/hq01105. Published December 23, 2010.
1. Brewer BW, Linder DE, Phelps CM. Situational correlates of emotional adjustment to athletic injury. Clin J Sport Med. 1995;5(4):241-245.
2. Brewer BW, Petrie TA. Psychopathology in sport and exercise. In: Van Raalte JL Brewer BW, eds. Exploring sport and exercise psychology. Washington, DC: American Psychological Association; 1996:257–274.
3. May J, Sieb G. Athletic injuries: psychosocial factors in the onset sequelae, rehabilitation and prevention. In: May JR, Asken MJ, eds. Sport psychology: the psychological health of the athlete. New York, NY: PMA Publishing; 1987: 157–185.
4. Quackenbush N, Crossman J. Injured athletes: a study of emotional responses. J Sport Behav. 1994;17:178-187.
5. Perna F, Roh J, Newcomer R, et al. Clinical depression among injured athletes: an empirical assessment. Presented at: Association for the Advancement of Applied Sport Psychology annual convention; September 1998; Hyannis, MA.
6. Leddy MH, Lambert MJ, Ogles BM. Psychological consequences of athletic injury among high-level competitors. Res Q Exerc Sport. 1994;65(4):347-354.
7. Schwenk TL. The stigmatisation and denial of mental illness in athletes. Br J Sports Med. 2000;34(1):4-5.
8. Rotella RJ, Heyman SR. Stress injury, and the psychological rehabilitation of athletes. In: Williams HR, ed. Applied sports psychology: personal growth to peak performance. 2nd ed. Mountain View, CA: Mayfield Publishing; 1993: 338–355.
9. Nixon HL, II. Explaining pain and injury attitudes and experiences in sport in terms of gender race, and sports status factors. Journal of Sport Social Issues. 1996;20(1):33-44.
10. Harris LL. Integrating and analyzing psychosocial and stage theories to challenge the development of the injured collegiate athlete. J Athl Train. 2003;38(1):75-82.
11. Brown C, Hartley DL. Athletic identity and career maturation of male college student athletes. International Journal of Sport Psychology. 1998;29(1):17-26.
12. Baum AL. Suicide in athletes: a review and commentary. Clin Sports Med. 2005;24(4):853-859, ix.
13. Ho J. Suicide on campus. CBS News. http://www.cbsnews.com/2100-500195_162-654130.html. Published February 11 2009. Accessed June 7, 2012.
14. Bunch J, Jones LH. Broncos WR Kenny McKinley found dead in apparent suicide. Denver Post. http://www.denverpost.com/sports/ci_16127852. Published September 20 2010. Accessed June 7, 2012.
15. Saraceno J. Junior Seau’s death came with ‘zero warning.’ USA Today. http://www.usatoday.com/sports/football/nfl/story/2012-05-02/junior-seau-dead-gunshot/54712488/1. Published May 3 2012. Accessed June 7, 2012.
16. Smith AM, Milliner EK. Injured athletes and the risk of suicide. J Athl Train. 1994;29(4):337-341.
17. Putukian M, Wilfert M. National Collegiate Athletic Association. Student-athletes also face dangers from depression. http://fs.ncaa.org/Docs/NCAANewsArchive/2004/Association-Wide/student-athletes+also+face+dangers+from+depression+-+4-12-04.html. Published April 12 2004. Accessed June 6, 2012.
18. Perna FM, Antoni MH, Baum A, et al. Cognitive behavioral stress management effects on injury and illness among competitive athletes: a randomized clinical trial. Ann Behav Med. 2003;25(1):66-73.
19. Armstrong LE, VanHeest JL. The unknown mechanism of the overtraining syndrome: clues from depression and psychoneuroimmunology. Sports Med. 2002;32(3):185-209.
20. Newcomer RR, Perna FM. Features of posttraumatic distress among adolescent athletes. J Athl Train. 2003;38(2):163-166.
21. Newcomer R, Roh J, Perna F, et al. Injury as a traumatic experience: Intrusive thoughts and avoidance behavior associated with injury among college student-athletes. J Appl Sport Psychol. 1998;10(suppl):S54.
22. Hildebrand KM, Johnson DJ, Bogle K. Comparison of patterns of alcohol use between high school and college athletes and non-athletes. College Student Journal. 2001;35:358-365.
23. Wilson GS, Pritchard ME, Schaffer J. Athletic status and drinking behavior in college students: the influence of gender and coping styles. J Am Coll Health. 2004;52(6):269-273.
24. Wadler GI. American College of Sports Medicine. Cocaine abuse in sports. http://www.acsm.org/docs/current-comments/cocainabuse.pdf. Accessed June 6, 2012.
25. Mayo Clinic. Performance-enhancing drugs: know the risks. http://www.mayoclinic.com/health/performance-enhancing-drugs/hq01105. Published December 23, 2010.
CNS Events Not Immediately Fatal in Mantle Cell Lymphomas
AMSTERDAM – Although it is rare and the prognosis for patients is often poor, the presence of central nervous system involvement at the time of diagnosis of mantle cell lymphoma is not always immediately fatal, according to findings from an international study.
According to the European Mantle Cell Lymphoma Network (EMCLN) findings, the crude prevalence of CNS events was 0.9% at the time of diagnosis and 4.1% at any time. The multicenter, retrospective study found that the median time to a CNS event’s occurring was 15.2 months, with an overall survival of 3.9 months after the event was identified, but some patients were still alive 2 years later.
"We now have some better descriptors about what the expectations and outcome of patients with central nervous system involvement are," Dr. John Seymour said in an interview at the annual congress of the European Hematology Association.
Dr. Seymour, professor and chair of the hematology service at Australia’s Peter MacCallum Cancer Centre in East Melbourne, Victoria, added that even though the overall prognosis of patients who develop CNS involvement is very poor, there are some patients who do better than others.
There is "a subgroup [of patients] who are able to receive high-dose ara-c [cytarabine] or high-dose methotrexate treatment, who are young and fit enough, who do somewhat better," Dr. Seymour said. "A proportion will be alive at 2 years, so it’s not an inevitably, rapidly fatal, and ... futile situation."
Mantle cell lymphomas are a rare type of non-Hodgkin’s lymphoma (NHL), accounting for just less than 3% of all NHL cases in the United States and affecting primarily more elderly patients (Cancer 2008;113:791-8).CNS involvement is also a rare and often devastating event, but it has not previously been very well characterized. As a result, it’s not known whether CNS prophylaxis is of benefit to patients.
The aim of the EMCLN study, therefore, was to look at the problem in more detail, to determine the prevalence of CNS involvement, and to look for any clinically defining features, effect of treatment, and patient outcomes.
A retrospective database review by EMCLN members in 12 centers identified 1,396 patients with mantle cell lymphoma, of whom 1,339 had no CNS involvement. Of the 57 patients with CNS involvement, most (44) developed it at some point during the course of their follow-up.
At diagnosis of mantle cell lymphoma, the patients who developed CNS involvement had a median age of 61 years, but this ranged from 38 years to 82 years; patients were predominantly men (70%), with stage IV (91%) disease, and 28% had blastoid histology. Isolated CNS involvement occurred in 15 cases.
Prominent features were a high MIPI (Mantle Cell Lymphoma International Prognostic Index) score (61% of cases), a Ki-67 greater than 30% in 69% of patients, and increased beta2-microglobulin and lactate dehydrogenase in 77% and 75% of cases, respectively. The bone marrow and the peripheral blood were the most common extranodal sites involved, affecting two or more sites in 61% of patients.
At diagnosis of CNS involvement, patients’ neurologic symptoms included weakness, altered mental state, headache, and ocular problems such as double vision. Other symptoms – such as sensory disturbances, pain, sciatica, dizziness, vertigo, ataxia, seizure, and dysphagia – occurred but were less frequent.
CSF cytology and flow cytometry showed a high sensitivity for identifying CNS involvement, with 85% having positive cytology and 91% a positive flow cytometry result.
"Patients had a range of chemotherapies prior to developing central nervous system involvement, but receipt of these regimens was not totally protective," Dr. Seymour said. Data were not collected to enable the relative risk of CNS development with the regimens received.
Chemotherapy was the most frequent treatment strategy to allay CNS disease (67%), and some patients did appear to achieve a complete remission of the CNS disease as a result. In an exploratory analysis, these patients also tended to have improved overall survival, as did those with lower white cell counts (less than 10.9 x 109/L), and who received treatment with high-dose antimetabolites.
"In the longer term, these data will provide a foundation for us to identify predictive factors, to identify – ahead of the event – those people at increased risk," Dr. Seymour said, adding his hope that this will allow preventive steps to be taken.
Dr. Seymour had no conflicts of interest.
AMSTERDAM – Although it is rare and the prognosis for patients is often poor, the presence of central nervous system involvement at the time of diagnosis of mantle cell lymphoma is not always immediately fatal, according to findings from an international study.
According to the European Mantle Cell Lymphoma Network (EMCLN) findings, the crude prevalence of CNS events was 0.9% at the time of diagnosis and 4.1% at any time. The multicenter, retrospective study found that the median time to a CNS event’s occurring was 15.2 months, with an overall survival of 3.9 months after the event was identified, but some patients were still alive 2 years later.
"We now have some better descriptors about what the expectations and outcome of patients with central nervous system involvement are," Dr. John Seymour said in an interview at the annual congress of the European Hematology Association.
Dr. Seymour, professor and chair of the hematology service at Australia’s Peter MacCallum Cancer Centre in East Melbourne, Victoria, added that even though the overall prognosis of patients who develop CNS involvement is very poor, there are some patients who do better than others.
There is "a subgroup [of patients] who are able to receive high-dose ara-c [cytarabine] or high-dose methotrexate treatment, who are young and fit enough, who do somewhat better," Dr. Seymour said. "A proportion will be alive at 2 years, so it’s not an inevitably, rapidly fatal, and ... futile situation."
Mantle cell lymphomas are a rare type of non-Hodgkin’s lymphoma (NHL), accounting for just less than 3% of all NHL cases in the United States and affecting primarily more elderly patients (Cancer 2008;113:791-8).CNS involvement is also a rare and often devastating event, but it has not previously been very well characterized. As a result, it’s not known whether CNS prophylaxis is of benefit to patients.
The aim of the EMCLN study, therefore, was to look at the problem in more detail, to determine the prevalence of CNS involvement, and to look for any clinically defining features, effect of treatment, and patient outcomes.
A retrospective database review by EMCLN members in 12 centers identified 1,396 patients with mantle cell lymphoma, of whom 1,339 had no CNS involvement. Of the 57 patients with CNS involvement, most (44) developed it at some point during the course of their follow-up.
At diagnosis of mantle cell lymphoma, the patients who developed CNS involvement had a median age of 61 years, but this ranged from 38 years to 82 years; patients were predominantly men (70%), with stage IV (91%) disease, and 28% had blastoid histology. Isolated CNS involvement occurred in 15 cases.
Prominent features were a high MIPI (Mantle Cell Lymphoma International Prognostic Index) score (61% of cases), a Ki-67 greater than 30% in 69% of patients, and increased beta2-microglobulin and lactate dehydrogenase in 77% and 75% of cases, respectively. The bone marrow and the peripheral blood were the most common extranodal sites involved, affecting two or more sites in 61% of patients.
At diagnosis of CNS involvement, patients’ neurologic symptoms included weakness, altered mental state, headache, and ocular problems such as double vision. Other symptoms – such as sensory disturbances, pain, sciatica, dizziness, vertigo, ataxia, seizure, and dysphagia – occurred but were less frequent.
CSF cytology and flow cytometry showed a high sensitivity for identifying CNS involvement, with 85% having positive cytology and 91% a positive flow cytometry result.
"Patients had a range of chemotherapies prior to developing central nervous system involvement, but receipt of these regimens was not totally protective," Dr. Seymour said. Data were not collected to enable the relative risk of CNS development with the regimens received.
Chemotherapy was the most frequent treatment strategy to allay CNS disease (67%), and some patients did appear to achieve a complete remission of the CNS disease as a result. In an exploratory analysis, these patients also tended to have improved overall survival, as did those with lower white cell counts (less than 10.9 x 109/L), and who received treatment with high-dose antimetabolites.
"In the longer term, these data will provide a foundation for us to identify predictive factors, to identify – ahead of the event – those people at increased risk," Dr. Seymour said, adding his hope that this will allow preventive steps to be taken.
Dr. Seymour had no conflicts of interest.
AMSTERDAM – Although it is rare and the prognosis for patients is often poor, the presence of central nervous system involvement at the time of diagnosis of mantle cell lymphoma is not always immediately fatal, according to findings from an international study.
According to the European Mantle Cell Lymphoma Network (EMCLN) findings, the crude prevalence of CNS events was 0.9% at the time of diagnosis and 4.1% at any time. The multicenter, retrospective study found that the median time to a CNS event’s occurring was 15.2 months, with an overall survival of 3.9 months after the event was identified, but some patients were still alive 2 years later.
"We now have some better descriptors about what the expectations and outcome of patients with central nervous system involvement are," Dr. John Seymour said in an interview at the annual congress of the European Hematology Association.
Dr. Seymour, professor and chair of the hematology service at Australia’s Peter MacCallum Cancer Centre in East Melbourne, Victoria, added that even though the overall prognosis of patients who develop CNS involvement is very poor, there are some patients who do better than others.
There is "a subgroup [of patients] who are able to receive high-dose ara-c [cytarabine] or high-dose methotrexate treatment, who are young and fit enough, who do somewhat better," Dr. Seymour said. "A proportion will be alive at 2 years, so it’s not an inevitably, rapidly fatal, and ... futile situation."
Mantle cell lymphomas are a rare type of non-Hodgkin’s lymphoma (NHL), accounting for just less than 3% of all NHL cases in the United States and affecting primarily more elderly patients (Cancer 2008;113:791-8).CNS involvement is also a rare and often devastating event, but it has not previously been very well characterized. As a result, it’s not known whether CNS prophylaxis is of benefit to patients.
The aim of the EMCLN study, therefore, was to look at the problem in more detail, to determine the prevalence of CNS involvement, and to look for any clinically defining features, effect of treatment, and patient outcomes.
A retrospective database review by EMCLN members in 12 centers identified 1,396 patients with mantle cell lymphoma, of whom 1,339 had no CNS involvement. Of the 57 patients with CNS involvement, most (44) developed it at some point during the course of their follow-up.
At diagnosis of mantle cell lymphoma, the patients who developed CNS involvement had a median age of 61 years, but this ranged from 38 years to 82 years; patients were predominantly men (70%), with stage IV (91%) disease, and 28% had blastoid histology. Isolated CNS involvement occurred in 15 cases.
Prominent features were a high MIPI (Mantle Cell Lymphoma International Prognostic Index) score (61% of cases), a Ki-67 greater than 30% in 69% of patients, and increased beta2-microglobulin and lactate dehydrogenase in 77% and 75% of cases, respectively. The bone marrow and the peripheral blood were the most common extranodal sites involved, affecting two or more sites in 61% of patients.
At diagnosis of CNS involvement, patients’ neurologic symptoms included weakness, altered mental state, headache, and ocular problems such as double vision. Other symptoms – such as sensory disturbances, pain, sciatica, dizziness, vertigo, ataxia, seizure, and dysphagia – occurred but were less frequent.
CSF cytology and flow cytometry showed a high sensitivity for identifying CNS involvement, with 85% having positive cytology and 91% a positive flow cytometry result.
"Patients had a range of chemotherapies prior to developing central nervous system involvement, but receipt of these regimens was not totally protective," Dr. Seymour said. Data were not collected to enable the relative risk of CNS development with the regimens received.
Chemotherapy was the most frequent treatment strategy to allay CNS disease (67%), and some patients did appear to achieve a complete remission of the CNS disease as a result. In an exploratory analysis, these patients also tended to have improved overall survival, as did those with lower white cell counts (less than 10.9 x 109/L), and who received treatment with high-dose antimetabolites.
"In the longer term, these data will provide a foundation for us to identify predictive factors, to identify – ahead of the event – those people at increased risk," Dr. Seymour said, adding his hope that this will allow preventive steps to be taken.
Dr. Seymour had no conflicts of interest.
AT THE ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
Major Finding: Crude prevalences of CNS involvement at diagnosis and overall were 0.9% and 4.1%, respectively, with a median time to an event of 15.2 months and overall survival thereafter of 3.9 months.
Data Source: The EMCLN conducted a retrospective database review of 1,396 patients with mantle cell lymphoma in 12 centers.
Disclosures: Dr. Seymour had no conflicts of interest.
Public Reacts to Supreme Court ACA Ruling
The U.S. Supreme Court, in a 5-4 ruling, upheld the constitutionality of most provisions of the Affordable Care Act on June 28. Democrats claimed victory while Republicans resolved to repeal the law in Congress and use the justice's comments as ammunition against President Obama in the coming election. See our video for more details.
The U.S. Supreme Court, in a 5-4 ruling, upheld the constitutionality of most provisions of the Affordable Care Act on June 28. Democrats claimed victory while Republicans resolved to repeal the law in Congress and use the justice's comments as ammunition against President Obama in the coming election. See our video for more details.
The U.S. Supreme Court, in a 5-4 ruling, upheld the constitutionality of most provisions of the Affordable Care Act on June 28. Democrats claimed victory while Republicans resolved to repeal the law in Congress and use the justice's comments as ammunition against President Obama in the coming election. See our video for more details.
Statin Withdrawal After Major Surgery
Accumulating evidence suggests that perioperative treatment with 3‐hydroxy‐3‐methylglutaryl coenzyme‐A (HMG‐CoA) reductase inhibitors (or, statins) reduces the incidence of cardiovascular events during noncardiac surgery.16 This evidence has lead the European Society of Cardiology (ESC) and American College of Cardiology Foundation/American Heart Association (ACCF/AHA) to endorse the use of perioperative statins in patients already on this treatment or those at high‐risk of cardiovascular events.7, 8
However, statins are available only in oral formulation. Consequently, prolonged bowel recovery or clinical instability may interfere with use during surgery. Furthermore, many clinicians may not recognize the imperative of postoperative statin resumption, viewing them principally as lipid‐lowering entities and not as agents of perioperative benefit. Failure to resume statins postoperatively can be catastrophic, as the ensuing inflammation and thrombosis frequently culminates in myocardial infarction (MI) or death.9, 10
In this article, we review the potent anti‐inflammatory properties of statins and their role in preventing perioperative cardiac events. We outline the biochemical basis for perioperative statin benefit, summarizing the basic, clinical, and experimental evidence regarding statin withdrawal. We conclude by presenting strategies to avert postoperative statin cessation and outline a research agenda dedicated to informing this practice.
METHODS
We performed a literature search using MEDLINE via Ovid (1946present), EMBASE (1946present), Biosis (1926present), and Cochrane CENTRAL (1960present). We used Boolean logic to search for key terms including statins, 3‐hydroxy‐3‐methylglutaryl CoA reductase inhibitors, death, MI, stroke, acute coronary syndrome (ACS), and statin withdrawal or cessation. All studies published in full‐text or abstract form were included. A total of 489 articles were retrieved by this search (last updated March 15, 2012). For this narrative review, we focused on studies that examined adverse outcomes associated with statin withdrawal.
BIOCHEMICAL BASIS OF STATIN PLEIOTROPICITY
The nonlipid‐lowering or pleiotropic properties of statins are especially valuable in the perioperative setting.16, 11 Perioperative cardiac complications occur due to oxygen supply:demand mismatch, vascular inflammation, or a combination of these states. A significant perisurgical catecholamine surge produces unopposed sympathetic effects,12 increasing the risk of rupture of vulnerable coronary plaques, thrombus formation, and adverse cardiac events.13, 14 Similarly, augmented inflammatory responses and increased circulating coagulation factors further predispose to a hazardous perioperative milieu.15 Statins attenuate this vascular inflammatory response by suppressing the synthesis of mevalonate by inhibiting HMG‐CoA reductase. Suppression of mevalonate synthesis reduces the bioavailability of 2 important isoprenoid molecules: farnesyl‐pyrophosphate and geranylgeranyl‐pyrophosphate.16 Diminution of these isoprenoid intermediaries leads to reductions in the active intracellular signaling molecules Ras, Rho, and Rac, which play critical roles in vascular reactivity, endothelial function, and coagulation and inflammatory pathways.1723 The cumulative effect of these cellular changes is diminished inflammation during periods of surgical stress (Figure 1).

While the perioperative pleiotropicity of statins is of inherent clinical value, several studies have shown that these effects are lost and even reversed when statins are withdrawn.2428 During statin treatment, absence of isoprenoid intermediaries induces cytosolic accumulation of nonactivated Rho and Rac proteins. Abrupt cessation of statins activates Rho/Rac‐kinase pathways, leading to unregulated inflammation, platelet hyper‐activation, and endothelial dysfunction.24, 25, 28, 29 For instance, statin withdrawal in mice‐models leads to an overshoot activation of Rho, resulting in down‐regulation of endothelial nitric oxide production,25 activation of nicotinamide adenine dinucleotide phosphate (NAD[P]H)‐oxidase, and increased superoxide production.29 In another mouse‐model, statin withdrawal was associated with up‐regulation of key pro‐thrombotic molecules including platelet factor 4 and beta‐thromboglobulin.24 In human studies, a platelet hyper‐activation state (manifested by increased platelet P‐selectin expression and enhanced platelet aggregation) occurs after statin discontinuation.27 Furthermore, withdrawal of statins in patients with hyperlipidemia increases inflammatory markers such as C‐reactive protein and interleukin‐6.26 In the perioperative context, absence of these important anti‐inflammatory properties increases the risk of cardiac events.9, 10
EVIDENCE SUGGESTING BENEFIT FROM PERIOPERATIVE STATIN TREATMENT
Retrospective studies first suggested clinical benefit from perioperative statin treatment. In a case‐control study involving 2816 patients undergoing vascular surgery at Erasmus Medical Center, statin use was associated with substantially decreased postoperative mortality (adjusted odd ratio [OR] 0.22, 95% confidence interval [CI] 0.100.47).5 In a subsequent retrospective cohort study of 780,591 patients who underwent major noncardiac surgery, the risk of postoperative mortality was considerably lower among statin users (unadjusted OR 0.68, 95% CI 0.640.72) compared to patients who did not receive, or received delayed treatment with statins.3 A third retrospective study of 1163 vascular surgery patients found that statins prevented perioperative cardiac complications including death, MI, congestive heart failure, and ventricular tachyarrhythmias (OR 0.52, 95% CI 0.350.76).4
The benefit from statin treatment found in retrospective studies prompted the first double‐blinded, randomized controlled trial (RCT) of perioperative statin use. In 2004, Durazzo and colleagues1 randomized 100 statin‐naive patients scheduled to undergo elective aortic, femoro‐popliteal, or carotid surgery to receive either 20 mg of atorvastatin or placebo for 45 days. Vascular surgery was performed, on average, 31 days after randomization. Atorvastatin therapy reduced the incidence of death from cardiac causes, nonfatal acute MI, ischemic stroke, and unstable angina (26% in the placebo group vs 8% in the atorvastatin group; P = 0.031).1 Although the small size of the trial rendered it underpowered to show a mortality benefit, this remains the first RCT to demonstrate a protective perioperative effect of statins.
In the 2009 Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE)‐III trial, Schouten and colleagues6 randomized 497 high‐risk, statin‐naive patients undergoing vascular surgery to receive, in addition to a beta‐blocker, either fluvastatin or placebo before surgery (median of 37 days). Postoperative myocardial ischemia (hazard ratio [HR] 0.55, 95% CI 0.340.88), and combined death from cardiovascular causes or nonfatal MI (HR 0.47, 95% CI 0.240.94), occurred less frequently in the treatment group.6 In 2009, the same group published DECREASE‐IV, a multicenter, prospective, open‐label, 2 2 factorial design trial of 1066 intermediate‐risk patients, scheduled to undergo elective, noncardiac surgery. Patients were assigned to bisoprolol, fluvastatin, combination treatment, or control therapy before surgery (median of 34 days). Although those randomized to fluvastatin demonstrated lower incidence of 30‐day cardiac death and MI than control (HR 0.65, 95% CI 0.351.10), these outcomes failed to reach statistical significance as the trial was principally powered to examine the effects of perioperative beta‐blockade.30
Using this pool of data, a meta‐analysis of 15 studies (223,010 patients) found a substantial 38% reduction in the risk of mortality after cardiac surgery (1.9% vs 3.1%; P = 0.0001) and an even greater 59% reduction in the risk of mortality following vascular surgery (1.7% vs 6.1%; P = 0.0001) with perioperative statin therapy. When including noncardiac surgery, a 44% reduction in mortality was observed (2.2% vs 3.2%; P < 0.01).2 We performed a similar meta‐analysis of 15 RCTs involving 2292 patients to determine whether perioperative statin treatment in statin‐naive patients, undergoing either cardiac or noncardiac surgery, improved clinical outcomes. Our analysis also found statistically significant reductions in the risk of MI associated with perioperative statin use in both cardiac and noncardiac surgery (risk reduction [RR] 0.53, 95% CI 0.380.74) and atrial fibrillation in statin‐naive patients undergoing cardiac surgery (RR 0.56, 95% CI 0.450.69).31 Taken together, a large volume of evidence supports the use of statins in surgical settings.
In view of this evidence, the ACCF/AHA perioperative guidelines for noncardiac surgery endorsed statins as an important risk‐reducing intervention in those undergoing noncardiac surgery, and recommended continued use in patients on chronic statin treatment scheduled for noncardiac surgery (Level of Evidence B, Class I; Benefits >>> Risk). Initiating statins in patients undergoing vascular surgery, with or without risk factors, was considered reasonable (Level of Evidence B, Class IIa; Benefits >> Risk).7 Current ESC perioperative guidelines in noncardiac surgery offer similar recommendations to those of ACCF/AHA, but differ by categorizing the recommendation to initiate statins in patients at high cardiovascular risk as a Class I recommendation.8
CLINICAL CONSEQUENCES OF STATIN WITHDRAWAL
Although statins provide important cardiac benefits, an important limitation to their perioperative use remains their oral‐only formulation. Thus, patients who are unable to resume oral intake may fail to resume treatment. Perioperative statin cessation has been hypothesized to lead to a statin withdrawal phenomenon. The evidence that supports the existence of this phenomenon comes from 3 distinct populations: ACS, ischemic stroke, and perioperative patients (Table 1).
Author (ref) Year | Design | Study Population | Sample Size (N) (Total/ Continuation/Discontinuation) | Clinical Setting and Context | Timing of Statin Discontinuation | Study Outcome | Results (Withdrawal vs Continuation) |
---|---|---|---|---|---|---|---|
| |||||||
Heeschen et al33 2002 | Retrospective cohort | Mostly men (68%) in early 60s | 1616/379/86 | Chest pain in ACS | During or after admission | Incidence of death and nonfatal MI | OR (95% CI) |
2.93 (1.646.27) | |||||||
Spencer et al32 2004 | Retrospective cohort | Mostly men (62%) in late 60s | 68,506/9001/487 | NonST‐segment elevation MI | During the first 24 hr of hospitalization | In‐hospital death | HR (95% CI) |
1.83 (1.582.13) | |||||||
Daskalopoulou et al34 2008 | Retrospective cohort | 60% men in late 60s | 9939/2026/137 Non‐users 2124 (reference group) | Acute MI | Within 1 yr of the coronary event | 1‐yr all‐cause mortality | HR (95% CI) |
1.88 (1.133.07)* | |||||||
Colivicchi et al36 2007 | Prospective cohort | 51% men in early 70s | 631/385/246 | Ischemic stroke | Mean 48.6 days | 1‐yr all‐cause mortality | HR (95% CI) |
2.78 (1.963.72) | |||||||
Blanco et al37 2007 | RCT | 51% men in mid‐60s | 215/46/43 | Ischemic stroke | N/A | Risk of death or dependency at 3 mo | OR (95% CI) |
4.66 (1.4614.91) | |||||||
Early neurologic deterioration | OR (95% CI) | ||||||
7.08 (2.7318.37) | |||||||
Le Manach et al9 2007 | Quasi‐experimental (prepost) | Mostly men (89%) in late‐60s | 669/178/491 | Infra‐renal aortic surgery | Median of 4 days off statins | Postoperative troponin release, MI | OR (95% CI) |
2.9 (1.65.5) | |||||||
Schouten et al10 2007 | Prospective cohort | Mostly men (75%) in mid‐60s | 298/228/70 | Aortic and lower extremity vascular surgery | Median of 3 days off statins | Postoperative troponin release | HR (95% CI) |
4.6 (2.29.6) | |||||||
Combination of postoperative MI and CV death | HR (95% CI) | ||||||
7.5 (2.820.1) | |||||||
Schouten et al6 2009 | RCT | Mostly men (75%) in mid‐60s | 250/189/61 | Vascular surgery (carotid, abdominal aortic, endovascular, and lower extremity arterial) | Median of 2 days off statins | Postoperative myocardial ischemia and combined death from cardiovascular causes or nonfatal MI | OR (95% CI) |
1.1 (0.482.52) |
Statin Withdrawal in Acute Coronary Syndromes
Several studies have demonstrated an association between statin withdrawal and heightened risk of cardiovascular events in ACS.3234 In a retrospective analysis of 1616 patients presenting with ACS, withdrawal of statins during or after admission was associated with more frequent death and nonfatal MI compared to those who continued therapy (OR 2.93, 95% CI 1.646.27).33 In another retrospective observational study of 68,606 nonST‐segment elevation MI patients, statin cessation during the first 24 hours of hospitalization was independently associated with adverse outcomes including in‐hospital death (adjusted HR 1.83; 95% CI 1.582.13), cardiac arrest, and cardiogenic shock.32 In a population‐based, cohort study in the United Kingdom, statin cessation following an acute MI was independently associated with greater all‐cause mortality at 1‐year (adjusted HR 1.88, 95% CI 1.133.07).34
The significantly increased risk of adverse outcomes associated with the interruption of statins in ACS may be moderated by vascular inflammation related to the inciting coronary event, as statin discontinuation in patients with stable cardiac conditions was not associated with increased risk of cardiovascular events in a large‐scale, double‐blind, parallel‐group study.35
Statin Withdrawal in Ischemic Stroke
Adverse events associated with statin withdrawal have also been reported in patients with cerebrovascular disease. In a prospective observational study of 631 consecutive stroke survivors, those who discontinued statins (owing to mild adverse effects or unclear reasons) experienced increased mortality during the first year after the event (adjusted HR 2.78, 95% CI 1.963.72).36 Using a controversial study design aimed at evaluating the effects of stopping oral intake (including chronic medications) during the first days of acute stroke, Blanco and colleagues37 randomized 89 stroke victims on chronic statins to either continue medications or experience statin withdrawal following admission. Statin withdrawal was independently associated with increased risk of mortality and dependency at 3 months (OR 4.66, 95% CI 1.4614.91).37
Perioperative Statin Withdrawal
In the perioperative setting, statin withdrawal has also been associated with adverse outcomes. Using a quasi‐experimental design, Le Manach et al.9 evaluated the risk of cardiac complications after infra‐renal aortic surgery when immediate, postoperative resumption of statins was adopted at their institution. The investigators compared the risk of developing MI, cardiac death, or abnormal troponin release in 491 patients who did not get early postoperative statin resumption (pre‐intervention group) to 178 patients who did. Statin withdrawal for 4 days was demonstrated to be an independent predictor of postoperative troponin leak and MI (OR 2.9, 95% CI 1.65.5). Similarly, Schouten et al.10 investigated the risk of adverse events related to interruption of long‐term statins by examining cardiac outcomes in 298 statin users undergoing major vascular surgery. Among the 70 patients who experienced statin withdrawal, an increased risk of postoperative troponin release (HR 4.6, 95% CI 2.29.6), and the composite endpoint of MI and cardiovascular death (HR 7.5, 95% CI 2.820.1), was observed compared to those who resumed treatment. Not unexpectedly, the most common reason for statin cessation was inability to take oral medications after surgery. However, even in patients who discontinued statins, the use of extended‐release fluvastatin was associated with fewer perioperative cardiac events than other statins. Furthermore, extended‐release fluvastatin was also held for 2 days following surgery (owing to inability to take the drug orally), in 25% of patients in the DECREASE‐III study. However, no impact in the rate of adverse outcomes was noted despite this interruption (OR 1.1, 95% CI 0.482.52).6 Although the authors surmised that the extended formulation of fluvastatin had provided sustained levels of statin activity despite lack of timely oral intake, it is important to note that this theory may not be generalizable to chronic statin users, as they were not enrolled in this study. Conversely, some patients may have experienced postoperative ileus for longer than 2 days, perhaps resulting in confounding or attenuation of the effect noted in the study.
CLINICAL INSIGHTS INTO FAILURE OF POSTOPERATIVE STATIN RESUMPTION
We hypothesize that failure to resume perioperative statins may occur for 4 cardinal reasons. First, resumption of an oral agent frequently proves clinically challenging when complications such as postoperative ileus, nausea, and vomiting peak. To date, no intravenous statin formulations are available, although phase‐I studies are currently underway.38 Second, it is not inconceivable that perioperative clinical instability may overshadow the resumption of statin treatment. Third, clinicians may also remain concerned regarding adverse effects of statins, a thought compounded by US Food and Drug Administration statin package inserts that specifically advocate for statins to be withheld during surgery. However, although the occurrence of elevated liver function tests and myopathy are theoretically important, the overwhelming majority of perioperative statin studies in noncardiac surgery have not found this to be a major occurrence.39 Nonetheless, a lack of uniform definitions and appropriate surveillance for adverse events are important limitations to this finding. In our recent systematic review, we were unable to provide refined estimates of these important side effects owing to differences in definition, variations in screening, and absence of standardized cutoffs used in studies.31 Finally, an important reason for failing to resume postoperative statins is that many physicians simply fail to recognize the perioperative importance of these agents.
STRATEGIES TO IMPROVE PERIOPERATIVE STATIN RESUMPTION
Using the existing evidence, we propose the following 4 clinical strategies to assist in avoiding a statin withdrawal state.
Nasogastric Administration
Utilizing a post‐pyloric nasogastric tube is a straightforward solution to provide statins in those who cannot otherwise tolerate oral intake due to nausea or emesis. Although this solution is hardly innovative, it is relevant as it forces consideration of the need to resume postoperative statins by available means. While the development of a high nasogastric output or a prolonged ileus may limit the applicability of this intervention, it is important that this option be considered as opposed to expectant watching for the clinical return of bowel function. Simvastatin, atorvastatin, rosuvastatin, and pravastatin can be crushed and delivered through this route.40
Development of Reminder Systems
Computerized reminder systems have proved important in ensuring the resumption of deep venous thrombosis prophylaxis and other preventative care compliance in hospitalized patients.41, 42 Using this process, pharmacist‐ or electronic health record‐based reminder systems could be implemented to ensure that statins are restarted when clinically feasible. Further studies are needed to test whether this approach can lead to improved outcomes.
Medication Reconciliation Prior to Hospital Discharge
Statin withdrawal highlights the pertinence of a robust, medical reconciliation process prior to the patient's departure from the hospital. In this context, the development of policies using single‐ or multi‐faceted interventions that promote cooperation between inpatient physicians, surgeons, and pharmacists with outpatient primary care providers are necessary.43
Preoperative Transition to Extended Release Statin Formulations
An innovative approach to minimizing statin withdrawal involves preoperative transition to an extended‐release statin formulation. This strategy may be of particular value in patients where prolonged bowel nonavailability is likely, such as those undergoing gastrointestinal surgery, or when prolonged postoperative dietary restriction (eg, NPO [nil per os]: nothing by mouth) status is expected (Figure 2).

CONCLUSIONS AND FUTURE DIRECTIONS
Sudden withdrawal of perioperative statins results in adverse clinical outcomes. Individuals engaged in the care of patients during surgery such as hospitalists, anesthesiologists, and surgeons must become more cognizant of a statin withdrawal state.
An important limitation associated with the study of perioperative statin withdrawal remains the ambiguity regarding the extent of the problem in the United States. Therefore, a logical first step could be the use of infrastructure within the National Surgical Quality Improvement Program (NSQIP) to understand the epidemiology of perioperative statin use and consequences associated with statin discontinuation.44 Mandating such quality reporting could easily be built into current NSQIP performance metrics. These data would help inform a research agenda targeting patients that experience statin withdrawal and strategies most likely to prevent it.
Note Added in Proof
Disclosure: Nothing to report.
- Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg. 2004;39(5):967–975. , , , et al.
- Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology. 2006;105(6):1260–1272; quiz 1289–1290. , , , , , .
- Lipid‐lowering therapy and in‐hospital mortality following major noncardiac surgery. JAMA. 2004;291(17):2092–2099. , , , , .
- Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol. 2005;45(3):336–342. , , , et al.
- Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003;107(14):1848–1851. , , , et al.
- Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009;361(10):980–989. , , , et al.
- ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation. 2007;116(17):e418–e499. , , , et al.
- Guidelines for pre‐operative cardiac risk assessment and perioperative cardiac management in non‐cardiac surgery. Eur Heart J. 2009;30(22):2769–2812. , , , et al.
- The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg. 2007;104(6):1326–1333. , , , et al.
- Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol. 2007;100(2):316–320. , , , et al.
- Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 suppl 1):III39–III43. .
- Persistent endocrine stress response in patients undergoing cardiac surgery. J Endocrinol Invest. 1998;21(1):12–19. , , , , , .
- Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol. 1996;57(1):37–44. , , , , , .
- Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. Can Med Assoc J. 2005;173(6):627–634. , , , , , .
- Perioperative cardiac morbidity. Anesthesiology. 1990;72(1):153–184. .
- Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003;5(5):372–378. , .
- Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129–1135. , , , .
- Roles of rho‐associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol. 2007;49(6):698–705. , , , et al.
- Inhibition of rho‐associated kinase results in suppression of neointimal formation of balloon‐injured arteries. Circulation. 2000;101(17):2030–2033. , , , et al.
- Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis. 2002;162(1):179–185. , , , .
- Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108(10):1429–1437. , , , et al.
- Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37–44. , , .
- Inhibition of geranylgeranylation reduces angiotensin II‐mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59(3):646–654. , , , et al.
- Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003;34(2):551–557. , , , et al.
- Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000;102(25):3104–3110. , , , et al.
- Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta. 2006;366(1–2):269–273. , , , et al.
- Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost. 2003;90(3):476–482. , , , et al.
- Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis. 2009;207(1):191–194. , , , et al.
- Effects of statins on endothelium and signaling mechanisms. Stroke. 2004;35(11 suppl 1):2708–2711. , .
- Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate‐risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE‐IV). Ann Surg. 2009;249(6):921–926. , , , et al.
- Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta‐analysis. Arch Surg. 2012;147(2):181–189. , , , et al.
- Early withdrawal of statin therapy in patients with non‐ST‐segment elevation myocardial infarction: National Registry of Myocardial Infarction. Arch Intern Med. 2004;164(19):2162–2168. , , , et al.
- Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105(12):1446–1452. , , , , , .
- Discontinuation of statin therapy following an acute myocardial infarction: a population‐based study. Eur Heart J. 2008;29(17):2083–2091. , , , , , .
- There is no evidence for an increase in acute coronary syndromes after short‐term abrupt discontinuation of statins in stable cardiac patients. Circulation. 2004;110(16):2333–2335. .
- Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke. 2007;38(10):2652–2657. , , , .
- Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69(9):904–910. , , , et al.
- Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke. 2008;39(2):433–438. , , , et al.
- Safety of perioperative statin use in high‐risk patients undergoing major vascular surgery. Am J Cardiol. 2005;95(5):658–660. , , , et al.
- Lexi‐Comp Online™, Lexi‐Drugs™, Hudson, OH: Lexi‐Comp, Inc; December 7, 2011.
- A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med. 2001;345(13):965–970. , , , , , .
- Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969–977. , , , et al.
- Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review. Br J Clin Pharmacol. January 13, 2012. doi: 10.1111/j.1365–2125.2012.04178.x. , , , .
- American College of Surgeons National Surgical Quality Improvement Program. Available at: http://www.acsnsqip.org. Accessed December 15, 2012.
Accumulating evidence suggests that perioperative treatment with 3‐hydroxy‐3‐methylglutaryl coenzyme‐A (HMG‐CoA) reductase inhibitors (or, statins) reduces the incidence of cardiovascular events during noncardiac surgery.16 This evidence has lead the European Society of Cardiology (ESC) and American College of Cardiology Foundation/American Heart Association (ACCF/AHA) to endorse the use of perioperative statins in patients already on this treatment or those at high‐risk of cardiovascular events.7, 8
However, statins are available only in oral formulation. Consequently, prolonged bowel recovery or clinical instability may interfere with use during surgery. Furthermore, many clinicians may not recognize the imperative of postoperative statin resumption, viewing them principally as lipid‐lowering entities and not as agents of perioperative benefit. Failure to resume statins postoperatively can be catastrophic, as the ensuing inflammation and thrombosis frequently culminates in myocardial infarction (MI) or death.9, 10
In this article, we review the potent anti‐inflammatory properties of statins and their role in preventing perioperative cardiac events. We outline the biochemical basis for perioperative statin benefit, summarizing the basic, clinical, and experimental evidence regarding statin withdrawal. We conclude by presenting strategies to avert postoperative statin cessation and outline a research agenda dedicated to informing this practice.
METHODS
We performed a literature search using MEDLINE via Ovid (1946present), EMBASE (1946present), Biosis (1926present), and Cochrane CENTRAL (1960present). We used Boolean logic to search for key terms including statins, 3‐hydroxy‐3‐methylglutaryl CoA reductase inhibitors, death, MI, stroke, acute coronary syndrome (ACS), and statin withdrawal or cessation. All studies published in full‐text or abstract form were included. A total of 489 articles were retrieved by this search (last updated March 15, 2012). For this narrative review, we focused on studies that examined adverse outcomes associated with statin withdrawal.
BIOCHEMICAL BASIS OF STATIN PLEIOTROPICITY
The nonlipid‐lowering or pleiotropic properties of statins are especially valuable in the perioperative setting.16, 11 Perioperative cardiac complications occur due to oxygen supply:demand mismatch, vascular inflammation, or a combination of these states. A significant perisurgical catecholamine surge produces unopposed sympathetic effects,12 increasing the risk of rupture of vulnerable coronary plaques, thrombus formation, and adverse cardiac events.13, 14 Similarly, augmented inflammatory responses and increased circulating coagulation factors further predispose to a hazardous perioperative milieu.15 Statins attenuate this vascular inflammatory response by suppressing the synthesis of mevalonate by inhibiting HMG‐CoA reductase. Suppression of mevalonate synthesis reduces the bioavailability of 2 important isoprenoid molecules: farnesyl‐pyrophosphate and geranylgeranyl‐pyrophosphate.16 Diminution of these isoprenoid intermediaries leads to reductions in the active intracellular signaling molecules Ras, Rho, and Rac, which play critical roles in vascular reactivity, endothelial function, and coagulation and inflammatory pathways.1723 The cumulative effect of these cellular changes is diminished inflammation during periods of surgical stress (Figure 1).

While the perioperative pleiotropicity of statins is of inherent clinical value, several studies have shown that these effects are lost and even reversed when statins are withdrawn.2428 During statin treatment, absence of isoprenoid intermediaries induces cytosolic accumulation of nonactivated Rho and Rac proteins. Abrupt cessation of statins activates Rho/Rac‐kinase pathways, leading to unregulated inflammation, platelet hyper‐activation, and endothelial dysfunction.24, 25, 28, 29 For instance, statin withdrawal in mice‐models leads to an overshoot activation of Rho, resulting in down‐regulation of endothelial nitric oxide production,25 activation of nicotinamide adenine dinucleotide phosphate (NAD[P]H)‐oxidase, and increased superoxide production.29 In another mouse‐model, statin withdrawal was associated with up‐regulation of key pro‐thrombotic molecules including platelet factor 4 and beta‐thromboglobulin.24 In human studies, a platelet hyper‐activation state (manifested by increased platelet P‐selectin expression and enhanced platelet aggregation) occurs after statin discontinuation.27 Furthermore, withdrawal of statins in patients with hyperlipidemia increases inflammatory markers such as C‐reactive protein and interleukin‐6.26 In the perioperative context, absence of these important anti‐inflammatory properties increases the risk of cardiac events.9, 10
EVIDENCE SUGGESTING BENEFIT FROM PERIOPERATIVE STATIN TREATMENT
Retrospective studies first suggested clinical benefit from perioperative statin treatment. In a case‐control study involving 2816 patients undergoing vascular surgery at Erasmus Medical Center, statin use was associated with substantially decreased postoperative mortality (adjusted odd ratio [OR] 0.22, 95% confidence interval [CI] 0.100.47).5 In a subsequent retrospective cohort study of 780,591 patients who underwent major noncardiac surgery, the risk of postoperative mortality was considerably lower among statin users (unadjusted OR 0.68, 95% CI 0.640.72) compared to patients who did not receive, or received delayed treatment with statins.3 A third retrospective study of 1163 vascular surgery patients found that statins prevented perioperative cardiac complications including death, MI, congestive heart failure, and ventricular tachyarrhythmias (OR 0.52, 95% CI 0.350.76).4
The benefit from statin treatment found in retrospective studies prompted the first double‐blinded, randomized controlled trial (RCT) of perioperative statin use. In 2004, Durazzo and colleagues1 randomized 100 statin‐naive patients scheduled to undergo elective aortic, femoro‐popliteal, or carotid surgery to receive either 20 mg of atorvastatin or placebo for 45 days. Vascular surgery was performed, on average, 31 days after randomization. Atorvastatin therapy reduced the incidence of death from cardiac causes, nonfatal acute MI, ischemic stroke, and unstable angina (26% in the placebo group vs 8% in the atorvastatin group; P = 0.031).1 Although the small size of the trial rendered it underpowered to show a mortality benefit, this remains the first RCT to demonstrate a protective perioperative effect of statins.
In the 2009 Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE)‐III trial, Schouten and colleagues6 randomized 497 high‐risk, statin‐naive patients undergoing vascular surgery to receive, in addition to a beta‐blocker, either fluvastatin or placebo before surgery (median of 37 days). Postoperative myocardial ischemia (hazard ratio [HR] 0.55, 95% CI 0.340.88), and combined death from cardiovascular causes or nonfatal MI (HR 0.47, 95% CI 0.240.94), occurred less frequently in the treatment group.6 In 2009, the same group published DECREASE‐IV, a multicenter, prospective, open‐label, 2 2 factorial design trial of 1066 intermediate‐risk patients, scheduled to undergo elective, noncardiac surgery. Patients were assigned to bisoprolol, fluvastatin, combination treatment, or control therapy before surgery (median of 34 days). Although those randomized to fluvastatin demonstrated lower incidence of 30‐day cardiac death and MI than control (HR 0.65, 95% CI 0.351.10), these outcomes failed to reach statistical significance as the trial was principally powered to examine the effects of perioperative beta‐blockade.30
Using this pool of data, a meta‐analysis of 15 studies (223,010 patients) found a substantial 38% reduction in the risk of mortality after cardiac surgery (1.9% vs 3.1%; P = 0.0001) and an even greater 59% reduction in the risk of mortality following vascular surgery (1.7% vs 6.1%; P = 0.0001) with perioperative statin therapy. When including noncardiac surgery, a 44% reduction in mortality was observed (2.2% vs 3.2%; P < 0.01).2 We performed a similar meta‐analysis of 15 RCTs involving 2292 patients to determine whether perioperative statin treatment in statin‐naive patients, undergoing either cardiac or noncardiac surgery, improved clinical outcomes. Our analysis also found statistically significant reductions in the risk of MI associated with perioperative statin use in both cardiac and noncardiac surgery (risk reduction [RR] 0.53, 95% CI 0.380.74) and atrial fibrillation in statin‐naive patients undergoing cardiac surgery (RR 0.56, 95% CI 0.450.69).31 Taken together, a large volume of evidence supports the use of statins in surgical settings.
In view of this evidence, the ACCF/AHA perioperative guidelines for noncardiac surgery endorsed statins as an important risk‐reducing intervention in those undergoing noncardiac surgery, and recommended continued use in patients on chronic statin treatment scheduled for noncardiac surgery (Level of Evidence B, Class I; Benefits >>> Risk). Initiating statins in patients undergoing vascular surgery, with or without risk factors, was considered reasonable (Level of Evidence B, Class IIa; Benefits >> Risk).7 Current ESC perioperative guidelines in noncardiac surgery offer similar recommendations to those of ACCF/AHA, but differ by categorizing the recommendation to initiate statins in patients at high cardiovascular risk as a Class I recommendation.8
CLINICAL CONSEQUENCES OF STATIN WITHDRAWAL
Although statins provide important cardiac benefits, an important limitation to their perioperative use remains their oral‐only formulation. Thus, patients who are unable to resume oral intake may fail to resume treatment. Perioperative statin cessation has been hypothesized to lead to a statin withdrawal phenomenon. The evidence that supports the existence of this phenomenon comes from 3 distinct populations: ACS, ischemic stroke, and perioperative patients (Table 1).
Author (ref) Year | Design | Study Population | Sample Size (N) (Total/ Continuation/Discontinuation) | Clinical Setting and Context | Timing of Statin Discontinuation | Study Outcome | Results (Withdrawal vs Continuation) |
---|---|---|---|---|---|---|---|
| |||||||
Heeschen et al33 2002 | Retrospective cohort | Mostly men (68%) in early 60s | 1616/379/86 | Chest pain in ACS | During or after admission | Incidence of death and nonfatal MI | OR (95% CI) |
2.93 (1.646.27) | |||||||
Spencer et al32 2004 | Retrospective cohort | Mostly men (62%) in late 60s | 68,506/9001/487 | NonST‐segment elevation MI | During the first 24 hr of hospitalization | In‐hospital death | HR (95% CI) |
1.83 (1.582.13) | |||||||
Daskalopoulou et al34 2008 | Retrospective cohort | 60% men in late 60s | 9939/2026/137 Non‐users 2124 (reference group) | Acute MI | Within 1 yr of the coronary event | 1‐yr all‐cause mortality | HR (95% CI) |
1.88 (1.133.07)* | |||||||
Colivicchi et al36 2007 | Prospective cohort | 51% men in early 70s | 631/385/246 | Ischemic stroke | Mean 48.6 days | 1‐yr all‐cause mortality | HR (95% CI) |
2.78 (1.963.72) | |||||||
Blanco et al37 2007 | RCT | 51% men in mid‐60s | 215/46/43 | Ischemic stroke | N/A | Risk of death or dependency at 3 mo | OR (95% CI) |
4.66 (1.4614.91) | |||||||
Early neurologic deterioration | OR (95% CI) | ||||||
7.08 (2.7318.37) | |||||||
Le Manach et al9 2007 | Quasi‐experimental (prepost) | Mostly men (89%) in late‐60s | 669/178/491 | Infra‐renal aortic surgery | Median of 4 days off statins | Postoperative troponin release, MI | OR (95% CI) |
2.9 (1.65.5) | |||||||
Schouten et al10 2007 | Prospective cohort | Mostly men (75%) in mid‐60s | 298/228/70 | Aortic and lower extremity vascular surgery | Median of 3 days off statins | Postoperative troponin release | HR (95% CI) |
4.6 (2.29.6) | |||||||
Combination of postoperative MI and CV death | HR (95% CI) | ||||||
7.5 (2.820.1) | |||||||
Schouten et al6 2009 | RCT | Mostly men (75%) in mid‐60s | 250/189/61 | Vascular surgery (carotid, abdominal aortic, endovascular, and lower extremity arterial) | Median of 2 days off statins | Postoperative myocardial ischemia and combined death from cardiovascular causes or nonfatal MI | OR (95% CI) |
1.1 (0.482.52) |
Statin Withdrawal in Acute Coronary Syndromes
Several studies have demonstrated an association between statin withdrawal and heightened risk of cardiovascular events in ACS.3234 In a retrospective analysis of 1616 patients presenting with ACS, withdrawal of statins during or after admission was associated with more frequent death and nonfatal MI compared to those who continued therapy (OR 2.93, 95% CI 1.646.27).33 In another retrospective observational study of 68,606 nonST‐segment elevation MI patients, statin cessation during the first 24 hours of hospitalization was independently associated with adverse outcomes including in‐hospital death (adjusted HR 1.83; 95% CI 1.582.13), cardiac arrest, and cardiogenic shock.32 In a population‐based, cohort study in the United Kingdom, statin cessation following an acute MI was independently associated with greater all‐cause mortality at 1‐year (adjusted HR 1.88, 95% CI 1.133.07).34
The significantly increased risk of adverse outcomes associated with the interruption of statins in ACS may be moderated by vascular inflammation related to the inciting coronary event, as statin discontinuation in patients with stable cardiac conditions was not associated with increased risk of cardiovascular events in a large‐scale, double‐blind, parallel‐group study.35
Statin Withdrawal in Ischemic Stroke
Adverse events associated with statin withdrawal have also been reported in patients with cerebrovascular disease. In a prospective observational study of 631 consecutive stroke survivors, those who discontinued statins (owing to mild adverse effects or unclear reasons) experienced increased mortality during the first year after the event (adjusted HR 2.78, 95% CI 1.963.72).36 Using a controversial study design aimed at evaluating the effects of stopping oral intake (including chronic medications) during the first days of acute stroke, Blanco and colleagues37 randomized 89 stroke victims on chronic statins to either continue medications or experience statin withdrawal following admission. Statin withdrawal was independently associated with increased risk of mortality and dependency at 3 months (OR 4.66, 95% CI 1.4614.91).37
Perioperative Statin Withdrawal
In the perioperative setting, statin withdrawal has also been associated with adverse outcomes. Using a quasi‐experimental design, Le Manach et al.9 evaluated the risk of cardiac complications after infra‐renal aortic surgery when immediate, postoperative resumption of statins was adopted at their institution. The investigators compared the risk of developing MI, cardiac death, or abnormal troponin release in 491 patients who did not get early postoperative statin resumption (pre‐intervention group) to 178 patients who did. Statin withdrawal for 4 days was demonstrated to be an independent predictor of postoperative troponin leak and MI (OR 2.9, 95% CI 1.65.5). Similarly, Schouten et al.10 investigated the risk of adverse events related to interruption of long‐term statins by examining cardiac outcomes in 298 statin users undergoing major vascular surgery. Among the 70 patients who experienced statin withdrawal, an increased risk of postoperative troponin release (HR 4.6, 95% CI 2.29.6), and the composite endpoint of MI and cardiovascular death (HR 7.5, 95% CI 2.820.1), was observed compared to those who resumed treatment. Not unexpectedly, the most common reason for statin cessation was inability to take oral medications after surgery. However, even in patients who discontinued statins, the use of extended‐release fluvastatin was associated with fewer perioperative cardiac events than other statins. Furthermore, extended‐release fluvastatin was also held for 2 days following surgery (owing to inability to take the drug orally), in 25% of patients in the DECREASE‐III study. However, no impact in the rate of adverse outcomes was noted despite this interruption (OR 1.1, 95% CI 0.482.52).6 Although the authors surmised that the extended formulation of fluvastatin had provided sustained levels of statin activity despite lack of timely oral intake, it is important to note that this theory may not be generalizable to chronic statin users, as they were not enrolled in this study. Conversely, some patients may have experienced postoperative ileus for longer than 2 days, perhaps resulting in confounding or attenuation of the effect noted in the study.
CLINICAL INSIGHTS INTO FAILURE OF POSTOPERATIVE STATIN RESUMPTION
We hypothesize that failure to resume perioperative statins may occur for 4 cardinal reasons. First, resumption of an oral agent frequently proves clinically challenging when complications such as postoperative ileus, nausea, and vomiting peak. To date, no intravenous statin formulations are available, although phase‐I studies are currently underway.38 Second, it is not inconceivable that perioperative clinical instability may overshadow the resumption of statin treatment. Third, clinicians may also remain concerned regarding adverse effects of statins, a thought compounded by US Food and Drug Administration statin package inserts that specifically advocate for statins to be withheld during surgery. However, although the occurrence of elevated liver function tests and myopathy are theoretically important, the overwhelming majority of perioperative statin studies in noncardiac surgery have not found this to be a major occurrence.39 Nonetheless, a lack of uniform definitions and appropriate surveillance for adverse events are important limitations to this finding. In our recent systematic review, we were unable to provide refined estimates of these important side effects owing to differences in definition, variations in screening, and absence of standardized cutoffs used in studies.31 Finally, an important reason for failing to resume postoperative statins is that many physicians simply fail to recognize the perioperative importance of these agents.
STRATEGIES TO IMPROVE PERIOPERATIVE STATIN RESUMPTION
Using the existing evidence, we propose the following 4 clinical strategies to assist in avoiding a statin withdrawal state.
Nasogastric Administration
Utilizing a post‐pyloric nasogastric tube is a straightforward solution to provide statins in those who cannot otherwise tolerate oral intake due to nausea or emesis. Although this solution is hardly innovative, it is relevant as it forces consideration of the need to resume postoperative statins by available means. While the development of a high nasogastric output or a prolonged ileus may limit the applicability of this intervention, it is important that this option be considered as opposed to expectant watching for the clinical return of bowel function. Simvastatin, atorvastatin, rosuvastatin, and pravastatin can be crushed and delivered through this route.40
Development of Reminder Systems
Computerized reminder systems have proved important in ensuring the resumption of deep venous thrombosis prophylaxis and other preventative care compliance in hospitalized patients.41, 42 Using this process, pharmacist‐ or electronic health record‐based reminder systems could be implemented to ensure that statins are restarted when clinically feasible. Further studies are needed to test whether this approach can lead to improved outcomes.
Medication Reconciliation Prior to Hospital Discharge
Statin withdrawal highlights the pertinence of a robust, medical reconciliation process prior to the patient's departure from the hospital. In this context, the development of policies using single‐ or multi‐faceted interventions that promote cooperation between inpatient physicians, surgeons, and pharmacists with outpatient primary care providers are necessary.43
Preoperative Transition to Extended Release Statin Formulations
An innovative approach to minimizing statin withdrawal involves preoperative transition to an extended‐release statin formulation. This strategy may be of particular value in patients where prolonged bowel nonavailability is likely, such as those undergoing gastrointestinal surgery, or when prolonged postoperative dietary restriction (eg, NPO [nil per os]: nothing by mouth) status is expected (Figure 2).

CONCLUSIONS AND FUTURE DIRECTIONS
Sudden withdrawal of perioperative statins results in adverse clinical outcomes. Individuals engaged in the care of patients during surgery such as hospitalists, anesthesiologists, and surgeons must become more cognizant of a statin withdrawal state.
An important limitation associated with the study of perioperative statin withdrawal remains the ambiguity regarding the extent of the problem in the United States. Therefore, a logical first step could be the use of infrastructure within the National Surgical Quality Improvement Program (NSQIP) to understand the epidemiology of perioperative statin use and consequences associated with statin discontinuation.44 Mandating such quality reporting could easily be built into current NSQIP performance metrics. These data would help inform a research agenda targeting patients that experience statin withdrawal and strategies most likely to prevent it.
Note Added in Proof
Disclosure: Nothing to report.
Accumulating evidence suggests that perioperative treatment with 3‐hydroxy‐3‐methylglutaryl coenzyme‐A (HMG‐CoA) reductase inhibitors (or, statins) reduces the incidence of cardiovascular events during noncardiac surgery.16 This evidence has lead the European Society of Cardiology (ESC) and American College of Cardiology Foundation/American Heart Association (ACCF/AHA) to endorse the use of perioperative statins in patients already on this treatment or those at high‐risk of cardiovascular events.7, 8
However, statins are available only in oral formulation. Consequently, prolonged bowel recovery or clinical instability may interfere with use during surgery. Furthermore, many clinicians may not recognize the imperative of postoperative statin resumption, viewing them principally as lipid‐lowering entities and not as agents of perioperative benefit. Failure to resume statins postoperatively can be catastrophic, as the ensuing inflammation and thrombosis frequently culminates in myocardial infarction (MI) or death.9, 10
In this article, we review the potent anti‐inflammatory properties of statins and their role in preventing perioperative cardiac events. We outline the biochemical basis for perioperative statin benefit, summarizing the basic, clinical, and experimental evidence regarding statin withdrawal. We conclude by presenting strategies to avert postoperative statin cessation and outline a research agenda dedicated to informing this practice.
METHODS
We performed a literature search using MEDLINE via Ovid (1946present), EMBASE (1946present), Biosis (1926present), and Cochrane CENTRAL (1960present). We used Boolean logic to search for key terms including statins, 3‐hydroxy‐3‐methylglutaryl CoA reductase inhibitors, death, MI, stroke, acute coronary syndrome (ACS), and statin withdrawal or cessation. All studies published in full‐text or abstract form were included. A total of 489 articles were retrieved by this search (last updated March 15, 2012). For this narrative review, we focused on studies that examined adverse outcomes associated with statin withdrawal.
BIOCHEMICAL BASIS OF STATIN PLEIOTROPICITY
The nonlipid‐lowering or pleiotropic properties of statins are especially valuable in the perioperative setting.16, 11 Perioperative cardiac complications occur due to oxygen supply:demand mismatch, vascular inflammation, or a combination of these states. A significant perisurgical catecholamine surge produces unopposed sympathetic effects,12 increasing the risk of rupture of vulnerable coronary plaques, thrombus formation, and adverse cardiac events.13, 14 Similarly, augmented inflammatory responses and increased circulating coagulation factors further predispose to a hazardous perioperative milieu.15 Statins attenuate this vascular inflammatory response by suppressing the synthesis of mevalonate by inhibiting HMG‐CoA reductase. Suppression of mevalonate synthesis reduces the bioavailability of 2 important isoprenoid molecules: farnesyl‐pyrophosphate and geranylgeranyl‐pyrophosphate.16 Diminution of these isoprenoid intermediaries leads to reductions in the active intracellular signaling molecules Ras, Rho, and Rac, which play critical roles in vascular reactivity, endothelial function, and coagulation and inflammatory pathways.1723 The cumulative effect of these cellular changes is diminished inflammation during periods of surgical stress (Figure 1).

While the perioperative pleiotropicity of statins is of inherent clinical value, several studies have shown that these effects are lost and even reversed when statins are withdrawn.2428 During statin treatment, absence of isoprenoid intermediaries induces cytosolic accumulation of nonactivated Rho and Rac proteins. Abrupt cessation of statins activates Rho/Rac‐kinase pathways, leading to unregulated inflammation, platelet hyper‐activation, and endothelial dysfunction.24, 25, 28, 29 For instance, statin withdrawal in mice‐models leads to an overshoot activation of Rho, resulting in down‐regulation of endothelial nitric oxide production,25 activation of nicotinamide adenine dinucleotide phosphate (NAD[P]H)‐oxidase, and increased superoxide production.29 In another mouse‐model, statin withdrawal was associated with up‐regulation of key pro‐thrombotic molecules including platelet factor 4 and beta‐thromboglobulin.24 In human studies, a platelet hyper‐activation state (manifested by increased platelet P‐selectin expression and enhanced platelet aggregation) occurs after statin discontinuation.27 Furthermore, withdrawal of statins in patients with hyperlipidemia increases inflammatory markers such as C‐reactive protein and interleukin‐6.26 In the perioperative context, absence of these important anti‐inflammatory properties increases the risk of cardiac events.9, 10
EVIDENCE SUGGESTING BENEFIT FROM PERIOPERATIVE STATIN TREATMENT
Retrospective studies first suggested clinical benefit from perioperative statin treatment. In a case‐control study involving 2816 patients undergoing vascular surgery at Erasmus Medical Center, statin use was associated with substantially decreased postoperative mortality (adjusted odd ratio [OR] 0.22, 95% confidence interval [CI] 0.100.47).5 In a subsequent retrospective cohort study of 780,591 patients who underwent major noncardiac surgery, the risk of postoperative mortality was considerably lower among statin users (unadjusted OR 0.68, 95% CI 0.640.72) compared to patients who did not receive, or received delayed treatment with statins.3 A third retrospective study of 1163 vascular surgery patients found that statins prevented perioperative cardiac complications including death, MI, congestive heart failure, and ventricular tachyarrhythmias (OR 0.52, 95% CI 0.350.76).4
The benefit from statin treatment found in retrospective studies prompted the first double‐blinded, randomized controlled trial (RCT) of perioperative statin use. In 2004, Durazzo and colleagues1 randomized 100 statin‐naive patients scheduled to undergo elective aortic, femoro‐popliteal, or carotid surgery to receive either 20 mg of atorvastatin or placebo for 45 days. Vascular surgery was performed, on average, 31 days after randomization. Atorvastatin therapy reduced the incidence of death from cardiac causes, nonfatal acute MI, ischemic stroke, and unstable angina (26% in the placebo group vs 8% in the atorvastatin group; P = 0.031).1 Although the small size of the trial rendered it underpowered to show a mortality benefit, this remains the first RCT to demonstrate a protective perioperative effect of statins.
In the 2009 Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE)‐III trial, Schouten and colleagues6 randomized 497 high‐risk, statin‐naive patients undergoing vascular surgery to receive, in addition to a beta‐blocker, either fluvastatin or placebo before surgery (median of 37 days). Postoperative myocardial ischemia (hazard ratio [HR] 0.55, 95% CI 0.340.88), and combined death from cardiovascular causes or nonfatal MI (HR 0.47, 95% CI 0.240.94), occurred less frequently in the treatment group.6 In 2009, the same group published DECREASE‐IV, a multicenter, prospective, open‐label, 2 2 factorial design trial of 1066 intermediate‐risk patients, scheduled to undergo elective, noncardiac surgery. Patients were assigned to bisoprolol, fluvastatin, combination treatment, or control therapy before surgery (median of 34 days). Although those randomized to fluvastatin demonstrated lower incidence of 30‐day cardiac death and MI than control (HR 0.65, 95% CI 0.351.10), these outcomes failed to reach statistical significance as the trial was principally powered to examine the effects of perioperative beta‐blockade.30
Using this pool of data, a meta‐analysis of 15 studies (223,010 patients) found a substantial 38% reduction in the risk of mortality after cardiac surgery (1.9% vs 3.1%; P = 0.0001) and an even greater 59% reduction in the risk of mortality following vascular surgery (1.7% vs 6.1%; P = 0.0001) with perioperative statin therapy. When including noncardiac surgery, a 44% reduction in mortality was observed (2.2% vs 3.2%; P < 0.01).2 We performed a similar meta‐analysis of 15 RCTs involving 2292 patients to determine whether perioperative statin treatment in statin‐naive patients, undergoing either cardiac or noncardiac surgery, improved clinical outcomes. Our analysis also found statistically significant reductions in the risk of MI associated with perioperative statin use in both cardiac and noncardiac surgery (risk reduction [RR] 0.53, 95% CI 0.380.74) and atrial fibrillation in statin‐naive patients undergoing cardiac surgery (RR 0.56, 95% CI 0.450.69).31 Taken together, a large volume of evidence supports the use of statins in surgical settings.
In view of this evidence, the ACCF/AHA perioperative guidelines for noncardiac surgery endorsed statins as an important risk‐reducing intervention in those undergoing noncardiac surgery, and recommended continued use in patients on chronic statin treatment scheduled for noncardiac surgery (Level of Evidence B, Class I; Benefits >>> Risk). Initiating statins in patients undergoing vascular surgery, with or without risk factors, was considered reasonable (Level of Evidence B, Class IIa; Benefits >> Risk).7 Current ESC perioperative guidelines in noncardiac surgery offer similar recommendations to those of ACCF/AHA, but differ by categorizing the recommendation to initiate statins in patients at high cardiovascular risk as a Class I recommendation.8
CLINICAL CONSEQUENCES OF STATIN WITHDRAWAL
Although statins provide important cardiac benefits, an important limitation to their perioperative use remains their oral‐only formulation. Thus, patients who are unable to resume oral intake may fail to resume treatment. Perioperative statin cessation has been hypothesized to lead to a statin withdrawal phenomenon. The evidence that supports the existence of this phenomenon comes from 3 distinct populations: ACS, ischemic stroke, and perioperative patients (Table 1).
Author (ref) Year | Design | Study Population | Sample Size (N) (Total/ Continuation/Discontinuation) | Clinical Setting and Context | Timing of Statin Discontinuation | Study Outcome | Results (Withdrawal vs Continuation) |
---|---|---|---|---|---|---|---|
| |||||||
Heeschen et al33 2002 | Retrospective cohort | Mostly men (68%) in early 60s | 1616/379/86 | Chest pain in ACS | During or after admission | Incidence of death and nonfatal MI | OR (95% CI) |
2.93 (1.646.27) | |||||||
Spencer et al32 2004 | Retrospective cohort | Mostly men (62%) in late 60s | 68,506/9001/487 | NonST‐segment elevation MI | During the first 24 hr of hospitalization | In‐hospital death | HR (95% CI) |
1.83 (1.582.13) | |||||||
Daskalopoulou et al34 2008 | Retrospective cohort | 60% men in late 60s | 9939/2026/137 Non‐users 2124 (reference group) | Acute MI | Within 1 yr of the coronary event | 1‐yr all‐cause mortality | HR (95% CI) |
1.88 (1.133.07)* | |||||||
Colivicchi et al36 2007 | Prospective cohort | 51% men in early 70s | 631/385/246 | Ischemic stroke | Mean 48.6 days | 1‐yr all‐cause mortality | HR (95% CI) |
2.78 (1.963.72) | |||||||
Blanco et al37 2007 | RCT | 51% men in mid‐60s | 215/46/43 | Ischemic stroke | N/A | Risk of death or dependency at 3 mo | OR (95% CI) |
4.66 (1.4614.91) | |||||||
Early neurologic deterioration | OR (95% CI) | ||||||
7.08 (2.7318.37) | |||||||
Le Manach et al9 2007 | Quasi‐experimental (prepost) | Mostly men (89%) in late‐60s | 669/178/491 | Infra‐renal aortic surgery | Median of 4 days off statins | Postoperative troponin release, MI | OR (95% CI) |
2.9 (1.65.5) | |||||||
Schouten et al10 2007 | Prospective cohort | Mostly men (75%) in mid‐60s | 298/228/70 | Aortic and lower extremity vascular surgery | Median of 3 days off statins | Postoperative troponin release | HR (95% CI) |
4.6 (2.29.6) | |||||||
Combination of postoperative MI and CV death | HR (95% CI) | ||||||
7.5 (2.820.1) | |||||||
Schouten et al6 2009 | RCT | Mostly men (75%) in mid‐60s | 250/189/61 | Vascular surgery (carotid, abdominal aortic, endovascular, and lower extremity arterial) | Median of 2 days off statins | Postoperative myocardial ischemia and combined death from cardiovascular causes or nonfatal MI | OR (95% CI) |
1.1 (0.482.52) |
Statin Withdrawal in Acute Coronary Syndromes
Several studies have demonstrated an association between statin withdrawal and heightened risk of cardiovascular events in ACS.3234 In a retrospective analysis of 1616 patients presenting with ACS, withdrawal of statins during or after admission was associated with more frequent death and nonfatal MI compared to those who continued therapy (OR 2.93, 95% CI 1.646.27).33 In another retrospective observational study of 68,606 nonST‐segment elevation MI patients, statin cessation during the first 24 hours of hospitalization was independently associated with adverse outcomes including in‐hospital death (adjusted HR 1.83; 95% CI 1.582.13), cardiac arrest, and cardiogenic shock.32 In a population‐based, cohort study in the United Kingdom, statin cessation following an acute MI was independently associated with greater all‐cause mortality at 1‐year (adjusted HR 1.88, 95% CI 1.133.07).34
The significantly increased risk of adverse outcomes associated with the interruption of statins in ACS may be moderated by vascular inflammation related to the inciting coronary event, as statin discontinuation in patients with stable cardiac conditions was not associated with increased risk of cardiovascular events in a large‐scale, double‐blind, parallel‐group study.35
Statin Withdrawal in Ischemic Stroke
Adverse events associated with statin withdrawal have also been reported in patients with cerebrovascular disease. In a prospective observational study of 631 consecutive stroke survivors, those who discontinued statins (owing to mild adverse effects or unclear reasons) experienced increased mortality during the first year after the event (adjusted HR 2.78, 95% CI 1.963.72).36 Using a controversial study design aimed at evaluating the effects of stopping oral intake (including chronic medications) during the first days of acute stroke, Blanco and colleagues37 randomized 89 stroke victims on chronic statins to either continue medications or experience statin withdrawal following admission. Statin withdrawal was independently associated with increased risk of mortality and dependency at 3 months (OR 4.66, 95% CI 1.4614.91).37
Perioperative Statin Withdrawal
In the perioperative setting, statin withdrawal has also been associated with adverse outcomes. Using a quasi‐experimental design, Le Manach et al.9 evaluated the risk of cardiac complications after infra‐renal aortic surgery when immediate, postoperative resumption of statins was adopted at their institution. The investigators compared the risk of developing MI, cardiac death, or abnormal troponin release in 491 patients who did not get early postoperative statin resumption (pre‐intervention group) to 178 patients who did. Statin withdrawal for 4 days was demonstrated to be an independent predictor of postoperative troponin leak and MI (OR 2.9, 95% CI 1.65.5). Similarly, Schouten et al.10 investigated the risk of adverse events related to interruption of long‐term statins by examining cardiac outcomes in 298 statin users undergoing major vascular surgery. Among the 70 patients who experienced statin withdrawal, an increased risk of postoperative troponin release (HR 4.6, 95% CI 2.29.6), and the composite endpoint of MI and cardiovascular death (HR 7.5, 95% CI 2.820.1), was observed compared to those who resumed treatment. Not unexpectedly, the most common reason for statin cessation was inability to take oral medications after surgery. However, even in patients who discontinued statins, the use of extended‐release fluvastatin was associated with fewer perioperative cardiac events than other statins. Furthermore, extended‐release fluvastatin was also held for 2 days following surgery (owing to inability to take the drug orally), in 25% of patients in the DECREASE‐III study. However, no impact in the rate of adverse outcomes was noted despite this interruption (OR 1.1, 95% CI 0.482.52).6 Although the authors surmised that the extended formulation of fluvastatin had provided sustained levels of statin activity despite lack of timely oral intake, it is important to note that this theory may not be generalizable to chronic statin users, as they were not enrolled in this study. Conversely, some patients may have experienced postoperative ileus for longer than 2 days, perhaps resulting in confounding or attenuation of the effect noted in the study.
CLINICAL INSIGHTS INTO FAILURE OF POSTOPERATIVE STATIN RESUMPTION
We hypothesize that failure to resume perioperative statins may occur for 4 cardinal reasons. First, resumption of an oral agent frequently proves clinically challenging when complications such as postoperative ileus, nausea, and vomiting peak. To date, no intravenous statin formulations are available, although phase‐I studies are currently underway.38 Second, it is not inconceivable that perioperative clinical instability may overshadow the resumption of statin treatment. Third, clinicians may also remain concerned regarding adverse effects of statins, a thought compounded by US Food and Drug Administration statin package inserts that specifically advocate for statins to be withheld during surgery. However, although the occurrence of elevated liver function tests and myopathy are theoretically important, the overwhelming majority of perioperative statin studies in noncardiac surgery have not found this to be a major occurrence.39 Nonetheless, a lack of uniform definitions and appropriate surveillance for adverse events are important limitations to this finding. In our recent systematic review, we were unable to provide refined estimates of these important side effects owing to differences in definition, variations in screening, and absence of standardized cutoffs used in studies.31 Finally, an important reason for failing to resume postoperative statins is that many physicians simply fail to recognize the perioperative importance of these agents.
STRATEGIES TO IMPROVE PERIOPERATIVE STATIN RESUMPTION
Using the existing evidence, we propose the following 4 clinical strategies to assist in avoiding a statin withdrawal state.
Nasogastric Administration
Utilizing a post‐pyloric nasogastric tube is a straightforward solution to provide statins in those who cannot otherwise tolerate oral intake due to nausea or emesis. Although this solution is hardly innovative, it is relevant as it forces consideration of the need to resume postoperative statins by available means. While the development of a high nasogastric output or a prolonged ileus may limit the applicability of this intervention, it is important that this option be considered as opposed to expectant watching for the clinical return of bowel function. Simvastatin, atorvastatin, rosuvastatin, and pravastatin can be crushed and delivered through this route.40
Development of Reminder Systems
Computerized reminder systems have proved important in ensuring the resumption of deep venous thrombosis prophylaxis and other preventative care compliance in hospitalized patients.41, 42 Using this process, pharmacist‐ or electronic health record‐based reminder systems could be implemented to ensure that statins are restarted when clinically feasible. Further studies are needed to test whether this approach can lead to improved outcomes.
Medication Reconciliation Prior to Hospital Discharge
Statin withdrawal highlights the pertinence of a robust, medical reconciliation process prior to the patient's departure from the hospital. In this context, the development of policies using single‐ or multi‐faceted interventions that promote cooperation between inpatient physicians, surgeons, and pharmacists with outpatient primary care providers are necessary.43
Preoperative Transition to Extended Release Statin Formulations
An innovative approach to minimizing statin withdrawal involves preoperative transition to an extended‐release statin formulation. This strategy may be of particular value in patients where prolonged bowel nonavailability is likely, such as those undergoing gastrointestinal surgery, or when prolonged postoperative dietary restriction (eg, NPO [nil per os]: nothing by mouth) status is expected (Figure 2).

CONCLUSIONS AND FUTURE DIRECTIONS
Sudden withdrawal of perioperative statins results in adverse clinical outcomes. Individuals engaged in the care of patients during surgery such as hospitalists, anesthesiologists, and surgeons must become more cognizant of a statin withdrawal state.
An important limitation associated with the study of perioperative statin withdrawal remains the ambiguity regarding the extent of the problem in the United States. Therefore, a logical first step could be the use of infrastructure within the National Surgical Quality Improvement Program (NSQIP) to understand the epidemiology of perioperative statin use and consequences associated with statin discontinuation.44 Mandating such quality reporting could easily be built into current NSQIP performance metrics. These data would help inform a research agenda targeting patients that experience statin withdrawal and strategies most likely to prevent it.
Note Added in Proof
Disclosure: Nothing to report.
- Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg. 2004;39(5):967–975. , , , et al.
- Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology. 2006;105(6):1260–1272; quiz 1289–1290. , , , , , .
- Lipid‐lowering therapy and in‐hospital mortality following major noncardiac surgery. JAMA. 2004;291(17):2092–2099. , , , , .
- Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol. 2005;45(3):336–342. , , , et al.
- Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003;107(14):1848–1851. , , , et al.
- Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009;361(10):980–989. , , , et al.
- ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation. 2007;116(17):e418–e499. , , , et al.
- Guidelines for pre‐operative cardiac risk assessment and perioperative cardiac management in non‐cardiac surgery. Eur Heart J. 2009;30(22):2769–2812. , , , et al.
- The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg. 2007;104(6):1326–1333. , , , et al.
- Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol. 2007;100(2):316–320. , , , et al.
- Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 suppl 1):III39–III43. .
- Persistent endocrine stress response in patients undergoing cardiac surgery. J Endocrinol Invest. 1998;21(1):12–19. , , , , , .
- Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol. 1996;57(1):37–44. , , , , , .
- Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. Can Med Assoc J. 2005;173(6):627–634. , , , , , .
- Perioperative cardiac morbidity. Anesthesiology. 1990;72(1):153–184. .
- Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003;5(5):372–378. , .
- Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129–1135. , , , .
- Roles of rho‐associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol. 2007;49(6):698–705. , , , et al.
- Inhibition of rho‐associated kinase results in suppression of neointimal formation of balloon‐injured arteries. Circulation. 2000;101(17):2030–2033. , , , et al.
- Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis. 2002;162(1):179–185. , , , .
- Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108(10):1429–1437. , , , et al.
- Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37–44. , , .
- Inhibition of geranylgeranylation reduces angiotensin II‐mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59(3):646–654. , , , et al.
- Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003;34(2):551–557. , , , et al.
- Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000;102(25):3104–3110. , , , et al.
- Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta. 2006;366(1–2):269–273. , , , et al.
- Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost. 2003;90(3):476–482. , , , et al.
- Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis. 2009;207(1):191–194. , , , et al.
- Effects of statins on endothelium and signaling mechanisms. Stroke. 2004;35(11 suppl 1):2708–2711. , .
- Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate‐risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE‐IV). Ann Surg. 2009;249(6):921–926. , , , et al.
- Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta‐analysis. Arch Surg. 2012;147(2):181–189. , , , et al.
- Early withdrawal of statin therapy in patients with non‐ST‐segment elevation myocardial infarction: National Registry of Myocardial Infarction. Arch Intern Med. 2004;164(19):2162–2168. , , , et al.
- Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105(12):1446–1452. , , , , , .
- Discontinuation of statin therapy following an acute myocardial infarction: a population‐based study. Eur Heart J. 2008;29(17):2083–2091. , , , , , .
- There is no evidence for an increase in acute coronary syndromes after short‐term abrupt discontinuation of statins in stable cardiac patients. Circulation. 2004;110(16):2333–2335. .
- Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke. 2007;38(10):2652–2657. , , , .
- Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69(9):904–910. , , , et al.
- Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke. 2008;39(2):433–438. , , , et al.
- Safety of perioperative statin use in high‐risk patients undergoing major vascular surgery. Am J Cardiol. 2005;95(5):658–660. , , , et al.
- Lexi‐Comp Online™, Lexi‐Drugs™, Hudson, OH: Lexi‐Comp, Inc; December 7, 2011.
- A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med. 2001;345(13):965–970. , , , , , .
- Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969–977. , , , et al.
- Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review. Br J Clin Pharmacol. January 13, 2012. doi: 10.1111/j.1365–2125.2012.04178.x. , , , .
- American College of Surgeons National Surgical Quality Improvement Program. Available at: http://www.acsnsqip.org. Accessed December 15, 2012.
- Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg. 2004;39(5):967–975. , , , et al.
- Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology. 2006;105(6):1260–1272; quiz 1289–1290. , , , , , .
- Lipid‐lowering therapy and in‐hospital mortality following major noncardiac surgery. JAMA. 2004;291(17):2092–2099. , , , , .
- Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol. 2005;45(3):336–342. , , , et al.
- Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003;107(14):1848–1851. , , , et al.
- Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009;361(10):980–989. , , , et al.
- ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation. 2007;116(17):e418–e499. , , , et al.
- Guidelines for pre‐operative cardiac risk assessment and perioperative cardiac management in non‐cardiac surgery. Eur Heart J. 2009;30(22):2769–2812. , , , et al.
- The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg. 2007;104(6):1326–1333. , , , et al.
- Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol. 2007;100(2):316–320. , , , et al.
- Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 suppl 1):III39–III43. .
- Persistent endocrine stress response in patients undergoing cardiac surgery. J Endocrinol Invest. 1998;21(1):12–19. , , , , , .
- Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol. 1996;57(1):37–44. , , , , , .
- Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. Can Med Assoc J. 2005;173(6):627–634. , , , , , .
- Perioperative cardiac morbidity. Anesthesiology. 1990;72(1):153–184. .
- Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003;5(5):372–378. , .
- Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129–1135. , , , .
- Roles of rho‐associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol. 2007;49(6):698–705. , , , et al.
- Inhibition of rho‐associated kinase results in suppression of neointimal formation of balloon‐injured arteries. Circulation. 2000;101(17):2030–2033. , , , et al.
- Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis. 2002;162(1):179–185. , , , .
- Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108(10):1429–1437. , , , et al.
- Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37–44. , , .
- Inhibition of geranylgeranylation reduces angiotensin II‐mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59(3):646–654. , , , et al.
- Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003;34(2):551–557. , , , et al.
- Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000;102(25):3104–3110. , , , et al.
- Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta. 2006;366(1–2):269–273. , , , et al.
- Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost. 2003;90(3):476–482. , , , et al.
- Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis. 2009;207(1):191–194. , , , et al.
- Effects of statins on endothelium and signaling mechanisms. Stroke. 2004;35(11 suppl 1):2708–2711. , .
- Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate‐risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE‐IV). Ann Surg. 2009;249(6):921–926. , , , et al.
- Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta‐analysis. Arch Surg. 2012;147(2):181–189. , , , et al.
- Early withdrawal of statin therapy in patients with non‐ST‐segment elevation myocardial infarction: National Registry of Myocardial Infarction. Arch Intern Med. 2004;164(19):2162–2168. , , , et al.
- Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105(12):1446–1452. , , , , , .
- Discontinuation of statin therapy following an acute myocardial infarction: a population‐based study. Eur Heart J. 2008;29(17):2083–2091. , , , , , .
- There is no evidence for an increase in acute coronary syndromes after short‐term abrupt discontinuation of statins in stable cardiac patients. Circulation. 2004;110(16):2333–2335. .
- Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke. 2007;38(10):2652–2657. , , , .
- Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69(9):904–910. , , , et al.
- Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke. 2008;39(2):433–438. , , , et al.
- Safety of perioperative statin use in high‐risk patients undergoing major vascular surgery. Am J Cardiol. 2005;95(5):658–660. , , , et al.
- Lexi‐Comp Online™, Lexi‐Drugs™, Hudson, OH: Lexi‐Comp, Inc; December 7, 2011.
- A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med. 2001;345(13):965–970. , , , , , .
- Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969–977. , , , et al.
- Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review. Br J Clin Pharmacol. January 13, 2012. doi: 10.1111/j.1365–2125.2012.04178.x. , , , .
- American College of Surgeons National Surgical Quality Improvement Program. Available at: http://www.acsnsqip.org. Accessed December 15, 2012.
Smartphone Use During Attending Rounds
Healthcare market research has predicted that over 80% of physicians will use smartphones by 2012.1 These handheld devices allow users immediate access to various forms of electronic media such as Internet, instant messaging, and e‐mail. Smartphones provide numerous benefits to physicians, including rapid access to medical references, research applications, and patient information.2 These devices have been used for teleconsultation3 and patient education,4 and applications have been developed for numerous clinical specialties.48
Housestaff perceive that communication improves when they use smartphones rather than traditional pagers on the inpatient service,9 and patients may have a positive view of physicians' use of handheld computers.10 Medical schools and residency programs are increasingly requiring smartphone ownership for their trainees, with the expectation that smartphone use will enhance the educational experience, ensure the highest level of patient care, improve user efficiency, and help control the costs associated with purchasing updated textbooks.7, 1113 In the future, hospitals may rely on smartphone technologies to help reduce the enormous economic burden created by inefficient communication.14
Despite their numerous benefits for physicians and patients, little is known about the potential for smartphones to distract users in clinical care settings. Studies from the psychology and traffic safety fields have documented untoward consequences when individuals use electronic devices to multitask.1519 Given these concerns, we investigated the prevalence and patterns of smartphone use during inpatient attending rounds, and whether these devices can distract team members in this period of important information transfer.
METHODS
At our institution, attending rounds are faculty‐led inpatient teaching rounds that focus on clinical care and patient management; these sessions may be conducted either in the classroom or at the bedside, depending on patient and learner needs, and faculty preference. Inpatient teams are comprised of 1 attending, housestaff, and third and fourth year medical students. Each team conducts attending rounds independently; these rounds range in length from 1 hour (Pediatrics) to 2 hours (Medicine).
A survey instrument was designed to evaluate smartphone usage patterns during hospital inpatient attending rounds, and perceived distraction from smartphones in this setting. A preliminary version of the survey was pilot tested by a group of housestaff for face validity, redundancy, and ease of use, and it was subsequently revised. For the purposes of this study, a smartphone was defined broadly as any mobile, personal communication device (cellphone, iPhone, Android, Blackberry, iPad, etc). Residents were asked about their own smartphone use, as well as their observations of supervising attendings and other learners' devices use during rounds (see Supporting Appendix 1 in the online version of this article).
In February 2011, the anonymous online survey was administered using Survey Monkey (
Respondents were not required to answer each question in order to complete the survey. With the exception of free‐text comments, all responses were either yes/no or were graded on a 5‐point frequency scale (1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = always). This scale was chosen because it allowed for adequate dispersion of responses, and for the identification of meaningful smartphone usage among respondents (score 3) and data dichotomization. The z test was used to compare the proportions between independent groups.
All free‐text comments were imported into a Microsoft Word table. Comments were separated into 2 groups: housestaff and attending. Each comment was hand‐coded by 2 authors (R.J.K.‐S. and R.S.) to reach consensus for 1 of the following 4 categories: the comment was a positive statement; a negative statement; a positive/negative statement; or a neutral one, ie, neither positive nor negative. The terms positive and negative here refer to whether the statement explicitly highlighted benefits of smartphone use or a negative aspect of smartphone use, respectively. A comment was coded as positive/negative if it highlighted both benefits and drawbacks in the same comment. In addition, each comment that mentioned texting or call functions was secondarily coded as personal, patient, both, or unknown depending on the purpose of the texting or calls described in each comment. Comments were also reviewed for possible subthemes.
RESULTS
The overall response rate was 73% (156/214), with 81% (116/143) of housestaff and 56% (40/71) of faculty participating. The mean tenure of faculty respondents was 13 years. Eighty‐nine percent (103/116) of residents and 98% (39/40) of faculty owned devices, with 57% of housestaff and 28% of attendings reporting regular personal use of smartphones during attending rounds (Table 1).
Smartphone User | Self‐Report % (n/N) | Resident Observations of Other Team Members % (n/N) | Faculty Observations of Trainees % (n/N) |
---|---|---|---|
| |||
Resident | 57% (59/103) | 91% (103/113)* | 73% (29/40) |
Faculty | 28% (11/39) | 43% (49/113)* | n/a |
Respondents reported that they used their smartphones during attending rounds for the following reasons: 1) patient care (85% residents, 48% faculty); 2) reading/responding to personal texts/e‐mails (37% residents, 12% faculty); and 3) other non‐patient care uses, such as Web surfing (15% residents, 0% faculty) (Tables 2 and 3). Nineteen percent of residents reported that they missed important clinical information due to distraction from smartphone use, as did 12% of attendings (Table 4). Respondents reported observing other team members using smartphones and missing important clinical data at higher rates than they reported for themselves (see Tables 1, 4, and 5). A majority of both residents (56%) and faculty (73%) agreed (score >3) that smartphones can be a serious distraction during attending rounds, and 77% of attendings affirmed that teaching hospitals should establish smartphone use codes of conduct in order to minimize unnecessary distraction during attending rounds.
Reason | Based on Housestaff Self‐Report (n = 85)* | Based on Trainee Observations of One Another (n = 112) | P Value |
---|---|---|---|
| |||
Patient care‐related use (ePocrates, MedCalc, Medline, Google Scholar) | 85% | 86% | NS |
Reading or responding to personal texts or e‐mail | 37% | 55% | <0.01 |
Other non‐patient care‐related use, Web surfing | 15% | 37% | <0.01 |
Reason | Based on Faculty Self‐Report (n = 25)* | Based on Housestaff Observations of Faculty (n = 91) | P Value |
---|---|---|---|
| |||
Patient care‐related use (ePocrates, MedCalc, Medline, Google Scholar) | 48% | 48% | NS |
Reading or responding to personal texts or e‐mail | 12% | 47% | <0.01 |
Other non‐patient care‐related use, Web surfing | 0% | 20% | <0.05 |
Smartphone User | Self‐Report % (n/N) |
---|---|
| |
Housestaff | 19% (18/85)* |
Faculty | 12% (3/25)* |
Smartphone User | Based on Housestaff Observation % (n/N) | Based on Faculty Observation % (n/N) |
---|---|---|
| ||
Trainee | 34% (38/112)* | 43% (17/40) |
Faculty | 20% (18/91)* | n/a |
Despite not requiring responses in order to complete the questionnaires, we found that, in general, few eligible faculty or residents skipped questions on the survey. Nevertheless, there was a substantial drop in responses (91/116) for the last 2 questions on the housestaff survey. These questions asked for resident observations of attending smartphone usage patterns during rounds, and whether they had seen attendings miss clinical information because of distractions from smartphone use.
There were 25 free‐text comments from residents and 11 from attendings. The resultant comments highlight differences in residents' and attendings' perspectives toward smartphone use during attending rounds. Housestaff comments included 7 positive comments, 7 positive/negative comments, 1 negative comment, and 10 neutral comments. A subtheme that emerged in 2 of the housestaff comments was the importance of personal autonomy in being able to use one's smartphone. Attending comments included 2 positive comments, 0 positive/negative comments, 4 negative comments, and 5 neutral comments. Faculty comments revealed that attendings use their smartphones' e‐mail/texting and call capabilities during rounds both for patient care issues (3 comments) and/or urgent family concerns (2 comments). In 2 other attending comments, the reason for calls/texts during rounds was not specified.
Housestaff comments included: I do not know why it is that attendings never use it these phones are so easy to use and [enhance] patient care in a number of ways, Depending on how they are used, if strictly for pt care then they can be a great mobile tool, Of course they can be a distraction, but they are also a very good tool. You take the good with the bad, If you are bored you will find other things to occupy your mind. If you can look up some info at the time of rounding you are actively participating. Please, do not make it worse than it is already, and It is a personal choice. Faculty negative comments highlighted the potential for distraction from the e‐mail beeps, the fact that some of the housestaff will be tuned into their SmartPhones, that residents frequently check their phones during roundsa distraction and frankly rude when the attending or fellow are giving a brief lecture, and that sometimes more focus is on the SmartPhone than rounds.
DISCUSSION
Physicians and their patients benefit from the wide‐ranging capabilities of personal, mobile communication devices in the healthcare environment. Smartphones house the latest medical references, provide access to patients' medical records and imaging studies, can photograph or video physical findings, and educate and monitor patients.28 Smartphones can facilitate information transfer in the medical setting and may improve housestaff efficiency and communication.9
Despite their significant benefits, smartphones introduce another source of interruption, multitasking, and distraction into the hospital environment. There is increasing awareness that breaks‐in‐task in the clinical setting may have negative consequences.2024 While some types of interruptions are beneficial and can facilitate patient care (eg, an alarm ringing to indicate abnormal vitals signs on a patient),2024 other forms of interruptions, even those that are self‐initiated,22 can be distracting and detrimental. Along these lines, recommendations for safe handoffs and information transfer have specifically included advice to minimize potential distractions.25
In addition, studies from the psychology and education literature have previously documented negative consequences on learning when individuals use electronic devices to multitask.1517 Students who used a laptop in class were likely to multitask, become distracted, and distract others; the more a student used the laptop in class, the lower the student's class performance.15 Multitasking with a cellphone during driving can be especially hazardous.18, 19 According to National Highway Traffic Safety Administration data, 20% of injury crashes in 2009 involved reports of distracted driving, and cellphones were implicated in 18% of distracted driving deaths that year.18
Little is known about any negative effects of using personal electronic devices in the context of patient care. A 2011 study of Internal Medicine residents who used smartphones for team communication documented both positive and negative consequences of smartphone use in the hospital setting. Negative consequences included frequent interruptions, a weakening of interprofessional behaviors as housestaff relied on texting over direct communication with nurses, and unprofessional housestaff behaviors.26 The Agency for Healthcare Quality and Research published a case report in which a resident's smartphone use during clinical care resulted in patient harm.27 To our knowledge, this is the first study to detail housestaff and faculty smartphone usage patterns and potential for user distractibility during inpatient attending rounds.
Our data show that device use during attending rounds is prevalent among residents and faculty alike, with the majority of use related to patient care. However, attendings were half as likely as residents to report using devices regularly during rounds. This finding may reflect attendings' inability to multitask while leading the rounds, or a deliberate role‐modeling of desired conduct during rounds. Generational differences may also play a role, with residents more likely than their older attendings to multitask and self‐interrupt. Along these lines, traffic safety research has found that younger drivers are more likely to text during driving; approximately 30% of drivers under 30 years old reported texting while driving in the previous 30 days, compared to 9% of respondents over 30 years old.19 Increased smartphone use by housestaff during rounds may also reflect attitudinal differences between the 2 groups. As seen in the free‐text comments, housestaff tended to emphasize the benefits of smartphone use, and with 1 exception, all negative housestaff comments were balanced by a positive statement. Faculty more commonly underscored the negative aspects of smartphone use during rounds, including the devices' adverse effects on housestaff professional behavior in this setting.
Faculty and housestaff consistently reported observing others using smartphones at higher rates than they reported for themselves. This discrepancy may reflect underrecognition of self‐use, or a discomfort in reporting self‐use during attending rounds. In addition, residents' observations of other trainees' usage of smartphones (91%) was higher than faculty observation of the same group (73%). Trainees' smartphone use may be less obvious to attendings who are involved in facilitating rounds. Alternatively, trainees may use their smartphones in subtle ways to prevent attending awareness.
There are several limitations to our study. Our research focused specifically on attending rounds. Smartphone usage patterns by faculty and housestaff at other times in the work day, such as during resident handoffs, at a patient's bedside, or during academic conferences, may differ. Nevertheless, we specifically chose to study smartphone use during attending rounds, as these sessions are discrete time frames during which important teaching occurs and clinical management decisions are made. With recent Accreditation Council for Graduate Medical Education (ACGME) work hour restrictions, these faculty‐led rounds may become increasingly important in ensuring the safe transition of patient care. Secondly, despite asking respondents how often they use their smartphones for personal texts or e‐mails, it was clear from the free‐text comments that respondents use their smartphone e‐mail/texting capabilities and take urgent calls during rounds for both patient care and/or family issues. It is not possible from the data to sort out the subset of respondents who use texting or e‐mailing exclusively for patient care during rounds. Third, we did not survey medical students on the teams, so it is possible that their device use on rounds differs from that of housestaff and faculty. Fourth, since the survey could be completed without answering every question, response rates for some items varied slightly; there was a substantial reduction in the number of eligible residents who answered the final 2 questions on the survey about their observations of attendings' smartphone usage patterns and distraction during rounds. While the flexibility in survey completion was intended to enhance overall study participation, it is unknown how nonresponders might have affected the study results; as such, those specific results should be interpreted with some caution. Finally, our findings were based on respondents' retrospective recall, and therefore may not accurately reflect true usage patterns. Timemotion studies with real‐time observation of smartphone use would provide more accurate data.
A majority of residents and attendings in our study agreed that smartphones can pose a serious distraction during attending rounds, and attendings strongly favored the institution of formal codes of conduct for smartphone use during inpatient attending rounds. The development of such policies are important for patient safety; at the same time, they are in line with medical institutions' increasing awareness about the need for guidelines regarding other aspects of digital professionalism.28 In February 2012, our hospital instituted a policy regarding appropriate device use during inpatient attending rounds (see Supporting Appendix 3 in the online version of this article). Because our research found differences in housestaff and faculty attitudes toward smartphone use during rounds, we developed our policy after discussion with, and feedback from, all members of the inpatient team, including faculty, residents, and medical students. Incorporating the various perspectives of all stakeholders can be helpful to institutions in developing guidelines that maximize the benefits of smartphone use in the learning environment, while reducing the potential for distraction and adverse outcomes.
Acknowledgements
Disclosure: Nothing to report.
- http://mobihealthnews.com/7505/72‐percent‐of‐us‐physicians‐use‐smartphones/. Accessed April 16, 2012. . 72 percent of US physicians use smartphones. MobiHealthNews. Available at:
- Smartphones in clinical practice, medical education, and research. Arch Intern Med. 2011;171(14):1294–1296. .
- Telemedicine using smartphones for oral and maxillofacial surgery consultation, communication, and treatment planning.J Oral Maxillofac Surg.2009;67:2505–2509. , .
- Mobile phones to improve the practice of neurology. Neurol Clin. 2010;28(2):395–410. .
- Infectious diseases resources for the iPhone. Clin Infect Dis. 2010;50(9):1268–1274. , , .
- Novel uses of smartphones in ophthalmology. Ophthalmology. 2010;117:1274–1274.e3. , , , .
- The uses of the iPhone for surgeons. Surgeon. 2011;9(1):44–48. , , .
- Smartphone apps for orthopaedic surgeons. Clin Orthop Relat Res. 2011;469(7):2042–2048. .
- The use of smartphones for clinical communication on internal medicine wards. J Hosp Med. 2010;5(9):553–559. , , , et al.
- Patient attitudes toward physician use of tablet computers in the exam room. Fam Med. 2010;42(9):643–647. , , , .
- http://med.stanford.edu/ism/2010/august/ipad.html. Accessed April 16, 2012. . iPads to be distributed to incoming class by Stanford Medical School. Available at:
- University of Virginia School of Medicine. Third year medical student mobile device requirement. Available at: http://www.medicine.virginia.edu/education/medical‐students/ome/edtech/pda_recom‐page/. Accessed April 16, 2012.
- http://www.acphospitalist.org/archives/2011/08/tablet. htm. Accessed April 16, 2012. . Tablet computers in the hospital. ACP Hospitalist 2011. Available at:
- http://www.rhsmith.umd.edu/chids/pdfs_docs/ResearchBriefings/CHIDS‐ResearchBriefing‐Vol3Issue1b.pdf. Accessed April 16, 2012. , , . Quantifying the economic impact of communication inefficiencies in US hospitals. Available at:
- In‐class laptop use and its effects on student learning. Computers 50(3):906–914. .
- Distractions, distractions: does instant messaging affect college students' performance on a concurrent reading comprehension task? CyberPsychology 12(1):51–53. , , .
- Can students really multitask? An experimental study of instant messaging while reading. Computers 54(4):927–931. , , , .
- US Department of Transportation. Statistics and facts about distracted driving. Available at: http://www.distraction.gov/stats‐and‐facts/index.html. Accessed November 17, 2011.
- Driving distracted. Consumer Reports. April 2011:22–25. See also: http://www.distraction.gov/files/for‐media/2011/2011–03‐04‐cr‐dot‐distracted‐driving‐initiative.pdf. Accessed November 25, 2011.
- Emergency department workplace interruptions: are emergency physicians “interrupt‐driven” and “multitasking”? Acad Emerg Med. 2000;7(11):1239–1243. , , , .
- Interruptions and multitasking in nursing care. Jt Comm J Qual Paient Saf. 2010;36(3):126–132. , .
- Interruptions and distractions in healthcare: review and reappraisal. Qual Saf Health Care. 2010;19(4):304–312. , .
- How hospitalists spend their time: insights on efficiency and safety. J Hosp Med. 2006;1(2):88–93. , , .
- Association of interruptions with an increased risk and severity of medication administration errors. Arch Intern Med. 2010;170(8):683–690. , , , , .
- Lost in translation: challenges and opportunities in physician‐to‐physician communication during patient handoffs. Acad Med. 2005;80(12):1094–1099. , , , .
- An evaluation of the use of smartphones to communicate between clinicians: a mixed‐methods study. J Med Internet Res. 2011;13(3):e59. , , , et al.
- Agency for Healthcare Research and Quality. Spotlight case. Order interrupted by text: multitasking mishap. Commentary by Halamka J. December 2011. Available at: http://www.webmm.ahrq.gov/case.aspx?caseID=257. Accessed April 16, 2012.
- Social media policies at US medical schools. Med Educ Online. 2010;15:5324. DOI: 10.3402/meo.v15i0.5324. , , , .
Healthcare market research has predicted that over 80% of physicians will use smartphones by 2012.1 These handheld devices allow users immediate access to various forms of electronic media such as Internet, instant messaging, and e‐mail. Smartphones provide numerous benefits to physicians, including rapid access to medical references, research applications, and patient information.2 These devices have been used for teleconsultation3 and patient education,4 and applications have been developed for numerous clinical specialties.48
Housestaff perceive that communication improves when they use smartphones rather than traditional pagers on the inpatient service,9 and patients may have a positive view of physicians' use of handheld computers.10 Medical schools and residency programs are increasingly requiring smartphone ownership for their trainees, with the expectation that smartphone use will enhance the educational experience, ensure the highest level of patient care, improve user efficiency, and help control the costs associated with purchasing updated textbooks.7, 1113 In the future, hospitals may rely on smartphone technologies to help reduce the enormous economic burden created by inefficient communication.14
Despite their numerous benefits for physicians and patients, little is known about the potential for smartphones to distract users in clinical care settings. Studies from the psychology and traffic safety fields have documented untoward consequences when individuals use electronic devices to multitask.1519 Given these concerns, we investigated the prevalence and patterns of smartphone use during inpatient attending rounds, and whether these devices can distract team members in this period of important information transfer.
METHODS
At our institution, attending rounds are faculty‐led inpatient teaching rounds that focus on clinical care and patient management; these sessions may be conducted either in the classroom or at the bedside, depending on patient and learner needs, and faculty preference. Inpatient teams are comprised of 1 attending, housestaff, and third and fourth year medical students. Each team conducts attending rounds independently; these rounds range in length from 1 hour (Pediatrics) to 2 hours (Medicine).
A survey instrument was designed to evaluate smartphone usage patterns during hospital inpatient attending rounds, and perceived distraction from smartphones in this setting. A preliminary version of the survey was pilot tested by a group of housestaff for face validity, redundancy, and ease of use, and it was subsequently revised. For the purposes of this study, a smartphone was defined broadly as any mobile, personal communication device (cellphone, iPhone, Android, Blackberry, iPad, etc). Residents were asked about their own smartphone use, as well as their observations of supervising attendings and other learners' devices use during rounds (see Supporting Appendix 1 in the online version of this article).
In February 2011, the anonymous online survey was administered using Survey Monkey (
Respondents were not required to answer each question in order to complete the survey. With the exception of free‐text comments, all responses were either yes/no or were graded on a 5‐point frequency scale (1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = always). This scale was chosen because it allowed for adequate dispersion of responses, and for the identification of meaningful smartphone usage among respondents (score 3) and data dichotomization. The z test was used to compare the proportions between independent groups.
All free‐text comments were imported into a Microsoft Word table. Comments were separated into 2 groups: housestaff and attending. Each comment was hand‐coded by 2 authors (R.J.K.‐S. and R.S.) to reach consensus for 1 of the following 4 categories: the comment was a positive statement; a negative statement; a positive/negative statement; or a neutral one, ie, neither positive nor negative. The terms positive and negative here refer to whether the statement explicitly highlighted benefits of smartphone use or a negative aspect of smartphone use, respectively. A comment was coded as positive/negative if it highlighted both benefits and drawbacks in the same comment. In addition, each comment that mentioned texting or call functions was secondarily coded as personal, patient, both, or unknown depending on the purpose of the texting or calls described in each comment. Comments were also reviewed for possible subthemes.
RESULTS
The overall response rate was 73% (156/214), with 81% (116/143) of housestaff and 56% (40/71) of faculty participating. The mean tenure of faculty respondents was 13 years. Eighty‐nine percent (103/116) of residents and 98% (39/40) of faculty owned devices, with 57% of housestaff and 28% of attendings reporting regular personal use of smartphones during attending rounds (Table 1).
Smartphone User | Self‐Report % (n/N) | Resident Observations of Other Team Members % (n/N) | Faculty Observations of Trainees % (n/N) |
---|---|---|---|
| |||
Resident | 57% (59/103) | 91% (103/113)* | 73% (29/40) |
Faculty | 28% (11/39) | 43% (49/113)* | n/a |
Respondents reported that they used their smartphones during attending rounds for the following reasons: 1) patient care (85% residents, 48% faculty); 2) reading/responding to personal texts/e‐mails (37% residents, 12% faculty); and 3) other non‐patient care uses, such as Web surfing (15% residents, 0% faculty) (Tables 2 and 3). Nineteen percent of residents reported that they missed important clinical information due to distraction from smartphone use, as did 12% of attendings (Table 4). Respondents reported observing other team members using smartphones and missing important clinical data at higher rates than they reported for themselves (see Tables 1, 4, and 5). A majority of both residents (56%) and faculty (73%) agreed (score >3) that smartphones can be a serious distraction during attending rounds, and 77% of attendings affirmed that teaching hospitals should establish smartphone use codes of conduct in order to minimize unnecessary distraction during attending rounds.
Reason | Based on Housestaff Self‐Report (n = 85)* | Based on Trainee Observations of One Another (n = 112) | P Value |
---|---|---|---|
| |||
Patient care‐related use (ePocrates, MedCalc, Medline, Google Scholar) | 85% | 86% | NS |
Reading or responding to personal texts or e‐mail | 37% | 55% | <0.01 |
Other non‐patient care‐related use, Web surfing | 15% | 37% | <0.01 |
Reason | Based on Faculty Self‐Report (n = 25)* | Based on Housestaff Observations of Faculty (n = 91) | P Value |
---|---|---|---|
| |||
Patient care‐related use (ePocrates, MedCalc, Medline, Google Scholar) | 48% | 48% | NS |
Reading or responding to personal texts or e‐mail | 12% | 47% | <0.01 |
Other non‐patient care‐related use, Web surfing | 0% | 20% | <0.05 |
Smartphone User | Self‐Report % (n/N) |
---|---|
| |
Housestaff | 19% (18/85)* |
Faculty | 12% (3/25)* |
Smartphone User | Based on Housestaff Observation % (n/N) | Based on Faculty Observation % (n/N) |
---|---|---|
| ||
Trainee | 34% (38/112)* | 43% (17/40) |
Faculty | 20% (18/91)* | n/a |
Despite not requiring responses in order to complete the questionnaires, we found that, in general, few eligible faculty or residents skipped questions on the survey. Nevertheless, there was a substantial drop in responses (91/116) for the last 2 questions on the housestaff survey. These questions asked for resident observations of attending smartphone usage patterns during rounds, and whether they had seen attendings miss clinical information because of distractions from smartphone use.
There were 25 free‐text comments from residents and 11 from attendings. The resultant comments highlight differences in residents' and attendings' perspectives toward smartphone use during attending rounds. Housestaff comments included 7 positive comments, 7 positive/negative comments, 1 negative comment, and 10 neutral comments. A subtheme that emerged in 2 of the housestaff comments was the importance of personal autonomy in being able to use one's smartphone. Attending comments included 2 positive comments, 0 positive/negative comments, 4 negative comments, and 5 neutral comments. Faculty comments revealed that attendings use their smartphones' e‐mail/texting and call capabilities during rounds both for patient care issues (3 comments) and/or urgent family concerns (2 comments). In 2 other attending comments, the reason for calls/texts during rounds was not specified.
Housestaff comments included: I do not know why it is that attendings never use it these phones are so easy to use and [enhance] patient care in a number of ways, Depending on how they are used, if strictly for pt care then they can be a great mobile tool, Of course they can be a distraction, but they are also a very good tool. You take the good with the bad, If you are bored you will find other things to occupy your mind. If you can look up some info at the time of rounding you are actively participating. Please, do not make it worse than it is already, and It is a personal choice. Faculty negative comments highlighted the potential for distraction from the e‐mail beeps, the fact that some of the housestaff will be tuned into their SmartPhones, that residents frequently check their phones during roundsa distraction and frankly rude when the attending or fellow are giving a brief lecture, and that sometimes more focus is on the SmartPhone than rounds.
DISCUSSION
Physicians and their patients benefit from the wide‐ranging capabilities of personal, mobile communication devices in the healthcare environment. Smartphones house the latest medical references, provide access to patients' medical records and imaging studies, can photograph or video physical findings, and educate and monitor patients.28 Smartphones can facilitate information transfer in the medical setting and may improve housestaff efficiency and communication.9
Despite their significant benefits, smartphones introduce another source of interruption, multitasking, and distraction into the hospital environment. There is increasing awareness that breaks‐in‐task in the clinical setting may have negative consequences.2024 While some types of interruptions are beneficial and can facilitate patient care (eg, an alarm ringing to indicate abnormal vitals signs on a patient),2024 other forms of interruptions, even those that are self‐initiated,22 can be distracting and detrimental. Along these lines, recommendations for safe handoffs and information transfer have specifically included advice to minimize potential distractions.25
In addition, studies from the psychology and education literature have previously documented negative consequences on learning when individuals use electronic devices to multitask.1517 Students who used a laptop in class were likely to multitask, become distracted, and distract others; the more a student used the laptop in class, the lower the student's class performance.15 Multitasking with a cellphone during driving can be especially hazardous.18, 19 According to National Highway Traffic Safety Administration data, 20% of injury crashes in 2009 involved reports of distracted driving, and cellphones were implicated in 18% of distracted driving deaths that year.18
Little is known about any negative effects of using personal electronic devices in the context of patient care. A 2011 study of Internal Medicine residents who used smartphones for team communication documented both positive and negative consequences of smartphone use in the hospital setting. Negative consequences included frequent interruptions, a weakening of interprofessional behaviors as housestaff relied on texting over direct communication with nurses, and unprofessional housestaff behaviors.26 The Agency for Healthcare Quality and Research published a case report in which a resident's smartphone use during clinical care resulted in patient harm.27 To our knowledge, this is the first study to detail housestaff and faculty smartphone usage patterns and potential for user distractibility during inpatient attending rounds.
Our data show that device use during attending rounds is prevalent among residents and faculty alike, with the majority of use related to patient care. However, attendings were half as likely as residents to report using devices regularly during rounds. This finding may reflect attendings' inability to multitask while leading the rounds, or a deliberate role‐modeling of desired conduct during rounds. Generational differences may also play a role, with residents more likely than their older attendings to multitask and self‐interrupt. Along these lines, traffic safety research has found that younger drivers are more likely to text during driving; approximately 30% of drivers under 30 years old reported texting while driving in the previous 30 days, compared to 9% of respondents over 30 years old.19 Increased smartphone use by housestaff during rounds may also reflect attitudinal differences between the 2 groups. As seen in the free‐text comments, housestaff tended to emphasize the benefits of smartphone use, and with 1 exception, all negative housestaff comments were balanced by a positive statement. Faculty more commonly underscored the negative aspects of smartphone use during rounds, including the devices' adverse effects on housestaff professional behavior in this setting.
Faculty and housestaff consistently reported observing others using smartphones at higher rates than they reported for themselves. This discrepancy may reflect underrecognition of self‐use, or a discomfort in reporting self‐use during attending rounds. In addition, residents' observations of other trainees' usage of smartphones (91%) was higher than faculty observation of the same group (73%). Trainees' smartphone use may be less obvious to attendings who are involved in facilitating rounds. Alternatively, trainees may use their smartphones in subtle ways to prevent attending awareness.
There are several limitations to our study. Our research focused specifically on attending rounds. Smartphone usage patterns by faculty and housestaff at other times in the work day, such as during resident handoffs, at a patient's bedside, or during academic conferences, may differ. Nevertheless, we specifically chose to study smartphone use during attending rounds, as these sessions are discrete time frames during which important teaching occurs and clinical management decisions are made. With recent Accreditation Council for Graduate Medical Education (ACGME) work hour restrictions, these faculty‐led rounds may become increasingly important in ensuring the safe transition of patient care. Secondly, despite asking respondents how often they use their smartphones for personal texts or e‐mails, it was clear from the free‐text comments that respondents use their smartphone e‐mail/texting capabilities and take urgent calls during rounds for both patient care and/or family issues. It is not possible from the data to sort out the subset of respondents who use texting or e‐mailing exclusively for patient care during rounds. Third, we did not survey medical students on the teams, so it is possible that their device use on rounds differs from that of housestaff and faculty. Fourth, since the survey could be completed without answering every question, response rates for some items varied slightly; there was a substantial reduction in the number of eligible residents who answered the final 2 questions on the survey about their observations of attendings' smartphone usage patterns and distraction during rounds. While the flexibility in survey completion was intended to enhance overall study participation, it is unknown how nonresponders might have affected the study results; as such, those specific results should be interpreted with some caution. Finally, our findings were based on respondents' retrospective recall, and therefore may not accurately reflect true usage patterns. Timemotion studies with real‐time observation of smartphone use would provide more accurate data.
A majority of residents and attendings in our study agreed that smartphones can pose a serious distraction during attending rounds, and attendings strongly favored the institution of formal codes of conduct for smartphone use during inpatient attending rounds. The development of such policies are important for patient safety; at the same time, they are in line with medical institutions' increasing awareness about the need for guidelines regarding other aspects of digital professionalism.28 In February 2012, our hospital instituted a policy regarding appropriate device use during inpatient attending rounds (see Supporting Appendix 3 in the online version of this article). Because our research found differences in housestaff and faculty attitudes toward smartphone use during rounds, we developed our policy after discussion with, and feedback from, all members of the inpatient team, including faculty, residents, and medical students. Incorporating the various perspectives of all stakeholders can be helpful to institutions in developing guidelines that maximize the benefits of smartphone use in the learning environment, while reducing the potential for distraction and adverse outcomes.
Acknowledgements
Disclosure: Nothing to report.
Healthcare market research has predicted that over 80% of physicians will use smartphones by 2012.1 These handheld devices allow users immediate access to various forms of electronic media such as Internet, instant messaging, and e‐mail. Smartphones provide numerous benefits to physicians, including rapid access to medical references, research applications, and patient information.2 These devices have been used for teleconsultation3 and patient education,4 and applications have been developed for numerous clinical specialties.48
Housestaff perceive that communication improves when they use smartphones rather than traditional pagers on the inpatient service,9 and patients may have a positive view of physicians' use of handheld computers.10 Medical schools and residency programs are increasingly requiring smartphone ownership for their trainees, with the expectation that smartphone use will enhance the educational experience, ensure the highest level of patient care, improve user efficiency, and help control the costs associated with purchasing updated textbooks.7, 1113 In the future, hospitals may rely on smartphone technologies to help reduce the enormous economic burden created by inefficient communication.14
Despite their numerous benefits for physicians and patients, little is known about the potential for smartphones to distract users in clinical care settings. Studies from the psychology and traffic safety fields have documented untoward consequences when individuals use electronic devices to multitask.1519 Given these concerns, we investigated the prevalence and patterns of smartphone use during inpatient attending rounds, and whether these devices can distract team members in this period of important information transfer.
METHODS
At our institution, attending rounds are faculty‐led inpatient teaching rounds that focus on clinical care and patient management; these sessions may be conducted either in the classroom or at the bedside, depending on patient and learner needs, and faculty preference. Inpatient teams are comprised of 1 attending, housestaff, and third and fourth year medical students. Each team conducts attending rounds independently; these rounds range in length from 1 hour (Pediatrics) to 2 hours (Medicine).
A survey instrument was designed to evaluate smartphone usage patterns during hospital inpatient attending rounds, and perceived distraction from smartphones in this setting. A preliminary version of the survey was pilot tested by a group of housestaff for face validity, redundancy, and ease of use, and it was subsequently revised. For the purposes of this study, a smartphone was defined broadly as any mobile, personal communication device (cellphone, iPhone, Android, Blackberry, iPad, etc). Residents were asked about their own smartphone use, as well as their observations of supervising attendings and other learners' devices use during rounds (see Supporting Appendix 1 in the online version of this article).
In February 2011, the anonymous online survey was administered using Survey Monkey (
Respondents were not required to answer each question in order to complete the survey. With the exception of free‐text comments, all responses were either yes/no or were graded on a 5‐point frequency scale (1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = always). This scale was chosen because it allowed for adequate dispersion of responses, and for the identification of meaningful smartphone usage among respondents (score 3) and data dichotomization. The z test was used to compare the proportions between independent groups.
All free‐text comments were imported into a Microsoft Word table. Comments were separated into 2 groups: housestaff and attending. Each comment was hand‐coded by 2 authors (R.J.K.‐S. and R.S.) to reach consensus for 1 of the following 4 categories: the comment was a positive statement; a negative statement; a positive/negative statement; or a neutral one, ie, neither positive nor negative. The terms positive and negative here refer to whether the statement explicitly highlighted benefits of smartphone use or a negative aspect of smartphone use, respectively. A comment was coded as positive/negative if it highlighted both benefits and drawbacks in the same comment. In addition, each comment that mentioned texting or call functions was secondarily coded as personal, patient, both, or unknown depending on the purpose of the texting or calls described in each comment. Comments were also reviewed for possible subthemes.
RESULTS
The overall response rate was 73% (156/214), with 81% (116/143) of housestaff and 56% (40/71) of faculty participating. The mean tenure of faculty respondents was 13 years. Eighty‐nine percent (103/116) of residents and 98% (39/40) of faculty owned devices, with 57% of housestaff and 28% of attendings reporting regular personal use of smartphones during attending rounds (Table 1).
Smartphone User | Self‐Report % (n/N) | Resident Observations of Other Team Members % (n/N) | Faculty Observations of Trainees % (n/N) |
---|---|---|---|
| |||
Resident | 57% (59/103) | 91% (103/113)* | 73% (29/40) |
Faculty | 28% (11/39) | 43% (49/113)* | n/a |
Respondents reported that they used their smartphones during attending rounds for the following reasons: 1) patient care (85% residents, 48% faculty); 2) reading/responding to personal texts/e‐mails (37% residents, 12% faculty); and 3) other non‐patient care uses, such as Web surfing (15% residents, 0% faculty) (Tables 2 and 3). Nineteen percent of residents reported that they missed important clinical information due to distraction from smartphone use, as did 12% of attendings (Table 4). Respondents reported observing other team members using smartphones and missing important clinical data at higher rates than they reported for themselves (see Tables 1, 4, and 5). A majority of both residents (56%) and faculty (73%) agreed (score >3) that smartphones can be a serious distraction during attending rounds, and 77% of attendings affirmed that teaching hospitals should establish smartphone use codes of conduct in order to minimize unnecessary distraction during attending rounds.
Reason | Based on Housestaff Self‐Report (n = 85)* | Based on Trainee Observations of One Another (n = 112) | P Value |
---|---|---|---|
| |||
Patient care‐related use (ePocrates, MedCalc, Medline, Google Scholar) | 85% | 86% | NS |
Reading or responding to personal texts or e‐mail | 37% | 55% | <0.01 |
Other non‐patient care‐related use, Web surfing | 15% | 37% | <0.01 |
Reason | Based on Faculty Self‐Report (n = 25)* | Based on Housestaff Observations of Faculty (n = 91) | P Value |
---|---|---|---|
| |||
Patient care‐related use (ePocrates, MedCalc, Medline, Google Scholar) | 48% | 48% | NS |
Reading or responding to personal texts or e‐mail | 12% | 47% | <0.01 |
Other non‐patient care‐related use, Web surfing | 0% | 20% | <0.05 |
Smartphone User | Self‐Report % (n/N) |
---|---|
| |
Housestaff | 19% (18/85)* |
Faculty | 12% (3/25)* |
Smartphone User | Based on Housestaff Observation % (n/N) | Based on Faculty Observation % (n/N) |
---|---|---|
| ||
Trainee | 34% (38/112)* | 43% (17/40) |
Faculty | 20% (18/91)* | n/a |
Despite not requiring responses in order to complete the questionnaires, we found that, in general, few eligible faculty or residents skipped questions on the survey. Nevertheless, there was a substantial drop in responses (91/116) for the last 2 questions on the housestaff survey. These questions asked for resident observations of attending smartphone usage patterns during rounds, and whether they had seen attendings miss clinical information because of distractions from smartphone use.
There were 25 free‐text comments from residents and 11 from attendings. The resultant comments highlight differences in residents' and attendings' perspectives toward smartphone use during attending rounds. Housestaff comments included 7 positive comments, 7 positive/negative comments, 1 negative comment, and 10 neutral comments. A subtheme that emerged in 2 of the housestaff comments was the importance of personal autonomy in being able to use one's smartphone. Attending comments included 2 positive comments, 0 positive/negative comments, 4 negative comments, and 5 neutral comments. Faculty comments revealed that attendings use their smartphones' e‐mail/texting and call capabilities during rounds both for patient care issues (3 comments) and/or urgent family concerns (2 comments). In 2 other attending comments, the reason for calls/texts during rounds was not specified.
Housestaff comments included: I do not know why it is that attendings never use it these phones are so easy to use and [enhance] patient care in a number of ways, Depending on how they are used, if strictly for pt care then they can be a great mobile tool, Of course they can be a distraction, but they are also a very good tool. You take the good with the bad, If you are bored you will find other things to occupy your mind. If you can look up some info at the time of rounding you are actively participating. Please, do not make it worse than it is already, and It is a personal choice. Faculty negative comments highlighted the potential for distraction from the e‐mail beeps, the fact that some of the housestaff will be tuned into their SmartPhones, that residents frequently check their phones during roundsa distraction and frankly rude when the attending or fellow are giving a brief lecture, and that sometimes more focus is on the SmartPhone than rounds.
DISCUSSION
Physicians and their patients benefit from the wide‐ranging capabilities of personal, mobile communication devices in the healthcare environment. Smartphones house the latest medical references, provide access to patients' medical records and imaging studies, can photograph or video physical findings, and educate and monitor patients.28 Smartphones can facilitate information transfer in the medical setting and may improve housestaff efficiency and communication.9
Despite their significant benefits, smartphones introduce another source of interruption, multitasking, and distraction into the hospital environment. There is increasing awareness that breaks‐in‐task in the clinical setting may have negative consequences.2024 While some types of interruptions are beneficial and can facilitate patient care (eg, an alarm ringing to indicate abnormal vitals signs on a patient),2024 other forms of interruptions, even those that are self‐initiated,22 can be distracting and detrimental. Along these lines, recommendations for safe handoffs and information transfer have specifically included advice to minimize potential distractions.25
In addition, studies from the psychology and education literature have previously documented negative consequences on learning when individuals use electronic devices to multitask.1517 Students who used a laptop in class were likely to multitask, become distracted, and distract others; the more a student used the laptop in class, the lower the student's class performance.15 Multitasking with a cellphone during driving can be especially hazardous.18, 19 According to National Highway Traffic Safety Administration data, 20% of injury crashes in 2009 involved reports of distracted driving, and cellphones were implicated in 18% of distracted driving deaths that year.18
Little is known about any negative effects of using personal electronic devices in the context of patient care. A 2011 study of Internal Medicine residents who used smartphones for team communication documented both positive and negative consequences of smartphone use in the hospital setting. Negative consequences included frequent interruptions, a weakening of interprofessional behaviors as housestaff relied on texting over direct communication with nurses, and unprofessional housestaff behaviors.26 The Agency for Healthcare Quality and Research published a case report in which a resident's smartphone use during clinical care resulted in patient harm.27 To our knowledge, this is the first study to detail housestaff and faculty smartphone usage patterns and potential for user distractibility during inpatient attending rounds.
Our data show that device use during attending rounds is prevalent among residents and faculty alike, with the majority of use related to patient care. However, attendings were half as likely as residents to report using devices regularly during rounds. This finding may reflect attendings' inability to multitask while leading the rounds, or a deliberate role‐modeling of desired conduct during rounds. Generational differences may also play a role, with residents more likely than their older attendings to multitask and self‐interrupt. Along these lines, traffic safety research has found that younger drivers are more likely to text during driving; approximately 30% of drivers under 30 years old reported texting while driving in the previous 30 days, compared to 9% of respondents over 30 years old.19 Increased smartphone use by housestaff during rounds may also reflect attitudinal differences between the 2 groups. As seen in the free‐text comments, housestaff tended to emphasize the benefits of smartphone use, and with 1 exception, all negative housestaff comments were balanced by a positive statement. Faculty more commonly underscored the negative aspects of smartphone use during rounds, including the devices' adverse effects on housestaff professional behavior in this setting.
Faculty and housestaff consistently reported observing others using smartphones at higher rates than they reported for themselves. This discrepancy may reflect underrecognition of self‐use, or a discomfort in reporting self‐use during attending rounds. In addition, residents' observations of other trainees' usage of smartphones (91%) was higher than faculty observation of the same group (73%). Trainees' smartphone use may be less obvious to attendings who are involved in facilitating rounds. Alternatively, trainees may use their smartphones in subtle ways to prevent attending awareness.
There are several limitations to our study. Our research focused specifically on attending rounds. Smartphone usage patterns by faculty and housestaff at other times in the work day, such as during resident handoffs, at a patient's bedside, or during academic conferences, may differ. Nevertheless, we specifically chose to study smartphone use during attending rounds, as these sessions are discrete time frames during which important teaching occurs and clinical management decisions are made. With recent Accreditation Council for Graduate Medical Education (ACGME) work hour restrictions, these faculty‐led rounds may become increasingly important in ensuring the safe transition of patient care. Secondly, despite asking respondents how often they use their smartphones for personal texts or e‐mails, it was clear from the free‐text comments that respondents use their smartphone e‐mail/texting capabilities and take urgent calls during rounds for both patient care and/or family issues. It is not possible from the data to sort out the subset of respondents who use texting or e‐mailing exclusively for patient care during rounds. Third, we did not survey medical students on the teams, so it is possible that their device use on rounds differs from that of housestaff and faculty. Fourth, since the survey could be completed without answering every question, response rates for some items varied slightly; there was a substantial reduction in the number of eligible residents who answered the final 2 questions on the survey about their observations of attendings' smartphone usage patterns and distraction during rounds. While the flexibility in survey completion was intended to enhance overall study participation, it is unknown how nonresponders might have affected the study results; as such, those specific results should be interpreted with some caution. Finally, our findings were based on respondents' retrospective recall, and therefore may not accurately reflect true usage patterns. Timemotion studies with real‐time observation of smartphone use would provide more accurate data.
A majority of residents and attendings in our study agreed that smartphones can pose a serious distraction during attending rounds, and attendings strongly favored the institution of formal codes of conduct for smartphone use during inpatient attending rounds. The development of such policies are important for patient safety; at the same time, they are in line with medical institutions' increasing awareness about the need for guidelines regarding other aspects of digital professionalism.28 In February 2012, our hospital instituted a policy regarding appropriate device use during inpatient attending rounds (see Supporting Appendix 3 in the online version of this article). Because our research found differences in housestaff and faculty attitudes toward smartphone use during rounds, we developed our policy after discussion with, and feedback from, all members of the inpatient team, including faculty, residents, and medical students. Incorporating the various perspectives of all stakeholders can be helpful to institutions in developing guidelines that maximize the benefits of smartphone use in the learning environment, while reducing the potential for distraction and adverse outcomes.
Acknowledgements
Disclosure: Nothing to report.
- http://mobihealthnews.com/7505/72‐percent‐of‐us‐physicians‐use‐smartphones/. Accessed April 16, 2012. . 72 percent of US physicians use smartphones. MobiHealthNews. Available at:
- Smartphones in clinical practice, medical education, and research. Arch Intern Med. 2011;171(14):1294–1296. .
- Telemedicine using smartphones for oral and maxillofacial surgery consultation, communication, and treatment planning.J Oral Maxillofac Surg.2009;67:2505–2509. , .
- Mobile phones to improve the practice of neurology. Neurol Clin. 2010;28(2):395–410. .
- Infectious diseases resources for the iPhone. Clin Infect Dis. 2010;50(9):1268–1274. , , .
- Novel uses of smartphones in ophthalmology. Ophthalmology. 2010;117:1274–1274.e3. , , , .
- The uses of the iPhone for surgeons. Surgeon. 2011;9(1):44–48. , , .
- Smartphone apps for orthopaedic surgeons. Clin Orthop Relat Res. 2011;469(7):2042–2048. .
- The use of smartphones for clinical communication on internal medicine wards. J Hosp Med. 2010;5(9):553–559. , , , et al.
- Patient attitudes toward physician use of tablet computers in the exam room. Fam Med. 2010;42(9):643–647. , , , .
- http://med.stanford.edu/ism/2010/august/ipad.html. Accessed April 16, 2012. . iPads to be distributed to incoming class by Stanford Medical School. Available at:
- University of Virginia School of Medicine. Third year medical student mobile device requirement. Available at: http://www.medicine.virginia.edu/education/medical‐students/ome/edtech/pda_recom‐page/. Accessed April 16, 2012.
- http://www.acphospitalist.org/archives/2011/08/tablet. htm. Accessed April 16, 2012. . Tablet computers in the hospital. ACP Hospitalist 2011. Available at:
- http://www.rhsmith.umd.edu/chids/pdfs_docs/ResearchBriefings/CHIDS‐ResearchBriefing‐Vol3Issue1b.pdf. Accessed April 16, 2012. , , . Quantifying the economic impact of communication inefficiencies in US hospitals. Available at:
- In‐class laptop use and its effects on student learning. Computers 50(3):906–914. .
- Distractions, distractions: does instant messaging affect college students' performance on a concurrent reading comprehension task? CyberPsychology 12(1):51–53. , , .
- Can students really multitask? An experimental study of instant messaging while reading. Computers 54(4):927–931. , , , .
- US Department of Transportation. Statistics and facts about distracted driving. Available at: http://www.distraction.gov/stats‐and‐facts/index.html. Accessed November 17, 2011.
- Driving distracted. Consumer Reports. April 2011:22–25. See also: http://www.distraction.gov/files/for‐media/2011/2011–03‐04‐cr‐dot‐distracted‐driving‐initiative.pdf. Accessed November 25, 2011.
- Emergency department workplace interruptions: are emergency physicians “interrupt‐driven” and “multitasking”? Acad Emerg Med. 2000;7(11):1239–1243. , , , .
- Interruptions and multitasking in nursing care. Jt Comm J Qual Paient Saf. 2010;36(3):126–132. , .
- Interruptions and distractions in healthcare: review and reappraisal. Qual Saf Health Care. 2010;19(4):304–312. , .
- How hospitalists spend their time: insights on efficiency and safety. J Hosp Med. 2006;1(2):88–93. , , .
- Association of interruptions with an increased risk and severity of medication administration errors. Arch Intern Med. 2010;170(8):683–690. , , , , .
- Lost in translation: challenges and opportunities in physician‐to‐physician communication during patient handoffs. Acad Med. 2005;80(12):1094–1099. , , , .
- An evaluation of the use of smartphones to communicate between clinicians: a mixed‐methods study. J Med Internet Res. 2011;13(3):e59. , , , et al.
- Agency for Healthcare Research and Quality. Spotlight case. Order interrupted by text: multitasking mishap. Commentary by Halamka J. December 2011. Available at: http://www.webmm.ahrq.gov/case.aspx?caseID=257. Accessed April 16, 2012.
- Social media policies at US medical schools. Med Educ Online. 2010;15:5324. DOI: 10.3402/meo.v15i0.5324. , , , .
- http://mobihealthnews.com/7505/72‐percent‐of‐us‐physicians‐use‐smartphones/. Accessed April 16, 2012. . 72 percent of US physicians use smartphones. MobiHealthNews. Available at:
- Smartphones in clinical practice, medical education, and research. Arch Intern Med. 2011;171(14):1294–1296. .
- Telemedicine using smartphones for oral and maxillofacial surgery consultation, communication, and treatment planning.J Oral Maxillofac Surg.2009;67:2505–2509. , .
- Mobile phones to improve the practice of neurology. Neurol Clin. 2010;28(2):395–410. .
- Infectious diseases resources for the iPhone. Clin Infect Dis. 2010;50(9):1268–1274. , , .
- Novel uses of smartphones in ophthalmology. Ophthalmology. 2010;117:1274–1274.e3. , , , .
- The uses of the iPhone for surgeons. Surgeon. 2011;9(1):44–48. , , .
- Smartphone apps for orthopaedic surgeons. Clin Orthop Relat Res. 2011;469(7):2042–2048. .
- The use of smartphones for clinical communication on internal medicine wards. J Hosp Med. 2010;5(9):553–559. , , , et al.
- Patient attitudes toward physician use of tablet computers in the exam room. Fam Med. 2010;42(9):643–647. , , , .
- http://med.stanford.edu/ism/2010/august/ipad.html. Accessed April 16, 2012. . iPads to be distributed to incoming class by Stanford Medical School. Available at:
- University of Virginia School of Medicine. Third year medical student mobile device requirement. Available at: http://www.medicine.virginia.edu/education/medical‐students/ome/edtech/pda_recom‐page/. Accessed April 16, 2012.
- http://www.acphospitalist.org/archives/2011/08/tablet. htm. Accessed April 16, 2012. . Tablet computers in the hospital. ACP Hospitalist 2011. Available at:
- http://www.rhsmith.umd.edu/chids/pdfs_docs/ResearchBriefings/CHIDS‐ResearchBriefing‐Vol3Issue1b.pdf. Accessed April 16, 2012. , , . Quantifying the economic impact of communication inefficiencies in US hospitals. Available at:
- In‐class laptop use and its effects on student learning. Computers 50(3):906–914. .
- Distractions, distractions: does instant messaging affect college students' performance on a concurrent reading comprehension task? CyberPsychology 12(1):51–53. , , .
- Can students really multitask? An experimental study of instant messaging while reading. Computers 54(4):927–931. , , , .
- US Department of Transportation. Statistics and facts about distracted driving. Available at: http://www.distraction.gov/stats‐and‐facts/index.html. Accessed November 17, 2011.
- Driving distracted. Consumer Reports. April 2011:22–25. See also: http://www.distraction.gov/files/for‐media/2011/2011–03‐04‐cr‐dot‐distracted‐driving‐initiative.pdf. Accessed November 25, 2011.
- Emergency department workplace interruptions: are emergency physicians “interrupt‐driven” and “multitasking”? Acad Emerg Med. 2000;7(11):1239–1243. , , , .
- Interruptions and multitasking in nursing care. Jt Comm J Qual Paient Saf. 2010;36(3):126–132. , .
- Interruptions and distractions in healthcare: review and reappraisal. Qual Saf Health Care. 2010;19(4):304–312. , .
- How hospitalists spend their time: insights on efficiency and safety. J Hosp Med. 2006;1(2):88–93. , , .
- Association of interruptions with an increased risk and severity of medication administration errors. Arch Intern Med. 2010;170(8):683–690. , , , , .
- Lost in translation: challenges and opportunities in physician‐to‐physician communication during patient handoffs. Acad Med. 2005;80(12):1094–1099. , , , .
- An evaluation of the use of smartphones to communicate between clinicians: a mixed‐methods study. J Med Internet Res. 2011;13(3):e59. , , , et al.
- Agency for Healthcare Research and Quality. Spotlight case. Order interrupted by text: multitasking mishap. Commentary by Halamka J. December 2011. Available at: http://www.webmm.ahrq.gov/case.aspx?caseID=257. Accessed April 16, 2012.
- Social media policies at US medical schools. Med Educ Online. 2010;15:5324. DOI: 10.3402/meo.v15i0.5324. , , , .
Copyright © 2012 Society of Hospital Medicine
New Study on Anticoagulation Therapies “Definitive Word” on Topic, Hospitalist Says
A recent report that states the choice between warfarin and aspirin in patients with heart failure and sinus rhythm should be individualized is the most definitive word to date on the topic, says a hospitalist focused on anticoagulation therapies.
The report, “Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm,” focused on patients in sinus rhythm who had reduced left ventricular ejection fraction (LVEF). The authors concluded that the reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage.
“The new thing about this study is it’s really the definitive, well-designed, large trial that provides guidance to us as to what is right,” says Margaret Fang, MD, MPH, an associate professor of medicine at the University of California at San Francisco (UCSF) and medical director of the UCSF Anticoagulation Clinic. “Is warfarin really the right decision?”
Dr. Fang notes that the report, known more commonly as the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, did find that, over time, warfarin began to show improvement over aspirin. But the improvements, which favored warfarin by the fourth year of the six-year trial, were deemed only marginally significant (P=.046).
A recent report that states the choice between warfarin and aspirin in patients with heart failure and sinus rhythm should be individualized is the most definitive word to date on the topic, says a hospitalist focused on anticoagulation therapies.
The report, “Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm,” focused on patients in sinus rhythm who had reduced left ventricular ejection fraction (LVEF). The authors concluded that the reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage.
“The new thing about this study is it’s really the definitive, well-designed, large trial that provides guidance to us as to what is right,” says Margaret Fang, MD, MPH, an associate professor of medicine at the University of California at San Francisco (UCSF) and medical director of the UCSF Anticoagulation Clinic. “Is warfarin really the right decision?”
Dr. Fang notes that the report, known more commonly as the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, did find that, over time, warfarin began to show improvement over aspirin. But the improvements, which favored warfarin by the fourth year of the six-year trial, were deemed only marginally significant (P=.046).
A recent report that states the choice between warfarin and aspirin in patients with heart failure and sinus rhythm should be individualized is the most definitive word to date on the topic, says a hospitalist focused on anticoagulation therapies.
The report, “Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm,” focused on patients in sinus rhythm who had reduced left ventricular ejection fraction (LVEF). The authors concluded that the reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage.
“The new thing about this study is it’s really the definitive, well-designed, large trial that provides guidance to us as to what is right,” says Margaret Fang, MD, MPH, an associate professor of medicine at the University of California at San Francisco (UCSF) and medical director of the UCSF Anticoagulation Clinic. “Is warfarin really the right decision?”
Dr. Fang notes that the report, known more commonly as the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, did find that, over time, warfarin began to show improvement over aspirin. But the improvements, which favored warfarin by the fourth year of the six-year trial, were deemed only marginally significant (P=.046).
ITL: Physician Reviews of HM-Relevant Research
Clinical question: Is the risk of recurrence of Clostridium difficile infection (CDI) increased by the use of “non-CDI” antimicrobial agents (inactive against C. diff) during or after CDI therapy?
Background: Recurrence of CDI is expected to increase with use of non-CDI antimicrobials. Previous studies have not distinguished between the timing of non-CDI agents during and after CDI treatment, nor examined the effect of frequency, duration, or type of non-CDI antibiotic therapy.
Study design: Retrospective cohort.
Setting: Academic Veterans Affairs medical center.
Synopsis: All patients with CDI over a three-year period were evaluated to determine the association between non-CDI antimicrobial during or within 30 days following CDI therapy and 90-day CDI recurrence. Of 246 patients, 57% received concurrent or subsequent non-CDI antimicrobials. CDI recurred in 40% of patients who received non-CDI antimicrobials and in 16% of those who did not (OR: 3.5, 95% CI: 1.9 to 6.5).
After multivariable adjustment (including age, duration of CDI treatment, comorbidity, hospital and ICU admission, and gastric acid suppression), those who received non-CDI antimicrobials during CDI therapy had no increased risk of recurrence. However, those who received any non-CDI antimicrobials after initial CDI treatment had an absolute recurrence rate of 48% with an adjusted OR of 3.02 (95% CI: 1.65 to 5.52). This increased risk of recurrence was unaffected by the number or duration of non-CDI antimicrobial prescriptions. Subgroup analysis by antimicrobial class revealed statistically significant associations only with beta-lactams and fluoroquinolones.
Bottom line: The risk of recurrence of CDI is tripled by exposure to non-CDI antimicrobials within 30 days after CDI treatment, irrespective of the number or duration of such exposures.
Citation: Drekonja DM, Amundson WH, DeCarolis DD, Kuskowski MA, Lederle FA, Johnson JR. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med. 2011;124:1081.e1-1081.e7.
Clinical question: Is the risk of recurrence of Clostridium difficile infection (CDI) increased by the use of “non-CDI” antimicrobial agents (inactive against C. diff) during or after CDI therapy?
Background: Recurrence of CDI is expected to increase with use of non-CDI antimicrobials. Previous studies have not distinguished between the timing of non-CDI agents during and after CDI treatment, nor examined the effect of frequency, duration, or type of non-CDI antibiotic therapy.
Study design: Retrospective cohort.
Setting: Academic Veterans Affairs medical center.
Synopsis: All patients with CDI over a three-year period were evaluated to determine the association between non-CDI antimicrobial during or within 30 days following CDI therapy and 90-day CDI recurrence. Of 246 patients, 57% received concurrent or subsequent non-CDI antimicrobials. CDI recurred in 40% of patients who received non-CDI antimicrobials and in 16% of those who did not (OR: 3.5, 95% CI: 1.9 to 6.5).
After multivariable adjustment (including age, duration of CDI treatment, comorbidity, hospital and ICU admission, and gastric acid suppression), those who received non-CDI antimicrobials during CDI therapy had no increased risk of recurrence. However, those who received any non-CDI antimicrobials after initial CDI treatment had an absolute recurrence rate of 48% with an adjusted OR of 3.02 (95% CI: 1.65 to 5.52). This increased risk of recurrence was unaffected by the number or duration of non-CDI antimicrobial prescriptions. Subgroup analysis by antimicrobial class revealed statistically significant associations only with beta-lactams and fluoroquinolones.
Bottom line: The risk of recurrence of CDI is tripled by exposure to non-CDI antimicrobials within 30 days after CDI treatment, irrespective of the number or duration of such exposures.
Citation: Drekonja DM, Amundson WH, DeCarolis DD, Kuskowski MA, Lederle FA, Johnson JR. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med. 2011;124:1081.e1-1081.e7.
Clinical question: Is the risk of recurrence of Clostridium difficile infection (CDI) increased by the use of “non-CDI” antimicrobial agents (inactive against C. diff) during or after CDI therapy?
Background: Recurrence of CDI is expected to increase with use of non-CDI antimicrobials. Previous studies have not distinguished between the timing of non-CDI agents during and after CDI treatment, nor examined the effect of frequency, duration, or type of non-CDI antibiotic therapy.
Study design: Retrospective cohort.
Setting: Academic Veterans Affairs medical center.
Synopsis: All patients with CDI over a three-year period were evaluated to determine the association between non-CDI antimicrobial during or within 30 days following CDI therapy and 90-day CDI recurrence. Of 246 patients, 57% received concurrent or subsequent non-CDI antimicrobials. CDI recurred in 40% of patients who received non-CDI antimicrobials and in 16% of those who did not (OR: 3.5, 95% CI: 1.9 to 6.5).
After multivariable adjustment (including age, duration of CDI treatment, comorbidity, hospital and ICU admission, and gastric acid suppression), those who received non-CDI antimicrobials during CDI therapy had no increased risk of recurrence. However, those who received any non-CDI antimicrobials after initial CDI treatment had an absolute recurrence rate of 48% with an adjusted OR of 3.02 (95% CI: 1.65 to 5.52). This increased risk of recurrence was unaffected by the number or duration of non-CDI antimicrobial prescriptions. Subgroup analysis by antimicrobial class revealed statistically significant associations only with beta-lactams and fluoroquinolones.
Bottom line: The risk of recurrence of CDI is tripled by exposure to non-CDI antimicrobials within 30 days after CDI treatment, irrespective of the number or duration of such exposures.
Citation: Drekonja DM, Amundson WH, DeCarolis DD, Kuskowski MA, Lederle FA, Johnson JR. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med. 2011;124:1081.e1-1081.e7.